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Abstract
β-cell replacement therapy is potentially a curative approach in treating diabetes, as demonstrated by the
success of pancreatic islet transplantation in type 1 diabetes. However, there are an insufficient number of
organ donors to meet the demand of this disease, which is increasing in prevalence. One strategy to increase
the supply of human β-cells for transplantation in type 1 diabetics, or to increase residual β-cell mass in type 2
diabetics, is to induce human β-cell replication. This strategy has not been implemented clinically because
adult human β-cells are largely quiescent and the capacity for proliferation decreases with age. I hypothesized
that changes in DNA methylation contribute to the age-related decline in proliferative capacity in human β-
cells, and that altering the DNA methylome in a targeted manner could improve proliferative capacity. To
investigate this hypothesis, I sought to profile the β-cell across the human lifespan, and to develop tools that
permit targeted DNA methylation modifications and efficiency in measuring DNA methylation. I conducted
RNA-Seq and whole-genome bisulfite sequencing (WGBS) to profile the aging human β-cell transcriptome
and DNA methylome. I found that there are significant changes in gene expression with age, and in DNA
methylation, particularly at islet-specific active enhancers. Further, I developed transcription activator-like
effector (TALE) fusion proteins conjugated to DNA methyltransferases (DNMTs) and demonstrated that
targeting TALE-DNMTs to the promoter of the CDKN2A locus, encoding the cell cycle inhibitor p16,
increases proliferation in primary human fibroblasts. Finally, I developed BisPCR2, a novel technique for
preparing targeted bisulfite next-generation sequencing libraries, which greatly improves the efficiency in
which DNA methylation can be measured at target regions. I demonstrated the utility of this tool to validate
genome-wide findings of type 2 diabetes CpG risk loci. Together, these novel datasets and epigenetic tools
poise the β-cell regeneration field to investigate targeted epigenetic modifications as a strategy to improve
proliferative capacity of adult human β-cells.
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ABSTRACT 
Targeted epigenetic editing to increase adult pancreatic β-cell proliferation 
Diana L. Bernstein 
Supervisor of Dissertation: Klaus Kaestner, Ph.D., M.S. 
β-cell replacement therapy is potentially a curative approach in treating diabetes, as 
demonstrated by the success of pancreatic islet transplantation in type 1 diabetes.  However, 
there are an insufficient number of organ donors to meet the demand of this disease, which is 
increasing in prevalence.  One strategy to increase the supply of human β-cells for 
transplantation in type 1 diabetics, or to increase residual β-cell mass in type 2 diabetics, is to 
induce human β-cell replication.  This strategy has not been implemented clinically because adult 
human β-cells are largely quiescent and the capacity for proliferation decreases with age.  I 
hypothesized that changes in DNA methylation contribute to the age-related decline in 
proliferative capacity in human β-cells, and that altering the DNA methylome in a targeted manner 
could improve proliferative capacity.  To investigate this hypothesis, I sought to profile the β-cell 
across the human lifespan, and to develop tools that permit targeted DNA methylation 
modifications and efficiency in measuring DNA methylation.  I conducted RNA-Seq and whole-
genome bisulfite sequencing (WGBS) to profile the aging human β-cell transcriptome and DNA 
methylome.  I found that there are significant changes in gene expression with age, and in DNA 
methylation, particularly at islet-specific active enhancers.  Further, I developed transcription 
activator-like effector (TALE) fusion proteins conjugated to DNA methyltransferases (DNMTs) and 
demonstrated that targeting TALE-DNMTs to the promoter of the CDKN2A locus, encoding the 
cell cycle inhibitor p16, increases proliferation in primary human fibroblasts.  Finally, I developed 
BisPCR2, a novel technique for preparing targeted bisulfite next-generation sequencing libraries, 
which greatly improves the efficiency in which DNA methylation can be measured at target 
regions.  I demonstrated the utility of this tool to validate genome-wide findings of type 2 diabetes 
CpG risk loci.  Together, these novel datasets and epigenetic tools poise the β-cell regeneration 
field to investigate targeted epigenetic modifications as a strategy to improve proliferative 
capacity of adult human β-cells. 
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β-cell replacement therapy for diabetes mellitus 
Human islet physiology & β-cell function  
The pancreas is a dual function organ composed of both exocrine and endocrine glands  
(Chandra and Liddle 2013).  The exocrine portion of the pancreas supports digestion by secreting 
pancreatic juices with digestive enzymes into the small intestine.  The endocrine portion of the 
pancreas, the Islets of Langerhans, is a nutrient sensing organ that is critical in the maintenance 
of glucose homeostasis by secreting hormones in response to changing blood glucose levels.  
Pancreatic islets are vascularized spheroid clusters of endocrine cells scattered throughout the 
pancreas comprising only about 1% of the pancreas by mass.  They are composed of several 
main cell types including α-, β-, δ- and PP-cells, which work in concert to regulate blood glucose  
(Vetere et al. 2014).  β-cells secrete insulin in response to elevated blood glucose to promote 
glucose uptake in peripheral tissues such as muscle, liver and adipose tissue, while suppressing 
hepatic glucose output.  α-cells fulfill the opposing function by secreting glucagon during periods 
of low blood glucose to mobilize alternative fuel sources, primarily by stimulating hepatic 
glycogenolysis and gluconeogenesis.  δ-cells secrete somatostatin to suppress hormone 
secretion of neighboring α- and β-cells to fine-tune the glucose response (Hauge-Evans et al. 
2009).  Finally, PP-cells secrete pancreatic polypeptide, which plays a role in regulating food 
intake (Batterham et al. 2003).  The β-cell is of particular interest because β-cell dysfunction is at 
the core of the pathogenesis of diabetes mellitus, a group of metabolic diseases affecting over 
347 million patients world-wide  (Wang et al. 2015c).  
Pancreatic β-cells are the sole source of insulin in the body, and insulin secretion is 
stimulated by high blood glucose levels.  In the fed state, when glucose levels are high, glucose 
crosses the cell membrane through facilitated diffusion mediated by GLUT1 transporters in 
humans, and GLUT2 transporters in mouse (Devos et al. 1995; McCulloch et al. 2011).  Once 
inside the cell, glucose enters glycolysis, raising intracellular ATP concentrations and thereby the 
ATP:ADP ratio.  Glucokinase (GK) converts glucose to glucose-6-phosphate and is the rate-
limiting enzyme in this process, acting as the glucose sensor.  In fact, mutations in or 
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overexpression of GK alters the set-point for glucose-stimulated insulin secretion (Osbak et al. 
2009).  The increase in ATP results in closure of ATP-sensitive K+ channels (KATP), causing 
membrane depolarization and opening of voltage-gated Ca2+ channels and Ca2+ influx.  Ca2+ 
influx is the penultimate step in insulin secretion, mediating fusion of insulin vesicles with the 
plasma membrane and secretion of insulin into the surrounding vasculature (Prentki et al. 2013). 
The ability of the β-cell, in concert with other islet endocrine cells, to regulate glucose 
homeostasis at the organismal level depends upon maintenance of sufficient functional β-cell 
mass, meaning both adequate β-cell number and glucose responsiveness. β-cell mass is 
maintained by a balance between β-cell renewal and apoptosis.  If functional β-cell mass is not 
maintained, persistent elevation of blood glucose can have severe pathophysiological 
consequences.  
 
Diabetes mellitus  
Diabetes mellitus is a group of metabolic disorders characterized by loss of functional 
pancreatic β-cell mass leading to impaired glucose homeostasis, which manifests primarily as 
hyperglycemia.  The two main forms of this disease are type 1 and type 2 diabetes.  Type 1 
diabetes usually presents early in life and is a consequence of autoimmune destruction of β-cells. 
Type 2 diabetes is an age-associated disorder in which peripheral insulin resistance leads to β-
cell exhaustion and ultimately β-cell death or dysfunction.  Type 1 diabetes accounts for only 
about 5% of all cases while type 2 diabetes accounts for the remaining 95% (Vetere et al. 2014). 
Of increasing recognition are another set of disorders collectively known as maturity onset 
diabetes of the young (MODY), which are monogenic disorders caused by disruption of genes 
critical to β-cell function.   In total, MODY cases constitute between 2-5% of diabetes (Giuffrida 
and Reis 2005).  
All type 1 diabetes patients, and a subset of patients with other forms of diabetes, depend 
on exogenous insulin (Vetere et al. 2014).  While insulin replacement therapy and prescription 
medications are widely used to manage metabolic consequences of diabetes, none recapitulate 
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the precise and dynamic regulation of blood glucose by the β-cell.  Consequently, patients face 
considerable complications of abnormal glucose homeostasis including coronary artery disease, 
neuropathy, nephropathy, retinopathy, and peripheral vascular disease, and are at increased risk 
of adverse hypoglycemic events (McCall and Shapiro 2014; Roglic and Unwin 2010).  Thus, 
strategies aimed at replacing lost β-cells have emerged as an intense area of focus in the 
diabetes research community. 
 
β-cell replacement therapy  
The success of β-cell replacement therapy has been demonstrated convincingly in 
pancreatic islet transplantation, which has been shown to restore euglycemia in type 1 diabetics 
(McCall and Shapiro 2014).  In this procedure, human islets are isolated from deceased organ 
donors and injected into the portal vein of the patient taking up residence in the liver.  While the 
therapeutic benefit of islet transplantation is undisputed, poor graft survival and complications 
associated with chronic immunosuppression initially limited its implementation, and are ongoing 
areas of research.  The first attempts at islet transplantation can be traced back to as early as 
1893, although the field truly gained momentum only in the year 2000 with publication of the 
revolutionary “Edmonton Protocol”  (McCall and Shapiro 2014).   This protocol specified 
immediate transplantation of isolated islets under a glucocorticoid-free immunosuppression 
regimen (Shapiro et al. 2000).  Sufficient mass for transplantation was defined as greater than 
10,000 islet equivalents per kg recipient body weight.  All seven patients in this initial study 
achieved insulin independence following transplantation.  Building upon the “Edmonton Protocol,” 
pancreatic islet transplantation has shown to provide superior glycemic control, reduced 
hypoglycemic events, reduced secondary complications, and improved quality of life metrics in 
comparison to pharmaceutical treatments alone (Ryan et al. 2005; Cure et al. 2008; Poggioli et al. 
2006; Toso et al. 2007; McCall and Shapiro 2014; Rickels et al. 2013; Rickels et al. 2015).  
Despite these successes, this procedure cannot be applied widely in large part due to 
lack of organ donors.  As demand for islet transplantation increases, it is estimated that only 
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4,000 pancreata are available in the United States each year, with just a fraction of those in 
condition for islet transplantation.  Patients also frequently require islets from more than one 
donor, limiting the supply even further (Halban et al. 2010; Johnson and Jones 2012).  
Additionally, the islet grafts often survive for only 5 years, meaning patients may require multiple 
transplantations.  The successes and challenges of islet transplantation have thus ignited 
research efforts towards finding alternative sources of β-cells for replacement therapy.  These 
alternative sources include induced replication of pre-existing β-cells, transdifferentiation from 
other cell types, and differentiation of β-cell either from embryonic stem cells (ESCs) or induced 
pluripotent stem cells (iPSCs).  Induction of replication of pre-existing β-cells is a particularly 
attractive option since it has the greatest likelihood of maintaining β-cell identity.  However, this 
strategy has not been implemented so far because adult human β-cells are largely quiescent, and 
proliferative capacity decreases in an age-dependent manner (Reers et al. 2009; De Tata 2014).  
The islet transplantation setting to treat type 1 diabetes offers a unique opportunity 
because islet cells can be manipulated ex vivo prior to transplantation to optimize β-cell 
proliferation, function and survival.  For example, co-expression of growth factors and 
antiapoptotic genes, or expression of shRNAs targeting pro-apoptotic genes, in human islets prior 
to transplantation into non-obese diabetic severe combined immunodeficient (NOD-SCID) mice 
has shown to improve graft performance and survival (Mahato 2009).  One of the field’s current 
goals is to identify genes that promote β-cell proliferation.  Once the appropriate targets are 
identified, the same principles could be employed to treat type 2 diabetes to expand residual β-
cell mass in these patients.  The advantage of treating endogenous β-cells is that patients are not 
subject to challenges with immunosuppression and graft survival.  On the other hand, 
therapeutics must be suitable for systemic delivery, and target the β-cell specifically to minimize 
off-target effects, particularly because the other extreme of proliferation and enhanced survival is 
cancer.  Understanding what might drive human β-cell proliferation and survival has the potential 
to improve treatments for both type 1 and type 2 diabetes. 
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Replication of pre-existing β-cells for replacement therapy 
Establishment and maintenance of human β-cell mass 
While comparatively little is known about human pancreas development relative to model 
organisms, a few key studies have begun to provide insight into how and when β-cell mass is 
established (Jennings et al. 2015).  During human development, pancreatic progenitors are 
derived from the foregut endoderm, and endocrine progenitors are further specified by 
neurogenin 3 (NEUROG3), which increases rapidly following the embryonic period, approximately 
8 weeks post-conception.  This spike in NEUROG3 is concurrent with the appearance of β-cells, 
the first of the endocrine cells to differentiate in the human fetus.  By 10 weeks post-conception, 
clusters of β-cells are well-vascularized, and islets with complete complements of endocrine cells 
are present at 12-13 weeks post-conception.  Following β-cell differentiation, proliferation of 
precursor cells drops off dramatically, suggesting that after this point additional fetal β-cells are 
derived from self-duplication rather than neogenesis (Jennings et al. 2015). 
β-cell proliferation rates across the human lifespan have been gathered primarily through 
histological analysis of pancreas autopsy specimens in a limited number of studies.  It has been 
found that after birth, a neonatal burst of β-cell proliferation leads to a doubling of β-cell mass by 
5 years of age (Meier et al. 2008).  A more recent study determined that this neonatal burst 
occurs primarily in the first two years of life, with lower levels of proliferation persisting throughout 
childhood (Gregg et al. 2012).  By co-staining of insulin and Ki67 (a marker of cell proliferation) in 
pancreatic sections ranging in age from 24 weeks premature to 74 years old, Gregg and 
colleagues observed that at most, only 2% of β-cells are proliferating at any given time, and this 
number drops off precipitously after early childhood to nearly undetectable numbers (Figure 1.1).  
Further, Perl and colleagues measured thymidine analog incorporation in autopsy specimens 
from cancer patients who received either iododeoxyuridine (IdU) or bromodeoxyuridine (BrdU) 
therapy.  They observed proliferating β-cells in patients up to 20 years old, but not in patients 
over 30 years old, and by radiocarbon dating found that β-cells were very long-lived (Perl et al. 
2010).  This study suggests that basal β-cell proliferation is diminished within the first three 
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decades of life.  Similarly, Cnop and colleagues confirmed that human β-cells are very long-lived 
and that β-cell mass is established by approximately 20 years of age by measuring intracellular 
lipofuscin body (LB) accumulation as a marker for aging (Cnop et al. 2010).  Another study 
assessing pancreas donor samples ranging from 7 to 66 years old reported an age-dependent 
decline in proliferation, although proliferating cells were detected in all samples, regardless of age 
(Reers et al. 2009). 
Considering a peak proliferation rate of 2%, β-cells are somewhat unique in this regards 
as other neonatal tissues including liver, intestinal crypts, bone marrow and spleen, expand much 
more rapidly in the same timeframe  (Wang et al. 2015c).   Even the pancreas itself expands from 
approximately 3-5g at birth to on average 90g by adulthood  (Crelin 1973; Innes and Carey 1994).  
In summary, β-cell mass is established very early in life, and adult human β-cells are largely post-
mitotic.   
Amongst these observational studies of autopsy specimens, there is considerable 
variability in the reported rates of human β-cell proliferation, and a recent study calls into question 
the use of Ki67 as a proliferative marker in these particular specimens in attempt to reconcile 
such differences.  Sullivan and colleagues hypothesized that human autopsy and cadaver 
donation conditions result in decreased proliferative markers depending on storage and treatment 
of specimens (Sullivan et al. 2015). In this study, young murine and porcine pancreata were 
exposed to warm ischemia followed by cold ischemia to mimic human autopsy conditions, in 
comparison to immediate fixation, typically employed in animal models, and then Ki67 and PCNA 
were assessed by immunofluorescence.  Exposure to autopsy-like conditions resulted in 
decreased Ki67 and PCNA staining in β-cells, and a similar decay in Ki67 staining was also 
observed in acinar cells (Sullivan et al. 2015).  Thus, the precise landscape of human β-cell 
proliferation with age is still incomplete, and sample collection conditions need to be optimized.    
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Cell cycle regulation of human β-cells 
Many mitogenic signaling pathways have been implicated in the regulation of β-cell 
proliferation, all of which ultimately converge upon the core cell cycle machinery.  In rodent 
models, many of the intermediate signaling pathways have been described, including insulin 
receptor substrate/phosphatidylinositol-3 kinase/Akt (IRS-PI3K-Akt), glycogen synthase kinsase-3 
(GSK3), protein kinase Cζ (PKCζ) pathways, among others, although the corresponding 
pathways in human β-cells have not yet been mapped.  These studies are reviewed in detail 
elsewhere (Kulkarni et al. 2012; Bernal-Mizrachi et al. 2014; Stewart et al. 2015). 
The cell cycle, defined as the period of time between subsequent rounds of DNA 
replication and cell division, can be divided into four sequential phases, G1, S, G2, and M.  DNA 
replication, or synthesis, occurs during S-phase, and cellular division, or mitosis, occurs during M-
phase.  G1 and G2 are growth phases that precede S- and M- phases, respectively.  The cell 
cycle is punctuated by several checkpoints to ensure that the cellular environment is suitable for 
further progression, and to check the integrity of the genome.  During G1, if environmental 
conditions are not favorable, the cell can transition into a period of cell cycle arrest, or G0, where 
it may remain indefinitely.  While each checkpoint is critical to cell cycle progression, a strong 
body of evidence has demonstrated that the G1/S checkpoint is particularly critical for regulating 
mammalian β-cell proliferation (Tarabra et al. 2012).  
Central to the G1/S checkpoint is the retinoblastoma (Rb) pathway.  The Rb family of 
“pocket” proteins restrain cell cycle progression at the G1/S checkpoint by sequestering E2F 
transcription factors, which regulate expression of key cell cycle genes such as the A- and E- 
cyclins (Sherr and Roberts 1999). Phosphorylation of the Rb proteins by cyclin-dependent 
kinases (CDKs) disrupts the E2F/Rb interaction, permitting cell cycle progression. CDK4 and 
CDK6, stimulated by D-cyclins, are active early in G1, and CDK2, stimulated by E-cyclins, is 
active later in G1.  The CDK/cyclin complexes are negatively regulated by CDK inhibitors (CKIs), 
belonging to either the INK4 (p16INK4a, p15INK4b, p18INK4c, p19INK4d) or Cip/Kip (p21Cip1, p27Kip1, 
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p57Kip2) families.  p16, which specifically inhibits CDK4 and CDK6, is of particular relevance in 
mammalian β-cell proliferation (Salas et al. 2014).  
Studies profiling G1/S cell cycle regulators at the protein level demonstrate that with the 
exception of cyclin D2, all such proteins are present in the human β-cell (Fiaschi-Taesch et al. 
2013a). Interestingly, a study of 164 human cadaveric islet samples showed that the majority of 
the G1/S cell cycle regulators are localized to the cytoplasmic compartment, contrary to 
expectations.  Certain cell cycle inhibitors including Rb, p57, and sometimes p21, were nuclear.  
All but five samples were from donors over the age of 20, and thus this study does not provide 
insight into any potential age-related differences (Fiaschi-Taesch et al. 2013a). A follow-up study 
showed that over-expression of CDK6 and cyclin D3 led to altered subcellular localization of G1/S 
regulators and increased cell cycle entry of human β-cells (Fiaschi-Taesch et al. 2013b). These 
findings are particularly interesting because although cell cycle regulators are often regulated at 
the level of protein stability, certain regulators, such as p16, encoded by the CDKN2A locus, are 
known to increase dramatically in expression in an age-related manner, suggesting a concurrent 
role for transcriptional regulation  (Wang et al. 2015c).   
The balance between drivers of cell cycle progression, namely cyclins and CDKs, and 
inhibitors of cell cycle progression, namely the CKIs, determines cell cycle progression.  Efforts to 
overcome this checkpoint inhibition in β-cells have included pushing the cell cycle forward by 
overexpressing cyclins and CDKs, or by releasing the “brakes” by removing CKI’s.  In rodent 
models, both of these strategies have been successfully implemented, reviewed in detail 
elsewhere (Cozar-Castellano et al. 2006).  Some success has also been achieved in human β-
cells through over expression of cell cycle activators.  Takane and colleagues reported a 
reversible 20-fold increase in human β-cell proliferation with doxycycline-induced over expression 
of CDK6 and cyclin D1 (Takane et al. 2012).  The same group has reported increases in human 
β-cell proliferation by over-expressing CDK6 alone, as well as CDK4 in combination with cyclin 
D1 (Fiaschi-Taesch et al. 2010; Cozar-Castellano et al. 2004). 
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Suppression of cell cycle inhibitors has also been shown to increase human β-cell 
proliferation in a few key studies.  For instance, shRNA-mediated suppression of p57, which 
inhibits multiple cyclin/CDK complexes, was shown to increase human β-cell proliferation by 3-
fold following the transplantation of islets in to the hyperglycemic environment of diabetic NOD-
SCID mice (Avrahami et al. 2014).  Tamaki and colleagues further corroborated the importance of 
the Rb pathway by targeting multiple members of the Rb and p53 pathways by siRNA in human 
islets in culture.  siRNAs were delivered by electroporation of intact human islets and resulted in 
increased proliferation of up to 10% as measured by 5-ethynyl-2’-deoxyuridine (EdU) 
incorporation (Tamaki et al. 2014).  In this study, p16 was not independently assessed, and 
whether or not suppression of p16 is sufficient to restore proliferative capacity in human β-cells 
has yet to be determined.  Some points of caution when manipulating cell cycle regulators include 
potential oncogenic activation, cell cycle re-entry without completion, and limited functionality of 
newly replicated β-cells (Rieck et al. 2012). 
 
β-cell mass plasticity in response to increased metabolic demand 
Although β-cell mass is established prior to adulthood, it can reversibly expand in 
response to instances of increased metabolic demand such as in pregnancy and obesity, at least 
in rodents, and failure to do so can result in gestational diabetes or type 2 diabetes, respectively 
(Rieck and Kaestner 2010; Tarabra et al. 2012). The fact that only certain individuals are 
susceptible to disease under these circumstances suggests a genetic underpinning, which is also 
of interest to the β-cell regeneration field (Tarabra et al. 2012).  Plasticity of β-cell mass in 
response to increased demand for insulin has been investigated more thoroughly in rodent 
models than in humans, and the limited number of human studies suggest that the response in 
rodents is more robust.  For instance, one murine model of obesity, the liver specific insulin 
receptor knockout (LIRKO) mouse, shows a 30-fold increase in β-cell mass as a compensatory 
response to ambient insulin resistance (Okada et al. 2007; Michael et al. 2000).  However, the 
degree of β-cell mass expansion depends on the particular model system.  The C57Bl/6 mouse 
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strain, for instance, shows a more modest increase in β-cell mass of 2.2-fold when obesity is 
induced by high-fat diet (Sone and Kagawa 2005).  
On the other hand, based on assessment of autopsy specimens, obese non-diabetic 
individuals exhibited a 50% increase in β-cell volume in comparison to lean non-diabetic 
individuals (Butler et al. 2003).  This increase in β-cell volume was determined to be due to an 
increase in β-cell number rather than size, and thought to result from neogenesis as measured by 
counting insulin positive duct cells.  These findings are interesting because other studies have 
reported that the primary source of new β-cells is pre-existing β-cells in both humans and rodents 
(Meier et al. 2008; Dor et al. 2004; Georgia and Bhushan 2004).  In comparison, obese type 2 
diabetics showed a 63% decrease in β-cell mass relative to non-diabetic obese counterparts, 
which was attributed to apoptosis (Butler et al. 2003).  Other studies have reported similar 
increases in β-cell mass of 30-40% in obese non-diabetic human subjects (De Tata 2014).  
In rodent pregnancy models, β-cell mass increases from two- to five-fold, and levels 
return to normal within ten days postpartum as a result of increased apoptosis, decreased 
proliferation, and decreased β-cell size (Scaglia et al. 1995; Parsons et al. 1995). Some human 
studies have reported slightly lower increases in β-cell mass in pregnant women compared to 
non-pregnant women ranging from 1.4- to 2.4-fold (Butler et al. 2010; Vanassche et al. 1978). 
Interestingly, Butler and colleagues found the primary mechanism of β-cell expansion during 
human pregnancy was neogenesis compared to the replication-driven β-cell mass expansion well 
documented in rodents (Butler et al. 2010; Parsons et al. 1992; Rieck et al. 2009). During 
pregnancy, increased β-cell mass is mediated by hormones including placental lactogen, 
prolactin, growth hormone, and serotonin, and downstream signaling events are being explored in 
rodent models (Rieck and Kaestner 2010; Tarabra et al. 2012). Importantly, these responses to 
increased metabolic demand indicate that adult β-cell mass can expand, although the variation in 
observed responses, the lack of consensus on the origin of new β-cells, and the incomplete 
profile of signaling pathways suggest that further investigation is required to harness these 
models for potential therapeutic intervention.  
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Understanding complete mitogenic pathways from stimulus to downstream signaling to 
cell cycle progression is important because not all mitogens translate to productive completion of 
the cell cycle.  The ability of HNF4α, a nuclear receptor transcription factor, to drive human β-cell 
proliferation was investigated based on its requirement for murine β-cell replication in response to 
pregnancy and obesity (Gupta et al. 2007).  Interestingly, overexpression of the pancreas-specific 
isoform HNF4α8 in human β-cells prompted β-cells to enter, but not successfully complete, the 
cell cycle (Rieck et al. 2012).  Punctate BrdU incorporation along with assessment of other DNA 
damage markers suggested an uncoupling of mechanisms regulating the timing of DNA 
replication, resulting in cell cycle arrest during S-phase.  This study also re-evaluated the ability of 
Cdk6 and Cyclin D3 overexpression to stimulate human β-cell proliferation, independently or in 
combination with HNF4α8 overexpression.  While these cell cycle regulators seemed to push β-
cells through S-phase, as evident by increased Ki67 staining, the DNA damage response was still 
activated, ultimately leading to cell cycle arrest.  This study raises several interesting points.  
Firstly, the adult human β-cell is capable of initiating cell cycle re-entry.  Secondly, surrogate 
markers such as BrdU incorporation cannot be used in isolation as readout for β-cell proliferation.  
Finally, mechanistic studies in human β-cells are necessary to elucidate why certain stimuli lead 
to deregulated cell cycle progression, and in order to prioritize which targets are more likely to 
result in completion of the cell cycle. 
 
Adult human β-cells do not readily respond to mitogenic stimuli 
Age-related decline in β-cell proliferative capacity 
Even though adult β-cell mass exhibits plasticity during metabolic stress, evidence 
suggests that the capacity for β-cell regeneration decreases with age (Teta et al. 2005; Kushner 
2013). This may even be evident in the pregnancy population, since maternal age greater than 25 
is one of several risk factors for gestational diabetes (Cypryk et al. 2008).  An age-related decline 
in β-cell proliferative capacity has been thoroughly studied in several rodent models.  In β-cell 
injury models, including partial pancreatectomy and low-dose streptozotocin (STZ), proliferation 
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was induced more robustly in young β-cells compared to old β-cells.  Similar findings have been 
reported in response to mitogenic stimuli, including the glucagon-like peptide 1 (GLP-1) analog 
exendin-4 and obesity induced by high fat diet (Rankin and Kushner 2009; Tschen et al. 2009; 
Kushner 2013).   This phenomenon was also observed in a non-human primate model, i.e. 
middle-aged vervet monkeys, which showed a limited β-cell regenerative response to STZ 
(Saisho et al. 2011).  Thus, even in the presence of appropriate mitogenic stimuli, β-cells exhibit 
decreased ability to respond in an age-dependent fashion.  
While studies in human islets are limited, an age-related decline in human β-cell 
proliferative capacity has also been reported.  In one study, Tian and colleagues transplanted 
mouse and human islets from donors of various ages into diabetic mice and administered BrdU 
alone or with exendin-4 (Tian et al. 2011).  In grafts from both young and old mouse islet donors, 
proliferating β-cells were found even without exendin-4 treatment, although the percentage of 
proliferating β-cells was higher in young islet grafts.  Exendin-4 treatment augmented proliferation 
in both young and old β-cells in mouse islet grafts.  In the case of human islet donors, exendin-4 
augmented β-cell proliferation in grafts from donors younger than 22 years of age.  However, very 
little β-cell proliferation was detected in treated or untreated mice transplanted with human islets 
from donors older than 35 years of age, suggesting decreased proliferative capacity even in the 
presence of multiple mitogenic stimuli.  This study highlights an important recurring theme, which 
is that rodent β-cell findings cannot be directly translated to human β-cell physiology.  
What precisely mediates the age-related decline in proliferative capacity is at present 
poorly understood.  Much attention has been drawn to changes in expression of the cell cycle 
machinery with aging, discussed below.  Other hypotheses include loss of receptors mediating 
mitogenic signaling, age-dependent increase in the replication-refractory period, stochastic aging 
due to accumulation of somatic mutations, and cellular damage due to ER stress associated with 
secretory cells (Kushner 2013; Papa 2012).  An alternative hypothesis is that more broad age-
related changes in the β-cell epigenetic landscape contribute to transcriptional reprogramming, 
which may in turn affect expression of genes critical to cell cycle progression. 
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p16 contributes to β-cell aging 
 The human β-cell field is lacking a complete profile of age-associated changes.  
Nevertheless, limited human studies in combination with animal studies have led to a rudimentary 
model for the age-related decline in β-cell proliferative capacity, and p16, encoded by the 
CDKN2A locus, lies in the center of this model.  This proposed role of p16 is not surprising, since 
CDKN2A expression has been shown to increase with age in most rodent and human tissues, 
and has emerged as a biomarker of the aging process.  p16 is a master-regulator of cellular 
senescence, mediating its effects through the retinoblastoma pathway discussed previously.  
Additionally, CDKN2A is consistently a top hit in GWAS studies of age-related disorders including 
type 2 diabetes, coronary artery disease, myocardial infarction, and late-onset Alzheimer’s 
disease (Martin et al. 2014).  
In murine β-cells, p16 is a well-established mediator of age-related decline proliferative 
capacity.  It has been demonstrated that decreasing p16 levels through germline gene 
inactivation can rescue the proliferative capacity of mouse adult β-cells (Krishnamurthy et al. 
2006). Increased expression of Cdkn2a with age appears to be mediated by epigenetic 
mechanisms involving polycomb repressive complexes (PRC), PRC1 and PRC2.  PRC2 
suppresses transcription by depositing histone 3 lysine 27 trimethylation (H3K27me3), a 
repressive histone modification.  PRC1 subsequently recognizes H3K27 trimethylation and 
facilitates chromatin compaction by histone 2A (H2A) ubiquitylation, which in turn blocks 
recruitment of the histone 3 lysine 4 (H3K4) methyltransferase MLL1 (van Kruijsbergen et al. 
2015). Expression of Ezh2, an H3K27 histone methyltransferase associated with PRC2, 
decreases with age in murine β-cells, leading to de-repression of the Cdkn2a locus (Chen et al. 
2009).  PRC1 also contributes to repression of Cdkn2a, and age-related decrease in expression 
of Bmi-1, encoding a polycomb group protein that is critical for stability of PRC1, ultimately leads 
to transcriptional activation of Cdkn2a by permitting MLL1 recruitment (Dhawan et al. 2009).  
Additional studies have revealed that in β-cells Cdkn2a regulation is linked to key cellular 
signaling pathways, providing a potential connection between external mitogenic stimuli and cell 
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cycle progression.  For example, Chen and colleagues reported an age-dependent decline in 
platelet-derived growth factor receptor (PDGF) signaling, which attenuated Erk activation and 
thereby Ezh2 expression, ultimately leading to increased p16 and decreased β-cell proliferation 
(Chen et al. 2011). This age-dependent attenuation of PDGF signaling appeared conserved in 
human β-cells as well. Stiles and colleagues also showed that deletion of Pten, a negative 
regulator of the PI3K/Akt growth factor signaling pathway, enhanced Ezh2 expression and 
thereby H3K27 trimethylation of Cdkn2a, resulting in increased proliferation of adult murine β-
cells(Zeng et al. 2013). 
In humans, age-related accumulation of p16 is also associated with decreased 
proliferative capacity of β-cells.  Kohler and colleagues correlated β-cell proliferation with protein 
levels of p16 and other cell cycle regulators in fetal and adult pancreatic tissue sections (Koehler 
et al. 2011). In line with other studies, they reported average proliferation of 3.5% in fetal β-cells 
compared to 0.5% in adult β-cells based on co-immunostaining of ki67 and insulin.  p16 was 
detected in 63.1% of adult β-cells and just 8% of prenatal β-cells.  
 
Limitations in studying human β-cell proliferation 
Despite strong interest in β-cell regeneration research, this field has been greatly stunted 
due to technical challenges in working with human β-cells. Modeling β-cell replication in vitro has 
been a big hurdle, given that β-cell proliferation rates are so low in the adult human.  One of the 
major obstacles in the field is lack of a human β-cell line.  Rodent β-cell lines such as rat INS-1 
cells provide a convenient in vitro tool for studying β-cell physiology, but important differences 
between rodent and human β-cells, discussed below, have led to a search for a human cell line.  
Towards this goal, Ravassard and colleagues developed the EnodC-βH1 cell line, which was 
derived by targeted oncogenesis of human fetal pancreas tissue (Ravassard et al. 2011). 
However, this targeted oncogenesis procedure involved transformation with the immortalizing 
transgenes simian virus 40 large T antigen (SV40LT) and human telomerase reverse 
transcriptase (hTERT), making this cell line particularly poorly suited for proliferation studies.  To 
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address this issue, the same group generated the EndoC-βH2 cell line in which the immortalizing 
transgenes can be removed by Cre-mediated gene excision.  Removal of the transgenes resulted 
in decreased proliferation and improvements in β-cell identity features (Scharfmann et al. 2014).  
Despite these advances, EndoC cell lines are notoriously difficult to maintain in culture and have 
therefore not yet been put into widespread use.   
Without a reliable β-cell line, researchers have turned to primary human islets, which are 
obtained from deceased organ donors.  Only recently have human islets become more widely 
available for research purposes through distribution networks such as the Integrated Islet 
Distribution Program (IIDP).  The availability of human islets for research is subject to many of the 
same limitations as pancreatic islet transplantation, in that donors must meet certain health 
criteria, and there is a short window post-mortem during which islets must be isolated.  Further, 
the cost of conducting research with human islets is quite high in part due to the complex isolation 
procedure.  Additionally, human islets can only be maintained in culture for a matter of weeks, 
meaning that experiments must be short term.  Human islet xenotransplantation in mice either 
under the kidney capsule or the anterior chamber of the eye is one advance that has permitted 
long-term and physiologically relevant experiments.  Transplanted human islets start to become 
re-vascularized in as little as two days, and can restore euglycemia in diabetic animals (Menger 
et al. 2001; Sabek et al. 2005; Sakata et al. 2012).  
While rodent models continue to provide invaluable insight into β-cell biology, there are 
important differences that suggest caution should be taken when translating these studies into 
human physiology.  Firstly, islet structure itself differs between the two species in that the mouse 
islet is mantled, containing a core of β-cells that make up approximately 80% of the islet 
surrounded by a smaller number of other islet endocrine cell types on the periphery (Brissova et 
al. 2005; Cabrera et al. 2006).  (Figure 1.2A).  In contrast, β-cells make up approximately 50% of 
the cellular composition in human islets, and all endocrine cell types are scattered throughout the 
islet and along the surrounding vasculature (Cabrera et al. 2006).  These differences in islet cell 
composition and architecture have important implications in functionality.  For instance, the 
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mantled structure of the mouse islet lends itself to uniform oscillatory β-cell glucose 
responsiveness, which is not observed in the more homogenous human islet (Cabrera et al. 
2006).  Of particular relevance to the present work are differences in β-cell proliferation capacity 
and cell cycle machinery.  For example, Cdk6 is present in mouse β-cells while both CDK4 and 
CDK6 are present in human β-cells (Salas et al 2014, Fiaschi-Taesch et al 2013).  Further, cyclin 
D2 expression in mouse β-cells is significantly higher than other D-type cyclins, while in human β-
cells cyclin D2 protein is not detectable (Salas et al. 2014; Fiaschi-Taesch et al. 2013a). (Figure 
1.2B).   
In general, mouse β-cells show a much greater capacity for proliferation.  For example, 
mouse β-cell proliferation in the neonatal period ranges from 10-30%, and this rate is at most 2% 
in human neonatal β-cells  (Wang et al. 2015c).   Further, many mitogenic stimuli that robustly 
activate mouse β-cell proliferation have failed to do so in human β-cells  (Wang et al. 2015c).   
One striking example of the incongruence between mouse and human β-cell proliferation is the 
effect of betatrophin.  Melton and colleagues identified betatrophin as a circulating factor released 
from the liver that is capable of stimulating rodent β-cell proliferation under insulin resistance 
conditions by nearly 20-fold within a few days (Yi et al. 2013).  Jiao and colleagues subsequently 
confirmed these findings, and proved in a xenotransplantation model that betatrophin has no 
effect on proliferation of human β-cells (Jiao et al. 2014).  This example highlights the importance 
of validating each target in human β-cells.  
 
Epigenetic modification may permit adult human β-cell proliferation 
Epigenetics and DNA methylation overview 
While cell cycle regulators, such as p16, are reasonable targets for β-cell rejuvenation, it 
is possible that changes in levels of these proteins is part of a more widespread aging process, 
especially considering the extensive network of pathways implicated in the aging murine β-cell.  
Epigenetics, and in particular DNA methylation, is one potential explanation for what might govern 
the aging process.  Epigenetics refers to heritable changes in gene expression or other traits that 
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are not determined by changes in DNA sequence.  There are three broad categories of 
epigenetic modifications including DNA methylation, histone modifications, and non-coding RNAs.  
DNA methylation is the covalent addition of a methyl group to the C5 position of cytosine 
residues, typically in the context of CpG dinucleotides.  This mark may be of particular relevance 
to the aging process since it is a covalent, and therefore stable, modification directly to DNA, and 
is faithfully maintained through subsequent rounds of cell division.  DNA methylation was initially 
found to function in transcriptional repression, but a more complex role has been increasingly 
recognized. 
In addition to transcriptional regulation, DNA methylation is critical to maintaining genome 
integrity through inactivating transposable elements in repeat regions, for X chromosome 
inactivation in females, and to genomic imprinting (Reik et al. 2001).   The landscape of DNA 
methylation throughout the genome largely reflects these roles.  There are approximately 30 
million CpG dinucleotides in the human genome, making up about 1% of total nucleotide content.  
A fraction of these CpGs, 1-2%, are clustered in highly dense areas known as CpG islands 
(CGIs), while the majority of CpGs are dispersed sparsely throughout the genome.  A CGI is 
defined as a region greater than 500 bps with more than 50% CpG content  (Zampieri et al. 
2015).   More than half of all CGIs are associated with coding gene promoters, directly regulating 
gene expression by determining whether or not transcriptional machinery can bind.  Further, 
about 60-70% of all genes contain CGIs within the promoter region  (Jones et al. 2015).   The 
majority of the genome is highly methylated, which promotes genomic stability by limiting the 
activity of transposable elements, while certain regulatory elements, including CGIs and 
enhancers, are usually lowly methylated  (Stadler et al. 2011; Sheaffer et al. 2014).  
Although DNA methylation is considered to be a generally stable epigenetic modification, 
dynamic DNA methylation remodeling is crucial to embryonic development in mammals.  Post-
fertilization, the preimplantation embryo undergoes genome-wide DNA de-methylation in order to 
maintain cellular totipotency.  After implantation, DNA methylation patters are re-established to 
direct cellular differentiation.  A similar process of de-methylation followed by re-methylation is 
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observed in the development of primordial germ cells  (Zampieri et al. 2015).   These dramatic 
remodeling processes are somewhat in contrast to what is observed with respect to DNA 
methylation and aging, a phenomenon known as epigenetic drift. 
 
DNA methylation and β-cell aging 
 The term “epigenetic drift” refers to non-directional changes to the epigenome that occur 
with age.  Thus, there is in general a greater concordance of CpG methylation patterns between 
younger individuals than between older individuals.  Perhaps the most convincing example of 
epigenetic drift is in the case of monozygotic twins, in which it has been found that younger twin 
pairs are more epigenetically similar than older twin pairs as measured by methylated cytosine 
genomic content and acetylation levels of histones H3 and H4  (Fraga et al. 2005).   Lifestyle and 
the amount of lifetime spent together further contributed to epigenetic differences between 
monozygotic twins.  Such differences occurred throughout the genome in both repeat and single-
copy genes, and were correlated with gene expression.  These studies suggest that a general 
divergence of the epigenome with age is due to both environmental influences and stochastic 
errors that occur with time.  Simultaneously, certain directional changes have been observed with 
age, described by some as the “epigenetic clock”  (Jones et al. 2015).   Individual CpG sites can 
even be used to predict chronological age.  Hannum and colleagues developed a predictive 
model for apparent methylomic aging rate (AMAR) based on a set of 71 methylation markers, and 
were able to predict age with an accuracy of 91% within 4.9 years  (Hannum et al. 2013).   
Additionally, a study by Wagner and colleagues demonstrated that in blood samples, age could 
be predicted within five years from measuring DNA methylation at just three CpG sites  (Weidner 
et al. 2014).  
Directional changes can be considered in two groups, regions that lose methylation with 
age and regions that gain methylation with age.  These changes can be summarized as genome-
wide hypomethylation with specific sites susceptible to hypermethylation, particularly within CGI 
promoters  (Zampieri et al. 2015).  A study conducted by Heyn and colleagues compared DNA 
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methylomes of CD4+ T cells from a newborn and centenarian by whole genome bisulfite 
sequencing (WGBS)  (Heyn et al. 2012).  The centenarian genome was hypomethylated and less 
homogenously methylated than that of the newborn.  They found 17,930 differentially methylated 
regions (DMRs) covering 2.2% of all CpGs, and only 13% of these were hypermethylation events.    
These DMRs spanned all genomic compartments, but the majority were within intronic and 
intergenic regions, and only 10% were within promoter regions.  Further, 36% of DMRs occurred 
within lamin-associated domains (LADs).  Interestingly, several laminopathies such as 
Hutchinson-Guilford Progeria Syndrome (HGPS) are characterized by premature aging, 
suggesting a potential connection between defective nuclear lamina, aging, and the epigenomic 
landscape  (Heyn et al. 2013).  Hypermethylation events are rare but significant in the aging DNA 
methylome.  Some studies have found age-associated increases in DNA methylation to be 
preferentially located in CGIs, common in promoters, and these changes are frequently 
associated with inactivation of the corresponding gene.  Genes that undergo promoter 
hypermethylation with age are often associated with age-related disorders such as cancer and 
neurodegeneration  (Zampieri et al. 2015).   
The role of DNA methylation has been recently investigated specifically in the aging 
murine β-cell, with the hypothesis that changes in DNA methylation may contribute to the age-
related decline in proliferative capacity.  An integrative analysis was conducted of DNA 
methylation, histone modifications, gene expression and β-cell function in prepubescent and post-
fertile aged murine β-cells (Avrahami et al. 2015).  In line with other aging DNA methylome 
studies, this study demonstrated genome-wide epigenetic drift coupled with targeted changes in 
distal regulatory elements.  Epigenetic drift resulted in a leveling of the DNA methylome, while 
targeted changes were associated with cell cycle and β-cell function genes.  Indeed, this study 
identified age-related changes in Cdkn2a DNA methylation at putative distal regulatory elements 
that correlate with increased Cdkn2a expression in aged mouse β-cells.  Interestingly, these age-
related changes were associated with activation of metabolic regulators and improved β-cell 
function, challenging the current paradigm of β-cell failure as purely an aging phenomenon.  This 
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study has laid much of the groundwork for investigating epigenetic rejuvenation of aging β-cells, 
and one goal of the present work is to create a similar epigenetic aging profile for human β-cells.  
 
Strategies for modifying DNA methylation 
 A portion of this section was adapted from published work:  Bernstein DL, Le Lay JE, 
Ruano EG, Kaestner KH.  TALE-mediated epigenetic suppression of CDKN2A increases 
replication in human fibroblasts.  J Clin Invest. 2015 May;125(5):1998-2006. 
A critical consideration for pursuing epigenetic rejuvenation of adult human β-cells as a 
therapeutic strategy for diabetes is how to perturb DNA methylation in a targeted fashion.  
Epigenetic therapeutics to date are limited to small molecule inhibitors that target ubiquitously 
expressed epigenetic regulators, including DNA methyltransferases.  Thus, the entire genome, 
and the entire organism when administered systemically, is susceptible to the effects of such 
drugs.  The role for DNA methylation in establishing and maintaining functional β-cells is being 
increasingly recognized, both in a normal and diseased state, highlighting the importance of 
targeted strategies.  For example, it has recently been shown in mice that DNA methylation 
facilitates the functional maturation of postnatal β-cells  (Dhawan et al. 2015).  Further, as 
discussed, DNA methylation might play a role in enhancing β-cell function with age  (Avrahami et 
al. 2015).  On the other hand, a number of CpG susceptibility loci have connected DNA 
methylation and type 2 diabetes  (Dayeh et al. 2014).  Similarly, another study concluded that the 
promoter of the DLK1-MEG3 microRNA cluster is hypermethylated in type 2 diabetics, leading to 
decreased expression of this microRNA cluster, which regulates target genes that contribute to β-
cell apoptosis  (Kameswaran et al. 2014).  Thus, one can anticipate the potential concerns with 
modifying DNA methylation at the genome-wide level in the β-cell, necessitating the modification 
of DNA methylation in a cell-type and locus-specific manner. 
The main strategy for targeted epigenetic editing is fusion of catalytic domains of 
epigenetic modifiers to custom DNA binding proteins targeting genes of interest.  The clear 
advantage of targeted epigenetic editing over targeted transcriptional activation or repression is 
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the potential to have a more stable impact on gene expression.  Further, epigenetic modifications 
can be targeted to proximal or distal regulatory elements rather than simply promoters, which 
may be especially important in the context of aging. Current approaches include zinc fingers, 
TALEs, and clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR 
associated protein 9 (Cas9).  Zinc fingers represent one of the earliest examples of engineered 
DNA binding proteins, and have been coupled to a wide range of effector domains, including DNA 
methyltransferases, as discussed earlier.  Zinc finger DNA binding modules interact with a series 
of three base pairs, somewhat limiting potential target sequences.  Therefore, TALEs have largely 
replaced zinc fingers in these efforts since they are extremely modular, inexpensive, and quick to 
assemble.  
TALEs are DNA binding proteins endogenous to bacterial plant pathogens including the 
genus Xanthomonas.  This class of proteins binds to specific regulatory regions in the host 
genome to modulate gene expression and promote bacteria survival.  The central DNA binding 
domain of TALE proteins consists of a series of approximately 34-amino acid repeats, or 
monomers, which are polymorphic only at positions 12 and 13.  These polymorphic residues, 
termed the repeat-variable-di-residue (RVD), determine DNA binding specificity, as each amino 
acid pair preferentially binds to one of the four nucleotides  (Cermak et al. 2011).  Consequently, 
by assembling monomers in a particular order, TALEs can be engineered to bind specific DNA 
sequences.   
Customized TALEs have been used to modulate transcription through conjugation to 
activator domains, such as VP64, and repressor domains, such as the mSin interaction domain 
(SID) (Morbitzer et al. 2010; Cong et al. 2012).  More recently, TALEs have been employed to 
introduce targeted epigenetic changes such as histone demethylation, DNA methylation and DNA 
de-methylation, which have resulted in altered gene expression  (Mendenhall et al. 2013; Maeder 
et al. 2013; Bernstein et al. 2015b).  To our knowledge, we are the only group to date that has 
demonstrated a biological impact of targeted epigenetic editing, and we did so by decreasing 
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CDKN2A expression in primary human fibroblasts by targeted DNA methylation in order to 
increase proliferation  (Bernstein et al. 2015b).   
Shortly after the introduction of TALEs and TALE nucleases (TALENs), the CRISPR-
Cas9 system emerged as an exciting new tool for genomic engineering.  With this system, the 
Cas9 nuclease is guided to a target genomic DNA sequence by complementary base pair binding 
of a guide RNA (gRNA).  Progress has been made in optimizing this tool for genomic engineering 
in the past several years, and the field is now expanding into transcriptional regulation with the 
use of a catalytically deactivated, or dCas9, nuclease fused to transcriptional regulators or 
epigenetic modifiers. dCas9 has been employed for targeted epigenetic modification by fusing 
dCas9 to the p300 acetyltransferase or Kruppel-associated box (KRAB) repressor in order to 
activate and repress gene expression, respectively  (Hilton et al. 2015; Thakore et al. 2015).  The 
key potential advantage of CRISPR-Cas9 over TALEs is the flexibility in using guide RNAs rather 
than proteins for DNA targeting.  Further, it might be possible to simultaneously target multiple 
genes by using multiple gRNAs with a single Cas9 fusion protein.  However, in some instances 
multiple gRNAs are required to affect expression of a single gene, warranting further investigation 
into what facilitates sufficient targeting  (Hilton et al. 2015).  Despite differences in underlying 
mechanisms, any of these systems are subject to potential off-target effects, and improving 
specificity is an ongoing challenge in the field.  The preferred method is likely to be determined in 
a context-dependent manner.  
 
Summary 
β-cell replacement therapy holds the potential to cure diabetes, although limited sources 
of β-cells have hindered its widespread clinical application.  A key challenge in the field is that 
proliferative capacity of β-cells decreases with age, which may be caused by changes in 
epigenetic marks such as DNA methylation.  We hypothesize that age-related changes in DNA 
methylation contribute to transcriptional changes that facilitate reduced proliferative capacity in 
adult human β-cells.  There is an overwhelming need for a comprehensive landscape of the aging 
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human β-cell, and tools to modify gene expression in a targeted fashion.  The focus of this thesis 
was to develop resources for targeted DNA methylation to alter gene expression and thereby 
stimulate cell cycle progression, and to determine the methylome of the human β-cell during the 
aging process.  Chapter 2 describes the transcriptome and DNA methylome of β-cells throughout 
the human lifespan. Chapter 3 presents a novel technique of fusing custom DNA binding proteins, 
TALEs, to DNA methyltransferase catalytic domains to specifically methylate target genes and 
thereby decrease gene expression (Bernstein et al. 2015b).   p16 was selected as a target for 
validating this approach in primary human fibroblasts given the demonstrated role of p16 in 
decreased proliferative capacity of murine β-cells.  Finally, in Chapter 4, I present BisPCR2, a 
high-throughput and efficient method for targeted bisulfite next-generation sequencing (Bernstein 
et al. 2015a).   These resources may be useful in epigenetic rejuvenation of human adult β-cells, 
and in the more broad DNA methylation research community. 
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Figure 1.1.  Human β-cell proliferation during the human lifespan.  Graph illustrates 
approximate insulin and Ki67 co-positive cells as a percentage of total insulin positive cells in 
human cadaver sections across the human lifespan quantified by immunohistochemistry.  Note 
peak proliferation occurs in the early neonatal period and represents only about 2% of β-cells.  
Proliferation drops off rapidly in early childhood and is not readily detectable in adulthood.  Figure 
published in: Wang, P. et al. Diabetes mellitus-advances and challenges in human beta-cell 
proliferation. Nature Reviews Endocrinology, 2015; 11(4): 201-212. 
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Figure 1.2.  Mouse islets are not directly comparable to human islets.  (A) Comparison of 
mouse islet structure to human islet structure.  The mouse islet consists of a β-cell core 
surrounded by a mantle of other endocrine cell types, and β-cells constitute approximately 80% of 
all cells.  In the human islet, endocrine subtypes are dispersed throughout the islet, and β-cells 
make up about 50% of all cells.  (B) Key regulators in the β-cell G1/S cell cycle checkpoint.  Two 
key differences between mouse and human β-cells, identified by red text, are the presence of 
CDK6 and the absence of cyclin D2 in human β-cells.  Positive cell cycle regulators are indicated 
in blue and negative cell cycle regulators are indicated in orange.  Gray indicates epigenetic 
regulators of CDKN2A (p16). 
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Figure 1.3.  TALE-DNMT fusion proteins for targeted DNA methylation.  The repeat domain, 
or DNA binding domain, of transcription activator-like effectors (TALEs) consists of a series of 
monomers, each 34 amino acids long.  These monomers are identical in amino acid sequence 
with the exception of the amino acids at the 12th and 13th position, termed the repeat variable di-
residue (RVD), which determines which nucleotide the monomer interacts with.  The series of 
monomers thereby determine TALE DNA binding specificity.  Conjugating DNA methyltransferase 
(DNMT) catalytic domains DNMT3a and DNMT3L permits targeted DNA methylation to the 
genomic region specified by the DNA binding domain.  The amino acid RVD that preferentially 
interacts with each nucleotide is listed in the legend on the right of the diagram.  N-Term, N-
Terminus; C-Term, C-Terminus.  
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CHAPTER 2 – Profiling the human β-cell DNA methylome and transcriptome from 
birth to mature age. 
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Abstract 
 Pancreatic β-cell replacement therapy holds the potential to cure diabetes, although its 
widespread implementation has been limited due to a shortage of organ donors.  One strategy to 
increase the supply of human β-cells is to induce proliferation of pre-existing cells.  This strategy 
is hindered by the fact that proliferative capacity of human β-cells decreases with age.  We 
hypothesized that this age-dependent decline in proliferative capacity is accompanied by 
transcriptional changes that are dependent on changes in DNA methylation.  Thus, we sought to 
profile the transcriptome and DNA methylome of β-cells across the human lifespan.  We isolated 
human β-cells from 23 deceased organ donors ranging in age from three-months old to 64-years 
old and conducted RNA-Seq.  For a subset of samples we also performed whole-genome bisulfite 
sequencing (WGBS) to assess DNA methylation at single-base resolution, and integrated DNA 
methylome data with published datasets for human islet chromatin states and transcription factor 
binding.  We found that expression of key cell cycle inhibitors increases, while certain β-cell-
specific transcription factors are de-activated with age.  Further, we found that the DNA 
methylome is dynamic during human life, and that these changes occur preferentially at islet-
specific active enhancers that lose methylation with age. Future efforts will be directed towards 
integrating gene expression and DNA methylation findings in a comprehensive fashion. 
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Introduction 
Pancreatic β-cells lose the ability to proliferate with age, and restoring proliferative 
capacity in adult β-cells is an attractive therapeutic opportunity for treating diabetes.  This age-
related decline in proliferative capacity has been extensively studied in rodent model systems, 
and it has been clearly demonstrated that older β-cells do not respond as well as younger β-cells 
in β-cell injury models or in response to mitogenic stimuli  (Rankin and Kushner 2009; Tschen et 
al. 2009; Kushner 2013).  Due to challenges of working with primary human islets, human β-cell 
proliferation studies to date have largely been limited to candidate target approaches based on 
these rodent studies  (Takane et al. 2012; Fiaschi-Taesch et al. 2010; Cozar-Castellano et al. 
2004; Rieck et al. 2012).  However, important differences between rodent and human β-cell 
proliferation prevent direct translation, and thus the β-cell regeneration field is in need of a 
comprehensive profile of the aging human β-cell (Kulkarni et al. 2012).  
Since aging phenotypes are not likely the consequence of changes in DNA sequence, it 
is probable that epigenetic modifications, and in particular DNA methylation, contribute to the 
aging process  (Heyn et al. 2012; Zampieri et al. 2015; Jones et al. 2015; Avrahami et al. 2015).   
DNA methylation is defined by the addition of a methyl group most commonly to the 5C position 
of cytosine residues in the context of CpG dinucleotides.  This mark is faithfully maintained 
through subsequent rounds of DNA replication by remethylation of the newly synthesized DNA 
strand by DNA methyltransferase 1 (DNMT1), and thus has long been considered to be stable.  
However, recent studies in humans have demonstrated that DNA methylation at certain genomic 
regions, such as promoters and distal regulatory elements, is in fact dynamic during aging  (Heyn 
et al. 2012; McClay et al. 2014; Xiao et al. 2015).  
Transcriptional reprogramming mediated by changes in DNA methylation with age is one 
possible explanation for reduced proliferation in adult human β-cells.  Indeed, recent work by 
Avrahami and colleagues has demonstrated a compelling role for DNA methylation in mediating 
the decline in proliferative capacity of rodent β-cells (Avrahami et al. 2015).  This study included 
an integrative analysis of genome-wide DNA methylation, gene expression, histone modifications, 
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and β-cell-specific transcription factor binding, comparing pre-pubescent and post-fertile age 
mice.  Age-related changes in DNA methylation occurred preferentially at cell cycle regulators 
and also at important β-cell function genes, which correlated with an improvement in β-cell 
function.   
We sought to build a similar profile of the aging human β-cell to investigate changes in 
gene expression and the potential role of DNA methylation in this process.  We also sought to 
incorporate published datasets for genome-wide chromatin states and transcription factor binding 
in whole islets in order to better characterize differentially methylated regions (DMRs).  Towards 
this goal, we conducted RNA-Seq transcriptome profiling in β-cells across the human lifespan, 
ranging in age from three-months to 64-years old.  For a subset of these samples, we also 
performed whole genome shotgun bisulfite sequencing (WGBS) to profile the aging human β-cell 
methylome at single base resolution.  In the present work, we have established the 
aforementioned datasets and have begun to characterize the dynamics of DNA methylation in the 
aging human β-cell.  Ongoing efforts include integration of gene expression data and further 
analyses to determine precisely how DNA methylation contributes to the reduced proliferative 
capacity in human β-cells with age.    
 
Results 
In order to assess the contribution of DNA methylation to the age-related decline in 
human β-cell proliferation, we profiled gene expression and genome-wide DNA methylation at 
single base resolution for β-cells across the human lifespan, and incorporated published datasets 
of human whole islet chromatin states and transcription factor occupancy (Figure 2.1A).  Twenty-
three human islet samples from deceased organ donors were dispersed and FACS-sorted to 
isolate β-cells using cell surface antibodies developed by Dorrell and colleagues  (Dorrell et al. 
2008).  Genomic DNA and mRNA were extracted, and whole genome shotgun bisulfite 
sequencing (WGBS) was performed on a subset of 8 samples, while RNA-Seq was performed for 
all 23 samples (Table 2.1).  One sample, ICRH51, a four-year old donor, was determined to be a 
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putative outlier and was excluded from further analysis for both gene expression and DNA 
methylation.  WGBS samples included three young donors (6 months, 2 years and 8 years of 
age), and three old donors (47, 59, and 60 years of age).  We also included an 18-year old donor 
sample to assess a potential intermediate phenotype in our analysis, similar to the approach 
taken for the analysis of the CD4+ T cell methylome (Heyn et al. 2012).   
 
Characterization of old and young human β-cell DNA methylomes 
We first assessed global DNA methylation patterns in young and old human β-cells.  As 
anticipated, the majority of the genome in both young and old human β-cells is highly methylated, 
while promoters are largely unmethylated (Figure 2.1B).  In our WGBS analysis we applied the 
Hidden Markov Model developed by Stadler and colleagues to segment the methylome into three 
categories including fully methylated regions (FMRs) (> 50% methylation), lowly methylated 
regions (LMRs) (13.9 to 50% methylation), and unmethylated regions (< 13.9% methylation) 
(Stadler et al 2011).  We further narrowed our DNA methylome analysis to LMRs and UMRs to 
isolate potential regulatory elements such as promoters and enhancers.  We then categorized 
LMRs and UMRs for young and old β-cells by genomic elements such as proximal promoters or 
repeat elements (Figures 2.1C and 2.1D).  We found a very similar number and distribution of 
LMRs and UMRs in young and old β-cells, confirming the general uniformity in DNA methylation 
between the two groups.  
 
Differentially methylated regions between young and old human β-cells 
 After characterizing genome-wide DNA methylation in young and old human β-cells, we 
next identified differentially methylated regions (DMRs) by comparing the average methylation of 
the union of LMRs and UMRs between young and old samples.  In other words, we excluded 
from our analysis all genomic regions that are fully methylated during ontogeny, as these 
represent mostly repetitive regions and other non-dynamic genomic sequences.  Using a false 
discovery rate of 10%, a minimum of four CpGs per regions, and a minimum difference in 
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average methylation between young and old samples of 5%, we identified 1,082 DMRs, 588 of 
which lost methylation with age and 494 of which gained methylation with age (Figure 2.2A).  A 
greater average magnitude of change was observed in regions that lost methylation with age 
compared to those that gained methylation with age (Figure 2.2A).  We further grouped DMRs 
that gained or lost methylation with age by genomic region and found that the majority of DMRs 
occur in intergenic regions, regardless of the direction of change (Figure 2.2B).  DMRs at 
intergenic regions may be indicative of distal regulatory elements, such as enhancers or 
silencers, as found in several prior studies  (Stadler et al. 2011; Sheaffer et al. 2014; Avrahami et 
al. 2015).  The remainder of regions that gain methylation with age are relatively evenly 
distributed among repeats, exons, and introns, while the remainder of regions that lose 
methylation with age are mainly located within introns.  The magnitude and direction of changes 
in methylation within each genomic compartment is illustrated in Figure 2.2C, again emphasizing 
that the magnitude of change is greater in regions that lose methylation with age.  We also 
conducted a clustering analysis of DMRs across all seven WGBS samples and found that while 
the extreme old and young ages were quite similar to each other, the 18-year old donor sample 
showed an intermediate pattern, suggesting changes in DNA methylation occur gradually over 
the human lifespan (Figure 2.2D).     
 
LMRs and UMRs correlate with human islet regulatory regions 
Next, we focused our analysis on LMRs and UMRs because of their high likelihood of 
being regulatory regions.  We wanted to further interrogate this possibility by incorporating 
published datasets of chromatin states in human islets.  Pasquali and colleagues have 
assembled a profile of human islet regulatory regions by integrating open chromatin maps with 
key histone marks, CTCF binding sites, and islet-specific transcription factor binding sites  
(Pasquali et al. 2014).  Open chromatin sites were first determined by FAIRE-Seq in combination 
with ChIP-Seq for histone 2A.Z (H2A.Z).  Histone marks assessed include histone 3 lysine 4 
monomethylation (H3K4me1), histone 3 lysine 4 trimethylation (H3K4me3), and acetylation of 
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histone H3 at lysine 27 (H3K27ac).  Based on these datasets, Pasquali and colleagues defined 
five classes of regulatory regions, including promoters (C1), inactive enhancers (C2), active 
enhancers (C3), CCCTC-Binding Factor (CTCF) bound sites (C4), and other accessible 
chromatin sites (C5).  One key finding of this study was that active enhancers (C3) determine 
expression of islet-specific genes, and are preferentially bound by islet-specific transcription 
factors.  We investigated whether DNA methylation levels correlated with these regulatory 
regions, and whether DMRs specifically were enriched for any given category, such as active 
enhancers (C3).  
We first performed hierarchical clustering analysis of our LMR/UMR regions and each of 
the promoter (C1), inactive enhancer (C2), and active enhancer (C3) accessible chromatin sites, 
requiring that the center of the chromatin element defined by Pasquali and colleagues be 
contained within a UMR or LMR (Figure 2.3A, 2.3B and 2.3C).  We found that 11,654 
UMRs/LMRs overlapped with C1 sites, and that DNA methylation is largely unchanged across 
these sites with age (Figure 2.3A).  At inactive enhancers, 12,482 LMRs/UMRs overlapped with 
C2 sites, and there was an overall trend of decreased methylation with age.  This loss of DNA 
methylation with age was even more pronounced in active enhancers, in which 18,076 
LMRs/UMRs overlapped with C3 sites.  The magnitude of demethylation, here represented by a 
change in color, was larger for active than for inactive enhancers. 
We next determined how the C1-C5 regions overlapped with our LMR/UMR set.  We 
found that there was a highly significant preferential overlap of the C1-C4 accessible chromatin 
sites with LMRs/UMRs compared to the random genomic background defined by a set of 1,000 
randomly selected genes (p-value < 10-10) (Figure 2.3D).  Nearly all promoter (C1) regions were 
identified as an LMR/UMR, confirming that low levels of DNA methylation correlate with promoter-
associated histone marks.  Further, this finding also suggests that chromatin states at promoters 
are similar between sorted β-cells (our data) and whole islets, which is not surprising given the 
highly similar chromatin states of the two most abundant endocrine cell types, the α- and β-cell  
(Pasquali et al. 2014; Bramswig et al. 2013).  Similarly, roughly 90% of CTCF-bound (C4) regions 
35	  
	  
overlapped with LMR/UMRs, which is also expected since DNA methylation inhibits CTCF-
binding  (Phillips and Corces 2009; Wang et al. 2012).  Approximately 50% of inactive enhancer 
(C2) sites and 75% of active enhancer (C3) sites were identified as LMRs/UMRs.  It makes sense 
that only half of inactive enhancers (C2) were identified as LMRs or UMRs, since they may be 
more likely to be highly methylated (FMRs).  Following the same logic, it is also reasonable that a 
greater portion of active enhancer (C3) sites overlap with LMRs and UMRs.  Further, we and 
others, have shown that distal regulatory elements, such as enhancers, are critical in cell-type 
specific gene expression  (Stadler et al. 2011; Sheaffer et al. 2014; Avrahami et al. 2015).  
Differences in cell types may account for further differences between DNA methylation and 
chromatin state.    
 
Islet-specific active enhancers lose methylation with age 
 Having identified over 1,000 regions that show dynamic DNA methylation with age, we 
wanted to investigate chromatin state at DMRs to better understand if certain classes of 
regulatory regions are enriched.  We overlapped DMRs with C1-C5 open chromatin sites and 
found that slightly less than half of the DMRs were also classified as one of these five regions, the 
most common being enhancers (C2 and C3) (Figures 2.3E and 2.3F).  Since at this point we 
have narrowed down our analysis to age-related changes in DNA methylation in the β-cell, it is 
possible that the remaining DMRs are β-cell-specific and thus may not have been identified in the 
study of whole islets.  This set of regions will need to be analyzed independently.  The most 
prominent groups amongst the C1-C5 overlapping regions were active enhancers that lose 
methylation with age (207 regions) and inactive enhancers that gain methylation with age (73 
regions) (Figure 2.3G).  Demethylation of putative distal regulatory elements has been previously 
reported in the aging murine β-cell, and it will be interesting to investigate this group of regions in 
further detail  (Avrahami et al. 2015).  
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Identifying age-related patterns in gene expression  
Because our data represent a continuum of age, rather than two distinct classes of 
“young” and “old” β-cells, as was done for the murine aging study, we attempted a time course 
analysis of gene expression versus age (Figure 2.4).  Our goal was to use this time course 
analysis to identify critical regulators of proliferative capacity, and then to overlap this gene set 
with DMRs to elucidate a role for DNA methylation in regulating the aging process.  We decided 
to conduct regression analyses with both linear and log-linear models.  Unfortunately, our RNA-
Seq datasets were collected over a period of more than five years, and changes in RNA-Seq 
library preparation chemistry made by Illumina led to significant batch effects.  Thus, the datasets 
were subject to multiple layers of normalization.   
Nevertheless, the most significant gene expression of which increased with age in a 
linear fashion was CDKN2A, which encodes the cell cycle inhibitor p16, and is strongly implicated 
in the age-related decline in proliferative capacity in murine β-cells  (Krishnamurthy et al. 2006).   
We also found mRNA levels of another cell cycle inhibitor, CDKN2C (p18), to increase 
significantly with age, but in a log-linear fashion.  Further, amongst the genes that are down-
regulated with age are three β-cell-specific transcription factors, HNF4α, ISL1 and PDX1.  
Genetic variants of each of these genes have been associated with diabetes, and these 
transcription factors have been associated with proliferation and may interact with cell cycle 
machinery  (Bernardo et al. 2008; Yamagata 2014; Guo et al. 2011).   This linear regression 
analysis is useful in identifying a subset of genes that change in an age-related fashion, but 
importantly, it omits other possibilities such as step-wise changes.  Of these genes of interest, 
only CDKN2A is associated with DMRs, suggesting that the expression data should also be 
analyzed independently from DNA methylation.      
 
Discussion 
Here, we report 23 RNA-Seq and 7 WGBS datasets for β-cells throughout the human 
lifespan.  We began our analysis with a comparison of DNA methylation in young and old human 
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β-cells.  As identical cell types, until five years ago the dogma predicted that the DNA 
methylomes of young and old human β-cells are identical, because DNA methyltransferase 1 
faithfully remethylates the hemi-methylated DNA during and after S-phase.  Remarkably, we 
observed over 1,000 significant changes with age, which we argue are there by design, as they 
are not distributed randomly over the whole genome, but rather localized to specific regulatory 
elements.   
When the DNA methylome had been analyzed during murine aging β-cell, it was found 
that differentially methylated regions that lose methylation with aging were highly enriched for 
binding of β-cell transcription factors such as Pdx1, leading to the hypothesis that transcription 
factor binding in young β-cells marks specific regions for eventual demethylation (Avrahami et al. 
2015).   Therefore, we will further characterize these regions for transcription factor binding by 
motif analysis and by integrating whole islet transcription factor binding maps in the future.  It will 
also be interesting to investigate those DMRs (approximately 50%) that did not overlap with 
previously reported islet regulatory regions.  One obvious explanation is that these DMRs are β-
cell-specific and therefore were not identified in the whole islet approach.  A comparison of DNA 
methylation in α-cells at a subset of these regions might confirm whether or not they are β-cell-
specific.  These DMRs could also fall in genomic compartments not represented in the C1-C5 
regions, such as repeats or exons.  Nevertheless, active enhancers are a particularly exciting 
starting point for future analyses.   
The critical outstanding component of our analysis is the integration of our gene 
expression with our DNA methylation data.  We plan to approach this in multiple ways.  First, we 
will continue to pursue the time course analysis to identify genes that behave similarly in the 
aging process.  Due to the technical challenges we have encountered with this approach, we will 
also conduct a traditional two-state differential expression analysis of the extreme samples.  A 
third strategy is to categorize samples into age groups including pre-pubescent, pubescent, 
young adult and adult.  This third strategy may be preferred since it incorporates the principles of 
a time course analysis while permitting replicates and therefore greater statistical power. 
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A key challenge in assessing genome-wide DNA methylation is associating differentially 
methylated regions with genes.  The DNA methylome field has adopted a standard of assigning 
genes based on the relative position of DMRs to the nearest transcription start site (TSS).  While 
this strategy has led to useful insights about transcriptional regulation by DNA methylation, it is 
also likely to result in many mis-assigned DMR/gene relationships, as enhancers in particular are 
subject to chromatin looping interactions and can regulate promoters more than a million bases 
distal.  Thus, the closest gene may not be the only possible gene affected by a DMR.  For 
example, an enhancer located in an intron at the microRNA cluster MEG3 locus in human islets 
interacts not only with the MEG3 promoter, but also with the promoter of the protein-coding gene 
DLK1, and a second islet enhancer cluster that are each roughly 100 kb from the enhancer itself 
(personal communication with Vasumathi Kameswaran).  
We have made significant progress in building datasets that will lay the foundation for the 
aging human β-cell epigenome and transcriptome atlas.  We have profiled gene expression 
across the human lifespan, which can be used to assess changes in receptors, signaling 
pathways, and the cell cycle machinery that may lead to declined proliferative capacity in adult 
human β-cells.  We have also determined the DNA methylome of young and old human β-cells to 
begin to understand the potential role of DNA methylation in the aging process.  While we have 
started to characterize age-related changes in DNA methylation, much work remains to be done 
to understand transcriptional reprogramming in aging human β-cells and the precise mechanism 
by which DNA methylation may contribute. 
 
Methods 
Human β-cell isolation 
Islets from deceased organ donors were obtained from either the Diabetes Research 
Center of the University of Pennsylvania or the Integrated Islet Distribution Program (IIDP).  
Human β-cells were isolated from whole islets using fluorescence-activated cell sorting (FACS) 
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with cell surface antibodies developed by Dorrell and colleagues (Dorrell et al. 2008).   Genomic 
DNA and mRNA were extracted with the AllPrep DNA/RNA kit (Qiagen GmbH). 
 
RNA-Seq 
RNA-Seq libraries were prepared by the Next Generation Sequencing Core (NGSC) at 
the University of Pennsylvania (Philadelphia, PA) using the Ribo-Zero™ H/M/R Kit (6rxns) (Cat. 
No. MRZH116) with TruSeq™ RNA Sample Prep Kit, (Cat. No. RS-122-2001), and then TruSeq® 
Stranded Total RNA LT, cat #RS-122-2301 when the unstranded kit was discontinued in 2014.  
Sequencing and alignment were also performed by the Next Generation Sequencing Core 
(NGSC) at the University of Pennsylvania (Philadelphia, PA) as previously described except that 
sequences were aligned to the hg19 genome (Bramswig et al. 2013).  
 Linear and log-linear regression analyses were performed by the lab of Dr. Kyoung-Jae 
Won at the University of Pennsylvania (Philadelphia, PA).  Genes were initially selected for a 
minimum FPKM (fragments per kb per million) greater than 0.5 in at least six samples and a 
minimum fold-change greater than two between minimum and maximum samples.  Additional 
gene filtering was applied to remove exocrine-specific genes, which represent contamination 
(Bramswig et al 2013), and Chromosome Y genes to prevent gender bias.  RNA-Seq libraries 
were prepared with two slightly different kits, and thus batch effect correction was applied to each 
batch independently, which was possible because each batch contained an even distribution of 
ages.  Loess normalization was then applied, and finally the linear regression analysis was 
conducted using the lm() function in R. 
 
Whole-genome shotgun bisulfite sequencing (WGBS) 
 WGBS libraries were prepared using the Ovation® Ultralow Methyl-Seq Library Systems 
(NuGEN Technologies Inc.) per manufacturer’s instructions.  150ng of genomic DNA was 
sonicated using the M220 Focused-ultrasonicator™ (Covaris®) to shear DNA into approximately 
400 base pair fragments.  The Ovation® system was then used for end repair, ligation of 
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adaptors, and final repair steps.  Next, samples were subjected to bisulfite conversion and 
purification with the EpiTect Fast DNA Bisulfite Kit (Qiagen GmbH).  Bisulfite conversion was 
conducted under the cycling conditions recommended in the Ovation® Ultralow Methyl-Seq 
Library procedure.  Converted libraries were amplified, purified, and pooled for next generation 
sequencing (NGS).  Sequencing and DNA methylation analyses were performed by the Next 
Generation Sequencing Core at the University of Pennsylvania (Philadelphia, PA).  Sequences 
were aligned to the human (hg19) genome using BSeeker (Chen et al 2010). Average coverage 
was greater than 15X per CpG for each sample.  Segmentation of the methylome was conducted 
as previously described (Avrahami et al 2015).  To identify differentially methylated regions 
(DMRs), average DNA methylation was calculated among the three young or the three old 
samples for each CpG in a segment, and then average methylation was calculated across the 
segment.  Only CpGs with more than 10 reads for each sample were considered, and segments 
required a minimum of four CpGs.  Average methylation for each segment was compared by a 
two-tailed unpaired t-test (p-value < 0.05), and regions with a change greater than 5% were 
determined to be differentially methylated.  Analysis of these datasets was performed in 
collaboration with Dr. Kyoung-Jae Won’s lab and the Next Generation Sequencing Core (NGSC) 
at the University of Pennsylvania (Philadelphia, PA).   
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Table 2.1.  Human islet donor information. 
 
  
ID# Age#(yrs)# Sex# BMI# RNA2Seq##(old#kit)#
RNA2Seq##
(new#kit)# WGBS#
ACFU423( 3(mo( F( NA( ! 
ICRH53( 6(mo( F( 14.2( ! ! ! 
ICRH80( 19(mo( F( 18( ! 
ICRH76( 2( M( 13.6( ! ! 
ICRH51( 4( F( 16.1( ! ! 
ICRH59( 8( M( NA( ! ! 
CITH86( 10( F( NA( ! 
ICRH46( 14( M( 27.1( ! 
ICRH75( 17( F( 22.6( ! 
ICRH52( 18( M( NA( ! ! 
AAHP353( 19( M( 26.9( ! 
HP:15031:01( 23( F( 32.5( ! 
ICRH41( 28( M( 24.2( ! 
ICRH57( 40( M( NA( ! 
ICRH25( 47( M( 28.3( ! 
ABEL98( 47( F( 26.5( ! ! 
CITH53( 49( F( NA( ! ! 
ICRH39( 50( M( 29.1( ! 
CITH68( 52( M( NA( ! ! 
AAA1323( 53( F( 28.4( ! 
ACFC227( 59( F( 23.1( ! ! 
ABEF248( 60( F( 34.5( ! ! ! 
AAAL88( 64( M( 25.4( ! 
42	  
	  
 
Figure 2.1. Determination of the DNA methylome in young and old human β-cells.  (A) 
Experimental schema for assessing the role of DNA methylation in the human β-cell during the 
aging process. RNA-Seq and whole genome shotgun bisulfite sequencing (WGBS) were 
performed on young and old sorted human β-cells to identify differentially methylated regions 
(DMRs) that might contribute to changes in transcriptional regulation with age.  DMRs were 
further characterized by integrating published datasets on chromatin state and islet-specific 
transcription factor binding sites obtained from whole islets, distinguished by grey outlines 
(Pasquali et al 2014).  (B) Genome-wide distribution of CpG methylation in young and old human 
β-cells.  In young and old human β-cells, the entire genome is largely methylated, with the 
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exception of proximal promoters and 5’ untranslated regions (UTRs), as expected.  mCpG, 
methylated CpGs.  Genomic regions were defined as: distal, -1 kb to -5 kb from TSS; proximal, 0 
to -1 kb from the TSS; caudal, +5 kb from the end of the 3’ UTR. (C) Genome-wide distribution of 
unmethylated regions (UMRs) and lowly methylated regions (LMRs) in young human β-cells.  Pie 
chart on the left shows the genomic distribution of regions analyzed.  The total numbers of 
regions identified are listed below each pie chart.  Averages were calculated for each genomic 
region across the three young samples.  The color legend is the same as in (B).  (D) Genome-
wide distribution of UMRs and LMRs in old β-cells.  Data displayed as in (C).  
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Figure 2.2. The DNA methylome is dynamic with aging in the human β-cell. (A) Comparison 
of DNA methylation between young and old human β-cells at differentially methylated regions 
(DMRs).  Slightly more regions lose methylation with age (N=588) than gain methylation with age 
(N=494), and the magnitude of changes is greater in regions that lose methylation with age.  (B) 
Genomic distribution of DMRs that gain or lose methylation with age, in comparison to all DMRs.  
(C) Violin plots illustrating the magnitude and direction of changes in DNA methylation that occur 
at each DMR, grouped by genomic region.  (D) Hierarchical clustering analysis depicting the 
methylation state in each DMR for seven WGBS samples.  The extreme old and young samples 
are most similar to each other, while the 18 year-old sample shows an intermediate pattern.  
Donor age is indicated at the bottom of the heatmap.   
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Figure 2.3. Differentially methylated regions occur preferentially at islet regulatory 
elements.  DNA methylome data were compared to whole islet regulatory regions, as defined by 
Pasquali and colleagues (Pasquali et al. 2014).   Regions were defined as: C1, promoters; C2, 
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inactive enhancers; C3, active enhancers; C4, CTCF-bound sites; C5, other.  (A-D) Comparison 
of all UMRs and LMRs (potential regulatory regions) to whole islet regulatory regions.  (A) 
Hierarchical clustering analysis of percent CpG methylation of β-cell UMRs and LMRs that 
overlap with promoter (C1) regions.  Sample donor ages are displayed at the bottom of the 
heatmap.  Promoter (C1) regions are largely unmethlyated across all ages.  Note the scale 
ranges from 0-20% CpG methylation.  (B) Hierarchical clustering analysis of UMR and LMR 
overlap with inactive enhancer (C2) regions.  Data displayed as in (B) except that the scale 
ranges from 0-70%.  (C) Hierarchical clustering analysis of UMR and LMR overlap with active 
enhancer (C3) regions.  Data displayed as in (B).  (D) Percentage overlap of C1-C5 regions with 
UMRs and LMRs as compared to random genomic background (BG). (***p-value < 10-10, chi-
square test).  (E-G) Comparison of significant differentially methylated regions to whole islet 
regulatory regions.  (E) Pie charts of DMRs that gain or lose methylation with age illustrating the 
fraction of overlap with each whole islet regulatory region.  (F) Table displaying the number of 
DMRs that lost or gained methylation with age that overlap with each regulatory region.  Note the 
most prominent group is active enhancer (C3) regions that lose methylation with age.  (G) 
Comparison of percentage of DMRs that lose or gain methylation with age for C1-C3 regions.  
Active enhancers (C3) significantly tend to lose methylation with age, while inactive enhancers 
(C2) significantly tend to gain methylation with age. (*p-value < 0.05; **p-value < 10-3; ***p-value 
< 10-10, chi-square test).   
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Figure 2.4.  Gene expression changes with age in the human β-cell.  Hierarchical clustering 
analysis of genes that displayed significant changes in expression in either linear or log-linear 
fashion as a function of age in human β-cells.  See methods section for detailed description of 
regression analyses.  Donor ages are indicated at the bottom, and the number of genes in each 
category is listed in parentheses.  Samples in blue font are technical replicates prepared with two 
different RNA-Seq kits.  In instances where genes significantly changed in both linear and log-
linear manners, the gene was included in the model for which the p-value was lower.  (p-value < 
0.01). 
Log  
linear"
Simple  
linear"
Down 
(149)"
Up"
(154)"
"
Down (19)"
"
Up"
(85)"
1.5"
−1.5"
3m
o"
6m
o"
19
m
o" 2" 4" 8" 10
"
14
"
18
"
28
"
17
"
19
"
40
"
47
"
47
"
49
"
50
"
23
"
52
"
53
"
59
"
60
"
64
"
6m
o" 60
"
48	  
	  
 
Figure 2.5. Expression of cell cycle regulators and β-cell transcription factors change with 
age in opposite directions.  (A) Plots displaying expression as a function of age for two cell 
cycle regulators, CDKN2A (p16) and CDKN2C (p18) that are significantly increased with age.  
CDKN2A (p16) increases linearly with age, while CDKN2C (p18) increases in a log-linear manner 
(p-value < 0.01). FPKM, fragments per kilobase of transcript per million mapped reads.  (B) Plots 
displayed as in (A) for β-cell-specific transcription factors that decrease in expression with a 
function of age.  HNF4α and ISL1 decrease in a log-linear manner, while PDX1 decreases in a 
linear manner. 
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CHAPTER 3 - TALE-mediated epigenetic suppression of CDKN2A increases 
replication in human fibroblasts 
 
Adapted from published work: 
Bernstein DL, Le Lay JE, Ruano EG, Kaestner KH.  TALE-mediated epigenetic 
suppression of CDKN2A increases replication in human fibroblasts.  J Clin Invest. 2015 
May;125(5):1998-2006. 
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Abstract 
Current epigenetic therapeutics target ubiquitously expressed epigenetic regulators, 
meaning that controlling specific genes in selected cell types is impossible.  Thus, there is an 
overwhelming need to develop tools for targeted epigenetic modifications, and strategies to more 
efficiently correct aberrant gene expression in disease.  Towards this goal, we have developed a 
novel methodology for directing DNA methylation to specific gene loci by conjugating catalytic 
domains of DNA methyltransferases (DNMTs) to engineered transcription activator-like effectors 
(TALEs).  We demonstrate that these TALE-DNMTs direct DNA methylation specifically to the 
targeted gene locus in human cells.  Further, we show that minimizing direct nucleotide sequence 
repeats within the TALE moiety permits efficient lentivirus transduction, and thus easy targeting of 
primary cell types.  Finally, we demonstrate that directed DNA methylation of the CDNK2A locus, 
encoding the cyclin-dependent kinase inhibitor p16, results in decreased CDKN2A expression 
and increased replication of primary human fibroblasts, as intended.  This phenotypic change of 
the cells was reversed by overexpression of p16 cDNA, demonstrating the specificity of our 
epigenetic targeting. This improved technology will greatly expand the potential application of 
locus-specific epigenetic therapeutics.  
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Introduction 
Epigenetic modifications are a major determinant of gene expression programs, and 
inappropriate changes in these modifications can lead to a wide spectrum of diseases.  Cancer is 
perhaps the most widely recognized disease area associated with aberrant epigenetic changes, 
and more recently epigenetic changes have been implicated in neurological, metabolic, and 
cardiovascular diseases (Heerboth et al. 2014).  These modifications are known to be reversible, 
making them attractive drug targets. To date, clinicians have relied exclusively on general 
inhibitors of globally expressed epigenetic regulators, which are responsible for maintaining 
integrity of the entire genome (Cacabelos 2014).  Thus, unintended effects of such epigenetic 
inhibitors may be particularly pervasive and deleterious.  Therefore, there is a need for novel tools 
for interrogating specific epigenetic changes in the laboratory to enable novel therapeutic 
strategies.   
DNA methylation has emerged as an important mechanism governing cellular 
reprogramming processes such as cell differentiation, cellular senescence, and disease.  In 
mammalian cells, DNA methylation is most abundant on cytosine residues in the context of 
cytosine guanine dinucleotides, or CpG’s, and when occurring at enhancers and promoters, is 
frequently associated with gene repression (Jones 2012).  DNA methylation patterns are 
established by the de novo DNA methyltransferases, DNMT3a and DNMT3b, and propagated 
across cell divisions by the maintenance DNA methyltransferase, DNMT1 (Bergman and Cedar 
2013; Sheaffer et al. 2014). 
In an experimental or therapeutic setting, targeted de novo DNA methylation may be 
accomplished by tethering the catalytic domain of a DNA methyltransferase (DNMT) to DNA 
binding proteins designed to bind specific gene loci, thereby affecting gene expression.  Siddique 
and colleagues have pioneered this strategy by fusing DNMT catalytic subunits to an artificial zinc 
finger protein targeting the promoter of vascular endothelial cell growth factor A (VEGF-A) in a 
human cancer cell line, SOKV3 (Siddique et al. 2013).  However, challenges in designing artificial 
zinc fingers have limited the widespread use of this technology (Bogdanove and Voytas 2011).  
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Transcription activator-like effectors (TALEs) are a newer technology that is extremely modular, 
easy to assemble, and therefore a more efficient choice for targeted epigenome editing.  
The potential for implementing TALEs to direct targeted epigenetic modifications has 
become increasingly recognized, as shown in recent studies targeting DNA and histone 
demethylation (Maeder et al. 2013; Mendenhall et al. 2013).  However, this approach has not yet 
been used to repress gene expression by targeted DNA methylation.  A key hurdle in widespread 
use of TALEs is that they are incompatible with lentivirus technology, a common approach in 
stable transmission of genes into host genomes, particularly with primary cells.  The highly 
repetitive sequences of the TALE modules have a strong tendency to recombine, and we 
addressed this issue by reengineering the TALE repeat moieties to minimize direct DNA repeats 
without altering the coding sequence (Holkers et al. 2013).  
Our primary target for development of this novel “TALE-DNMT” strategy was the cell 
cycle inhibitor, p16, which is encoded by the CDKN2A gene (Figure 3.1A).  p16 is a universal 
regulator of cellular senescence, and CDKN2A was found to be the most common locus 
associated with age-related disease in a meta-analysis of GWAS conducted by Jeck and 
colleagues (Martin et al. 2014; Jeck et al. 2012).  Prior studies have shown that CDKN2A is 
regulated by DNA methylation, and decreasing p16 levels might aid in coaxing terminally 
differentiated cells back into the cell cycle, allowing for cell expansion for experimental or cell 
therapy uses (Herman et al. 1995; Krishnamurthy et al. 2006).  
Thus, we sought to target DNA methylation to the p16 (CDKN2A) locus using lentiviral 
delivery of TALE-DNMT fusion proteins to repress gene expression and thereby increase cellular 
proliferation.  We also characterized the specificity of TALE-mediated epigenetic modifications, 
which to date has not been reported.  Here, we show that epigenetic targeting of a single locus 
can indeed alter its gene expression and cellular functions without appreciable “off target” effects, 
thus demonstrating that the phenotype of primary human cells can be altered using epigenetic 
tools. 
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Results 
Custom TALE-DNMT fusion proteins direct DNA methylation to target loci 
Sanjana and colleagues have described a protocol for assembly of custom TALEs using 
monomer templates and TALE cloning backbones (Sanjana et al. 2012).  We modified these 
TALE constructs by conjugating a DNA methyltransferase catalytic subunit consisting of the C-
termini of DNMT3a and DNMT3L to the C-terminus of the TALE protein  (Siddique et al. 2013).   
The cloning backbone contains eGFP and was further modified to include a 3x Flag-tag, which 
we employed for cell sorting and protein detection, respectively.  We also constructed a 
catalytically inactive TALE-DNMT as a negative control by introducing a point mutation in the 
DNMT3a subunit at the E752A position (Rivenbark et al. 2012). TALE monomers were 
assembled into the backbone-cloning vector through a series of Golden Gate digestion-ligation 
reactions (Sanjana et al. 2012). Following this protocol, we constructed TALE-DNMTs targeting 
24-base pair sequences within the CDKN2A promoter (Kent et al. 2002).  The TALE-DNMT 
illustrated in Figure 3.1B is engineered to bind the target sequence 5’-
CCTCCTTCCTTGCCAACGCTGGCT-3’, at position -28 to -4 upstream of the p16 (CDKN2A) 
transcription start site.   
To test our strategy, we transfected HeLa cells, a human cervical adenocarcinoma cell 
line, with p16 TALE-DNMT wild-type and mutant expression constructs and compared DNA 
methylation of the CDKN2A locus between the two transfected populations, and also to untreated 
HeLa cells.  Cells were collected 48 hours post-transfection, and FACS-sorted for GFP to isolate 
transfected populations.  Average transfection efficiency was 12.1% and 14.6% for the wild-type 
and mutant constructs, respectively.  DNA methylation was then evaluated using bisulfite 
conversion of genomic DNA followed by PCR amplification and high throughput sequencing.  
Strikingly, we found that transfection of a single TALE-DNMT construct is sufficient to dramatically 
alter DNA methylation across the entire CpG island within the CDKN2A promoter (Figure 3.1C).  
DNA methylation was significantly elevated in the p16 TALE-DNMT GFP positive cells compared 
to both mutant GFP positive and untreated cells (P < 0.0001).  On average, DNA methylation 
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increased by 17% across the entire CpG island, and by as much as 66.5% at individual CpGs 
when comparing wild-type and mutant transfected populations (Figure 3.1C).  There was no 
difference between p16 TALE-DNMT mutant transfected and untreated populations, confirming 
that the E752A mutation completely eliminates the catalytic activity of the enzyme. 
Despite the dramatic increase in DNA methylation at the CDKN2A promoter, p16 
expression decreased by only a small amount in p16 TALE-DNMT wild-type transfected HeLa 
cells compared to mutant and uninfected populations (data not shown).  This is likely due to the 
fact that p16 expression is often upregulated in cervical cancers, and may be subject to aberrant 
regulatory mechanisms in these transformed cells (Ivanova et al. 2007; McLaughlin-Drubin et al. 
2013).  Thus, we hypothesized that a primary human cell line might be a more suitable system to 
study functionality at this particular target.  
 
Minimizing direct repeats in TALE modules permits lentiviral delivery  
We next considered alternate strategies for gene delivery that might be more suitable to 
targeting primary human cells, which are often difficult to transfect even ex vivo.  Lentiviral 
vectors provide an efficient method for stably introducing genes into host genomes of multiple cell 
types.  However, standard TALE technology is incompatible with lentiviral delivery due to the 
large number of tandem repeats in the TALE moiety that lead to sequence loss by DNA 
recombination (Holkers et al. 2013).  In order to promote efficient integration of intact TALEs into 
host genomes using lentivirus, we utilized the degeneracy of the genetic code to minimize direct 
repeats across the TALE DNA binding domain to build “jumbled” TALE-DNMTs (jTALE-DNMTs), 
similar to the strategy pursued by Yang and colleagues (Yang et al. 2013).  Furthermore, in order 
to accommodate the size limitation of the lentiviral genome, we made several modifications to the 
TALE-DNMT constructs by decreasing the number of repeats from 24 to 18, such that the revised 
TALE targets the sequence 5’-TCCTTGCCAACGCTGGCT-3’. We also truncated the promoter 
and removed the eGFP sequence.      
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We prepared lentivirus for wild-type and mutant p16 jTALE-DNMT constructs and tested 
their functionality in HeLa cells.  Western blots confirmed that full-length jTALE-DNMT protein 
was indeed produced following infection (Figure 3.2A).  In order to demonstrate that the entire, 
un-recombined jumbled TALE repeat moiety was integrated into the host genome, we PCR- 
amplified the repeat region from genomic DNA of transduced cells.  We also amplified the jTALE 
repeat region from cDNA to determine that the full-length repeat region was transcribed (Figure 
3.2B).  Together, these assays confirmed integration and expression of full-length TALE 
constructs.  We then established that p16 jTALE-DNMT lentiviruses target CpG methylation at the 
CDKN2A locus, with an average increase of 13.8% in the p16 jTALE-DNMT infected population 
compared to the mutant (Figure 3.2C).  The lesser extent of DNA methylation in the lentivirus 
infections compared to transfected cells is likely due to the fact that cells could not be sorted into 
infected populations. These data demonstrate convincingly that jumbled TALE repeats can be 
administered stably using lentiviral vectors, removing a significant obstacle for wide-spread 
application of the TALE technology.   
 
Targeted DNA methylation in primary human cells results in decreased gene expression of 
the target gene 
Having successfully developed jTALE-DNMTs for lentiviral delivery, we next tested if 
TALE-DNMTs can methylate the p16 (CDKN2A) locus in primary human fibroblasts.  After 
infection with wild-type and mutant p16 jTALE-DNMT constructs, DNA methylation was again 
evaluated by sodium bisulfite conversion followed by PCR amplification and high throughput 
sequencing.  Average DNA methylation was significantly increased by approximately 10% across 
the CDKN2A CpG island when comparing fibroblasts infected with wild-type and mutant p16 
jTALE-DNMTs (P < 0.005), with several CpGs showing increases in methylation of 30 to 50% 
(Figure 3.3A). To evaluate the functional consequence of increased CpG methylation at this 
locus, we measured p16 mRNA levels and found an approximately 50% decrease in p16 mRNA 
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levels in p16 jTALE-DNMT infected fibroblasts relative to mutant infected fibroblasts (P < 0.05) 
(Figure 3.3B).   
To further characterize the effects of the p16 TALE-DNMT locally and genome-wide, we 
measured DNA methylation at the two other CpG islands within the p16 (CDKN2A) locus, and at 
β-actin, a housekeeping gene located on a different chromosome (Figure 3.3C).  Interestingly, we 
found that the effect of the TALE-DNMT on average DNA methylation decreased with distance 
from the transcription start site at the p16 (CDKN2A) locus, as DNA methylation increased 
significantly by 6% at CGI2, but not significantly at CGI3.  The β-actin locus on chromosome 7 
was completely unaffected.   
Given the increase in DNA methylation observed at the adjacent CpG island, we 
considered the possibility that other nearby genes might display altered levels of DNA methylation 
(Figure 3.3D).  Indeed, we measured increased methylation in several genes adjacent to p16 
(CDKN2A), including p14ARF, another transcript within the CDKN2A locus, CDKN2B, and MTAP.  
No changes were observed in IFNE.  We next measured mRNA levels at these genes to 
determine the functional consequence of the increased DNA methylation and observed no 
changes in the mRNA levels of CDKN2B, or MTAP and IFNE (Figure 3.3E).  We also analyzed 
expression of the three other transcripts at the CDKN2A locus and did not observe a significant 
change in expression of p14ARF (Figure 3.3E), while p12 and p16γ, were not detectable by 
qPCR in human fibroblasts. 
In order to validate the broad applicability of the TALE-DNMT strategy, we also tested the 
p16 TALE-DNMT lentiviruses in primary human coronary artery smooth muscle cells (hCASMCs), 
and showed that p16 jTALE-DNMT wild-type infected cells had increased DNA methylation and a 
corresponding decrease in p16 (CDKN2A) expression compared to mutant infected cells (Figure 
3.4).  As further validation of our strategy we also designed a new p16 TALE-DNMT targeted to 
the p16 (CDKN2A) promoter 118 to 136 base pairs upstream from the transcription start site (5’-
TAACAGAGTGAACGCACT-3’).  This additional TALE-DNMT, p16 TALE-DNMT.2, also 
increased DNA methylation and led to even stronger repression of p16 transcription when 
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comparing wild-type and mutant infected cells (Figure 3.5).  Remarkably, this stronger gene 
repression was associated with fewer affected CpGs, suggesting that specific CpGs are more 
relevant than others.   In sum, the overall TALE-DNMT strategy can be extended to multiple 
primary human cell types and multiple target DNA binding sites. 
 
DNA methylation of the p16 (CDKN2A) locus results in increased replication in primary 
human cells 
Our goal in decreasing p16 expression is to more readily permit entry into the cell cycle.   
Therefore, we next evaluated rates of DNA replication in primary human fibroblasts infected with 
wild-type and mutant p16 jTALE-DNMTs.  Following infection and subsequent incubation for 72 
hours, we measured incorporation of the thymidine analogue 5-ethynyl-2’-deoxyuridine (EdU) by 
immunofluorescence staining after a 60-minute incubation period.  p16 jTALE-DNMTs increased 
DNA replication by nearly two-fold in the wild-type compared to mutant infected populations 
(Figures 3.6A and 3.6B). In order to confirm that the altered proliferation observed in p16 jTALE-
DNMT-transduced human fibroblasts was specifically due to suppression of p16 transcription, 
and not some unknown off-target effect, we restored p16 levels by co-infection with a lentivirus 
driving p16 expression under control of the CMV promoter. As shown in Figure 3.6B, re-
expression of p16 completely ablated the pro-proliferative effect of p16 jTALE-DNMT activity, 
providing strong evidence that increased replication in human fibroblasts was indeed caused by 
reduced p16 levels.  Since p16 mediates progression through the G1 phase of the cell cycle, we 
also wanted to confirm that increased DNA replication rates translated into cellular proliferation.  
We therefore calculated population-doubling time of infected human fibroblasts and found that 
this was reduced by 10% in the p16 jTALE-DNMT wild-type infected cells compared to mutant 
(Figure 3.6C).   
To further eliminate the possibility that increased proliferation of epigenetically targeted 
human fibroblasts might be impacted by other cell cycle regulators, we determined the expression 
levels of a panel of cyclin-dependent kinase inhibitors, cyclin-dependent kinases and other 
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molecules related to the p16 inhibitory pathway. As shown in Figure 3.6D, none of these cell 
cycle regulators were affected by p16 jTALE-DNMT infection comparing wild-type and mutant 
infected populations, attesting to the specificity of our strategy.  Although we demonstrated that 
p16 TALE-DNMT infection does not affect expression of other cell cycle regulators, we also 
assessed DNA methylation at these loci.  We found that some genes showed increased 
methylation while others did not (Figure 3.6E).  Since changes across cell cycle regulators are 
inconsistent, we cannot say for certain whether or not these changes are a direct consequence of 
p16 TALE-DNMT activity, or an indirect consequence of decreased p16 expression and 
accelerated proliferation. In summary, targeting DNA methylation to the p16 (CDKN2A) promoter 
led to changes in expression exclusively of the p16 transcript, resulting in increased cell 
proliferation, without altering the activity of other cell cycle regulator genes.  
 
Discussion 
We have demonstrated that customized TALEs can be employed to direct DNA 
methylation to specific gene loci, and thereby decrease gene expression.  We selected p16 as 
our primary target due to its role in mediating cellular senescence with the idea that epigenetic 
suppression of p16 might facilitate cell cycle entry in terminally differentiated cells in the context 
of regenerative medicine.  In developing this novel technology, we employed a primary human 
fibroblast cell line that is not transformed, in contrast to the majority of human cells lines, which 
are often subject to dysfunctional cell cycle regulation. Importantly, even in this readily dividing 
cell population we have shown that increasing DNA methylation at a single cell cycle inhibitor 
gene locus is sufficient to increase cellular proliferation. Further, the observed changes in 
replication rate were entirely dependent on suppression of the intended gene product, p16.  We 
have also proven that these targeted epigenetic modifiers can be delivered using lentiviral 
vectors, which will dramatically expand the breadth of their application in different biological 
systems.  We validated our findings of TALE-DNMT mediated targeted DNA methylation and p16 
suppression in primary human coronary artery smooth muscle cells, and with an independent 
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TALE-DNMT construct targeting the p16 (CDKN2A) locus, attesting to the broad applicability of 
this technology.  We have shown that the TALE-DNMT strategy is a powerful and robust tool that 
can be utilized to change cell fate.    
We also found that nearby loci are more likely to be susceptible to off-target effects by 
TALE-DNMTs than distal loci, which until now has been an underreported consequence of TALE-
mediated epigenetic modifiers.  These “near-target” effects appear to be distance dependent, and 
in our case functionally irrelevant as altered gene expression was detected only at the target 
gene, CDKN2A.  It is likely that the “near target” effects can be attributed to the three-dimensional 
structure of chromatin.  Chromatin interactions such as chromatin looping may bring nearby loci 
into the vicinity of the TALE-DNMT construct, permitting DNA methylation in the absence of direct 
TALE-DNA binding. We also observed small increases in DNA methylation at some but not all 
cell cycle inhibitors and other cell cycle regulators implicated in the p16/pRb pathway. Critically, 
these changes did not impact gene activity.  Nevertheless, future efforts will be directed towards 
further improving specificity by strategies such as attenuating DNMT subunit catalytic activity, or 
splitting the DNMT domain, similar to the TALEN system, such that two separate TALE fusion 
proteins are required for methyltransferase activity.  Also, the TALE-DNMT strategy may be 
further optimized through large-scale screens of TALEs to determine if certain target binding sites 
are more effective than others.   
Here, we demonstrate the utility of TALE-directed DNA methylation as a strategy for 
altering the epigenetic state in a targeted, locus-specific fashion.  We have amended this strategy 
to accommodate lentiviral delivery to primary human cells, and have shown that this system can 
be used to alter cellular behavior.  We also shed light on the specificity of TALE-mediated 
epigenetic targeting, which is an ongoing area of future investigation. This study may have 
widespread implications for investigating gene regulation, and in developing novel therapeutic 
strategies for correcting aberrant gene expression in disease. 
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Methods 
TALE target selection and construction 
Twenty-four base pair TALE target sequences within the CDKN2A promoter were 
selected using the web-based tool, TAL Effector-Nucleotide Targeter (TALE-NT) 2.0, which 
optimizes unique binding sites within a specified target region (Doyle et al. 2012; Cermak et al. 
2011).  The sequence targeted in the present work was 5’-CCTCCTTCCTTGCCAACGCTGGCT-
3’.  Cloning vectors and TALE repeat monomer plasmids were obtained from the TALE Toolbox 
kit (Addgene).  pTALETF vectors were modified to replace the VP64 domain with flag-tagged 
DNMT3a-3L by cloning. Following target selection, the 24 corresponding monomers were 
assembled into a modified TALE backbone containing either the DNMT3a-3L catalytic subunit or 
mutant DNMT3a-3L catalytic subunit through a series of golden gate digestion-ligation reactions, 
as described by Sanjana and colleagues (Sanjana et al. 2012).  The mutant DNMT catalytic 
domain contained a catalytically inactive DNMT3a subunit due to a point mutation, E752A 
(Rivenbark et al. 2012). The DNMT3a-3L DNA sequence was synthesized by Eurofins MWG 
Operon and cloned into the TALE backbone by restriction enzyme digestion followed by ligation.  
PCR primers including the E752A point mutation were used to amplify a DNA fragment from the 
TALE-DNMT plasmid containing the point mutation, and the fragment was subsequently cloned 
into the TALE-DNMT backbone by restriction enzyme digestion followed by ligation to generate 
the mutant construct.  The point mutation is underlined in the reverse primer (PCR primers, 
Forward: 5’-CAAGCCCCAAGAAGAAGAGA-3’ and Reverse: 5’-
CCCATGGCCACCACATTGGCAAAGAG-3’).  The complete coding sequence of the p16 TALE-
DNMT is provided in Figure 3.7.  
 
Jumbled TALE lentivirus design and construction 
Jumbled TALEs were designed by disrupting direct repeats greater than eleven 
nucleotides utilizing the degeneracy of the genetic code to change DNA sequence without 
altering protein coding sequence. In order to accommodate the size limitation of the lentiviral 
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genome, the TALE target sequence was decreased to 18 bases instead of 24, a minimal CMV 
promoter was used, and eGFP was removed.  The 18 base pair sequence targeted with the 
jumbled TALE was 5’-TCCTTGCCAACGCTGGCT-3’.  Series of plasmids containing jumbled 
sequences for 6 monomers were ordered from Eurofins MWG Operon with appropriate restriction 
sites such that these hexamers could be incorporated into the protocol described by Sanjana and 
colleagues at a Golden-Gate digestion-ligation step.  TALE-DNMT constructs were then cloned 
into a lentiviral vector obtained from The Wistar Institute Protein Expression Core (Philadelphia, 
PA).  Lentiviruses were also prepared by The Wistar Institute Protein Expression Core 
(Philadelphia, PA).  The coding sequence for the jumbled p16 TALE repeat domain is provided in 
Figure 3.8.  
 
Transfection of HeLa cells 
HeLa cells (American Type Culture Collection) were seeded at a density of 5x106 cells 
per 10cm3.  After 24 hours, cells were transfected with 12.5µg of plasmid DNA using 
Lipofectamine® 2000 reagent (Life TechnologiesTM) according to manufacturer's protocol.  Forty-
eight hours post-transfection, cells were trypsinized with 0.25% trypsin + EDTA and dispersed for 
FACS sorting for GFP.  FACS sorting was performed by the Flow Cytometry and Cell Sorting 
Resource Laboratory (FCCSRL) at the University of Pennsylvania (Philadelphia, PA).  Sorted 
populations were harvested using the Qiagen AllPrep DNA/RNA Mini Kit.   
 
DNA methylation analysis 
Genomic DNA was bisulfite-converted using the Qiagen EpiTect Bisulfite Kit (Qiagen 
GmbH) and target loci were PCR amplified using the PyroMark PCR Kit (Qiagen GmbH).  Four 
primer pairs were designed to PCR amplify across the entire CDKN2A CpG island within the 
promoter region.  Additional primer pairs were also designed to amplify regions within each 
control locus.  Primers were designed to amplify approximately 250-300 base pair regions at the 
CpG island closest to the transcription start site of each gene.  In instances when no CpG island 
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was present, a sequence within the gene promoter was chosen.  All primer sequences and 
genomic coordinates for each amplicon are listed in Table 3.1.  Pyromark PCR reactions were 
carried out per manufacturer’s instructions.  DNA sequencing libraries were prepared with the 
automated Ovation® SP+ Ultralow DR Multiplex System (NuGEN Technologies Inc.) and 
subsequently sequenced on an Illumina MiSeq with 150 base pair paired-end reads.  DNA 
sequences were aligned to an in silico bisulfite converted human genome using the BS Seeker 
program and analyzed by the Next Generation Sequencing Core at the University of 
Pennsylvania (Philadelphia, PA) (Chen et al. 2010).  Only CpGs with sequence coverage greater 
than 1000 reads were considered.  Average DNA methylation across regions was analyzed by 
one-way ANOVA with Tukey’s correction for multiple comparisons when comparing more than 
two groups, and by a two-tailed t-test when comparing two groups.  Individual CpGs were 
compared by multiple t-tests (P < 0.05).  All next-generation sequencing data was deposited to 
the Gene Expression Omnibus (GEO) public database according to MINSEQE-standards 
(accession# GSE66456). 
 
Quantitative real-time PCR for gene expression 
To assess mRNA levels, RNA extracted with the Qiagen AllPrep DNA/RNA Mini Kit was 
reverse-transcribed using SuperScript® II Reverse Transcriptase (Life TechnologiesTM) to 
synthesize cDNA.  qRT-PCR was performed on the Agilent Technologies Strategene Mx3000P 
using 2x Brilliant III SYBR® Green qPCR master mix plus ROX reference dye (Agilent 
Technologies).  Thermal profiles were set according to manufacturer’s protocol. mRNA levels 
were normalized to HPRT1.  qPCR primer sequences are listed in Table 3.2.  Differences in 
mRNA levels were compared by two-tailed t-tests (P < 0.05). 
 
PCR assay 
To demonstrate integration and transcription of full-length TALE DNA in lentiviral 
infections of HeLa cells, the TALE repeat moiety was amplified from genomic DNA and cDNA, 
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respectively, with Herculase II Fusion DNA polymerase. (TALE repeat primers, Forward: 5’-
CCAGTTGCTGAAGATCGCGAAGC-3’ and Reverse: 5’-TGCCACTCGATGTGATGTCCTC-3’).  
The Woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) present in lentiviral 
constructs was used as a control (Forward: 5’-AGCGTCGACAATCAACCTCT-3’ and Reverse: 5’-
GGCATTAAAGCAGCGTATCC-3’).  PCR products were purified using the QIAquick® PCR 
Purification Kit (Qiagen GmbH), and 100ng of each product was run on a 0.8% agarose gel. 
 
HeLa cell lentivirus transduction 
HeLa cells were seeded at a density of 1X106 cells per 10cm3 in DMEM culture medium 
supplemented with 10% fetal bovine serum and penicillin/streptomycin.  Twenty-four hours post-
seeding, cells were treated with 1X107 titration units of lentivirus.  Polybrene was added at a 
concentration of 8ng/µl to enhance viral infection. Cells were harvested four days post-infection 
for either DNA/RNA extraction or preparation of protein lysate as described. 
 
Western blotting 
Following transduction, cells were sedimented and homogenized in RIPA buffer. Cell 
lysates were sonicated, sedimented to remove cellular debris, and protein concentration was 
measured by the Millipore Direct Detect system.  50µg of protein lysate was denatured with DTT 
and separated by size on a NuPAGE 4-12% Bis-Tris gel (Life TechnologiesTM).  Samples were 
transferred onto a PVDF membrane (Novex by Life TechnologiesTM) and blocked with PBST 5% 
non-fat dry milk.  Membranes were incubated with anti-flag antibody (F1804-200UG monoclonal 
ANTI-FLAG® M2 antibody, SIGMA Life Sciences) and anti-β-actin antibody (β-actin antibody 
#4967, Cell Signaling Technology, Inc.), and then with HRP-conjugated secondary antibodies (sc-
2030 Goat anti-rabbit IgG-HRP and sc-2005 goat anti-mouse IgG-HRP, Santa Cruz 
Biotechnology).  Blots were developed using ECLTM Prime Western Blotting Detection Reagent 
(GE Healthcare). 
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Primary human fibroblast transduction 
Primary human foreskin fibroblasts purchased from ATCC, CCD-1112Sk (ATCC® CRL-
2429™), were seeded at a density of 1X106 cells per 10cm3 in IMDM culture medium 
supplemented with 10% fetal bovine serum and penicillin/streptomycin.  After 24 hours cells were 
infected with 1X107 titration units of lentivirus in complete medium with polybrene at a 
concentration of 8ng/µl and harvested 4 days later using the Qiagen AllPrep DNA/RNA Mini Kit.   
 
Primary human coronary artery smooth muscle cell (hCASMC) transduction 
Primary hCASMCs were purchased from Lonza (CC-2583) and plated in 6-well plates at 
a density of 75,000 cells per well in culture media prepared from the Lonza CloneticsTM SmGMTM-
2 BulletKitTM (CC-3182).  After 24 hours in culture, cells were infected with lentivirus as described 
for human fibroblasts. 
 
EdU Incorporation 
Primary human fibroblasts were plated in 8-well chamber slides and infected with either 
p16 jTALE-DNMT WT or Mut lentivirus as described above.  After 72 hours in culture, cells were 
incubated with 5-ethynyl-2’-deoxyuridine (EdU) for 1 hour.  EdU incorporation was visualized by 
immunofluorescence staining using the Click-iT® Plus EdU Imaging Kit, Alexa Fluor® 555 picolyl 
azide (Molecular Probes® by Life TechnologiesTM).  Percent EdU incorporation was calculated as 
the number of EdU positive cells divided by the total number of cells (n=7).  Differences in 
percent EdU incorporation were compared in a two-tailed t-test (P < 0.05).   
 
p16 re-expression 
For p16 re-expression experiments, a lentiviral vector incorporating the human p16 cDNA 
clone under a CMV promoter was purchased from OriGene Technologies, Inc. (Catalog No. 
RC220937L1).  Lentivirus was prepared by the Wistar Institute Protein Expression Core 
(Philadelphia, PA).  In separate EdU Incorporation experiments, CMV-p16 lentivirus was added in 
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combination with either p16 jTALE-DNMT WT or Mut lentivirus.  Titers for CMV-p16 lentivirus 
were reduced to approximately 1X106 titration units per 1 million cells. Percent EdU incorporation 
was calculated as the number of EdU positive cells divided by the total number of cells (n=4).  
Differences in percent EdU incorporation were compared in a two-tailed t-test.    
 
Population Doubling Time Assay 
Human fibroblasts were infected as described above, except that a lower seeding density 
of 4X105 cells per 10cm3 plate was used to prevent contact growth inhibition during the 4 day 
infection period.  Cells were counted prior to plating and at the end of the experiment.  Population 
doubling time (DT) as described by ATCC was calculated as DT = Tln2/ln(Xf/Xi) where T is 
incubation time (days), Xi is initial cell number and Xf is final cell number. 
 
Statistics 
Data is displayed as mean ± SEM, and at least three replicates were conducted for each 
experiment.  Data was assessed by one-way ANOVA with Tukey’s correction for multiple 
comparisons or by two-tailed t-test, as appropriate.  Significance was defined as P < 0.05.  
 
Study Approval 
All experiments were performed in accordance with guidelines set forth by the University 
of Pennsylvania.  Study approval was not required since no animals were used and primary 
human tissues were obtained from commercially available sources. 
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Figure 3.1. Targeted CpG methylation of the p16 (CDKN2A) locus using TALE-DNMT fusion 
proteins. (A) TALE-DNMT strategy for altering the epigenetic state of the p16 (CDKN2A) 
promoter. Locus-specific TALEs were fused to the catalytic domain of DNA methyltransferase 
(p16 TALE-DNMT), or a catalytically inactive DNA methyltransferase with the point mutation 
E752A (p16 TALE-DNMT Mut). (B) Detailed diagram of TALE-DNMT construct and target site in 
the p16 (CDKN2A) locus.  Black boxes indicate the three exons of the p16 transcript, and green 
boxes indicate CpG islands.  The TALE-DNMT was targeted to the CpG island at the promoter 
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just before the transcription start site. Legend on the right side of the diagram indicates which 
nucleotide is targeted by each of the four different TALE repeat monomers, which are color-
coded.  (C) Percent methylation of individual CpGs within the CDKN2A promoter in FACS-sorted 
GFP-positive populations compared to untreated HeLa cells. HeLa cells were transfected with the 
p16 TALE-DNMT wild-type or p16 TALE-DNMT mutant construct and cultured for 48 hours.  Cells 
were then FACS sorted for GFP to isolate transfected populations. DNA methylation was 
quantified by sequencing of PCR-amplified bisulfite-converted genomic DNA.  Graphs reflect 
percent DNA methylation at each CpG and its position relative to the transcription start site (mean 
± SEM; n = 3).  Diagram below the graph illustrates the region of the p16 (CDKN2A) promoter 
that was analyzed.  Data points outlined in black are significantly elevated in the p16 TALE-
DNMT population compared to the p16 TALE-DNMT mutant population (P < 0.05, multiple t-
tests).  
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Figure 3.2. Minimizing direct repeats permits lentiviral expression of TALE fusion proteins. 
HeLa cells were infected with p16 jumbled TALE-DNMT, p16 jumbled TALE-DNMT mutant, or 
GFP control lentiviruses and harvested after four days. (A) Western blot of HeLa cells infected 
with p16 jTALE-DNMT or p16 jTALE-DNMT mutant lentivirus showing production of the full-length 
protein. (B) PCR amplification of the full-length TALE repeat moiety from genomic DNA (gDNA), 
demonstrating integration of the intact construct into the host genome, and from cDNA, 
demonstrating transcription of full length mRNA, in infected HeLa cells.  Amplification of plasmid 
DNA is shown as a reference. jTALE, jumbled TALE;  WPRE, Woodchuck hepatitis virus 
posttranscriptional regulatory element.    (C) Percent DNA methylation of the p16 (CDKN2A) 
locus in HeLa cells infected with p16 jTALE-DNMT wild-type and p16 jTALE-DNMT mutant 
lentivirus (mean ± SEM; n = 3).  Data points outlined in black indicate CpGs in which DNA 
methylation is significantly elevated in p16 jTALE-DNMT wild-type infected cells compared to p16 
jTALE-DNMT mutant infected cells (P < 0.05, multiple t-tests).  
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Figure 3.3. Targeted CpG methylation at the p16 (CDKN2A) locus results in decreased 
gene expression in primary human cells.  Primary human fibroblasts were transduced with p16 
jTALE-DNMT wild-type or p16 jTALE-DNMT mutant lentiviruses and incubated for four days. (A) 
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percent DNA methylation at each CpG (mean ± SEM; n = 3) and position relative to the 
transcription start site.  Data points outlined in black are significantly elevated in the p16 jTALE-
DNMT population compared to the p16 jTALE-DNMT mutant population. P < 0.05, multiple t-
tests. (B) p16 transcript expression in fibroblasts treated with p16 jTALE-DNMT wild-type or 
mutant lentiviruses relative to the mutant negative control.  Expression levels were normalized to 
HPRT1 mRNA levels (mean ± SEM; n = 3).  *, P < 0.05, two-tailed t-test.  (C) Average percent 
DNA methylation of CpGs at each CpG island within the p16 (CDKN2A) locus and at β-actin 
(ACTB), a housekeeping gene located on a different chromosome.  The diagram below the graph 
illustrates the position of CpG islands at the p16 (CDKN2A) locus. (mean ± SEM; n = 3).  *, P < 
0.05; **, P < 0.01, two-tailed t-test. (D) Average percent methylation at genes adjacent to p16 
(CDKN2A), as described in (C). The diagram above the graph indicates the position of each gene 
relative to p16 (CDKN2A). (E) mRNA expression of genes adjacent to p16 (CDKN2A) in 
lentivirally-transduced human fibroblasts, determined as described in (B).  
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Figure 3.4.  p16 TALE-DNMT strategy can be employed in primary human coronary artery 
smooth muscle cells to decrease p16 expression.  Primary human coronary artery smooth 
muscle cells (hCASMCs) were infected with p16 jTALE-DNMT wild-type or mutant lentivirus.  
After 4 days of infection, cells were harvested and assessed for DNA methylation (A), and p16 
(CDKN2A) expression (B) as described in the main text.   
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Figure 3.5. Multiple p16 TALE-DNMT constructs can be designed to decrease p16 
expression.  An additional TALE-DNMT (p16 jTALE-DNMT.2) was designed to target the p16 
(CDKN2A) promoter region 118 to 139 base pairs upstream of the transcription start site.  Wild-
type and mutant infected with p16 jTALE-DNMT.2 were evaluated for DNA methylation (A) and 
p16 (CDKN2A) gene expression (B) as described in prior human fibroblast experiments.      
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Figure 3.6. Alterations in p16 levels due to p16 TALE-DNMT results in increased 
proliferation in primary human cells.  (A) Representative immunofluorescence image of EdU 
incorporation in human fibroblasts infected with wild-type or mutant p16 jTALE-DNMT lentivirus.  
After 72 hours infection, cells were incubated with EdU for 1 hour and stained for EdU.  Cell 
nuclei are stained blue (DAPI) and EdU positive nuclei are stained red. Images were taken at 10X 
magnification (n=7).  (B) Percent EdU incorporation of cells infected with p16 jTALE-DNMT wild-
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type or mutant lentivirus, with (n = 4) or without (n = 7) co-infection of CMV-p16 lentivirus.  Three 
random images were counted for each biological replicate (mean ± SEM).  ***, P < 0.001; n.s., 
not significant, two-tailed t-test. (C) Population doubling time of human fibroblasts infected with 
p16 jTALE-DNMT wild-type or mutant lentivirus. (mean ± SEM; n = 4). *, P < 0.05, two-tailed t-
test. (D) Transcript levels of cell cycle regulators in human fibroblasts transduced with wild-type 
p16 jTALE-DNMT lentivirus relative to mutant lentivirus. Expression was normalized to HPRT1 
mRNA levels (mean ± SEM; n = 3).  Two-tailed t-test.  (E) Average percent DNA methylation of 
CpGs at the nearest CpG island of cell cycle regulators evaluated in (D).  Average DNA 
methylation was measured by PCR amplification of bisulfite converted genomic DNA followed by 
high-throughput sequencing (mean ± SEM; n = 3). **, P < 0.01; ***, P < 0.001, two-tailed t-test.  
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Figure 3.7.  Coding sequence of p16 TALE-DNMT3a-3L. 
 
ATGTCGCGGACCCGGCTCCCTTCCCCACCCGCACCCAGCCCAGCGTTTTCGGCCGACTCGTTCTCAGACCT
GCTTAGGCAGTTCGACCCCTCACTGTTTAACACATCGTTGTTCGACTCCCTTCCTCCGTTTGGGGCGCACC
ATACGGAGGCGGCCACCGGGGAGTGGGATGAGGTGCAGTCGGGATTGAGAGCTGCGGATGCACCACCCCCA
ACCATGCGGGTGGCCGTCACCGCTGCCCGACCGCCGAGGGCGAAGCCCGCACCAAGGCGGAGGGCAGCGCA
ACCGTCCGACGCAAGCCCCGCAGCGCAAGTAGATTTGAGAACTTTGGGATATTCACAGCAGCAGCAGGAAA
AGATCAAGCCCAAAGTGAGGTCGACAGTCGCGCAGCATCACGAAGCGCTGGTGGGTCATGGGTTTACACAT
GCCCACATCGTAGCCTTGTCGCAGCACCCTGCAGCCCTTGGCACGGTCGCCGTCAAGTACCAGGACATGAT
TGCGGCGTTGCCGGAAGCCACACATGAGGCGATCGTCGGTGTGGGGAAACAGTGGAGCGGAGCCCGAGCGC
TTGAGGCCCTGTTGACGGTCGCGGGAGAGCTGAGAGGGCCTCCCCTTCAGCTGGACACGGGCCAGTTGCTG
AAGATCGCGAAGCGGGGAGGAGTCACGGCGGTCGAGGCGGTGCACGCGTGGCGCAATGCGCTCACGGGAGC
ACCCCTCAACCTGACCCCAGAGCAGGTCGTGGCAATTGCGAGCCATGACGGGGGAAAGCAGGCACTCGAAA
CCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGACTTACGCCAGAGCAGGTCGTGGCAATTGCG
AGCCATGACGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGG
ACTAACCCCAGAGCAGGTCGTGGCAATTGCGAGCAACGGAGGGGGAAAGCAGGCACTCGAAACCGTCCAGA
GGTTGCTGCCTGTGCTGTGCCAAGCGCACGGGTTGACCCCAGAGCAGGTCGTGGCAATTGCGAGCCATGAC
GGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGCCTGACCCC
AGAGCAGGTCGTGGCAATTGCGAGCCATGACGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGC
CTGTGCTGTGCCAAGCGCACGGACTGACACCAGAGCAGGTCGTGGCAATTGCGAGCAACGGAGGGGGAAAG
CAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGACTTACACCCGAACAAGT
CGTGGCAATTGCGAGCAACGGAGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGT
GCCAAGCGCACGGACTTACGCCAGAGCAGGTCGTGGCAATTGCGAGCCATGACGGGGGAAAGCAGGCACTC
GAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGACTAACCCCAGAGCAGGTCGTGGCAAT
TGCGAGCCATGACGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGC
ACGGGTTGACCCCAGAGCAGGTCGTGGCAATTGCGAGCAACGGAGGGGGAAAGCAGGCACTCGAAACCGTC
CAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGCCTGACCCCAGAGCAGGTCGTGGCAATTGCGAGCAA
CGGAGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGACTGA
CACCAGAGCAGGTCGTGGCAATTGCGAGCAACCACGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTG
CTGCCTGTGCTGTGCCAAGCGCACGGCCTCACCCCAGAGCAGGTCGTGGCAATTGCGAGCCATGACGGGGG
AAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGACTTACGCCAGAGC
AGGTCGTGGCAATTGCGAGCCATGACGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTG
CTGTGCCAAGCGCACGGACTAACCCCAGAGCAGGTCGTGGCAATTGCGAGCAACATCGGGGGAAAGCAGGC
ACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGGTTGACCCCAGAGCAGGTCGTGG
CAATTGCGAGCAACATCGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAA
GCGCACGGCCTGACCCCAGAGCAGGTCGTGGCAATTGCGAGCCATGACGGGGGAAAGCAGGCACTCGAAAC
CGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGACTGACACCAGAGCAGGTCGTGGCAATTGCGA
GCAACCACGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGTTATGTCAGGCCCATGGG
CTCACCCCAGAGCAGGTCGTGGCAATTGCGAGCCATGACGGGGGAAAGCAGGCACTCGAAACCGTCCAGAG
GTTGCTGCCTGTGCTGTGCCAAGCGCACGGACTTACGCCAGAGCAGGTCGTGGCAATTGCGAGCAACGGAG
GGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGACTAACCCCA
GAGCAGGTCGTGGCAATTGCGAGCAACCACGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCC
TGTGCTGTGCCAAGCGCACGGGTTGACCCCAGAGCAGGTCGTGGCAATTGCGAGCAACCACGGGGGAAAGC
AGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGCCTGACCCCAGAGCAGGTC
GTGGCAATTGCGAGCCATGACGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTG
CCAAGCGCACGGACTGACACCAGAGCAGGTCGTGGCAATTGCGAGCAACGGAGGGGGAAAGCAGGCACTCG
AAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGACTCACGCCTGAGCAGGTAGTGGCTATT
GCATCCCATGACGGGGGCAGACCCGCACTGGAGTCAATCGTGGCCCAGCTTTCGAGGCCGGACCCCGCGCT
GGCCGCACTCACTAATGATCATCTTGTAGCGCTGGCCTGCCTCGGCGGACGACCCGCCTTGGATGCGGTGA
AGAAGGGGCTCCCGCACGCGCCTGCATTGATTAAGCGGACCAACAGAAGGATTCCCGAGAGGACATCACAT
CGAGTGGCAGATCACGCGCAAGTGGTCCGCGTGCTCGGATTCTTCCAGTGTCACTCCCACCCCGCACAAGC
GTTCGATGACGCCATGACTCAATTTGGTATGTCGAGACACGGACTGCTGCAGCTCTTTCGTAGAGTCGGTG
TCACAGAACTCGAGGCCCGCTCGGGCACACTGCCTCCCGCCTCCCAGCGGTGGGACAGGATTCTCCAAGCG
AGCGGTATGAAACGCGCGAAGCCTTCACCTACGTCAACTCAGACACCTGACCAGGCGAGCCTTCATGCGTT
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CGCAGACTCGCTGGAGAGGGATTTGGACGCGCCCTCGCCCATGCATGAAGGGGACCAAACTCGCGCGTCAG
CAAGCCCCAAGAAGAAGAGAAAGGTGGAGGCCAGCGGTACCAACCATGACCAGGAATTTGACCCCCCAAAG
GTTTACCCACCTGTGCCAGCTGAGAAGAGGAAGCCCATCCGCGTGCTGTCTCTCTTTGATGGGATTGCTAC
AGGGCTCCTGGTGCTGAAGGACCTGGGCATCCAAGTGGACCGCTACATTGCCTCCGAGGTGTGTGAGGACT
CCATCACGGTGGGCATGGTGCGGCACCAGGGAAAGATCATGTACGTCGGGGACGTCCGCAGCGTCACACAG
AAGCATATCCAGGAGTGGGGCCCATTCGACCTGGTGATTGGAGGCAGTCCCTGCAATGACCTCTCCATTGT
CAACCCTGCCCGCAAGGGACTTTATGAGGGTACTGGCCGCCTCTTCTTTGAGTTCTACCGCCTCCTGCATG
ATGCGCGGCCCAAGGAGGGAGATGATCGCCCCTTCTTCTGGCTCTTTGAGAATGTGGTGGCCATGGGCGTT
AGTGACAAGAGGGACATCTCGCGATTTCTTGAGTCTAACCCCGTGATGATTGACGCCAAAGAAGTGTCTGC
TGCACACAGGGCCCGTTACTTCTGGGGTAACCTTCCTGGCATGAACAGGCCTTTGGCATCCACTGTGAATG
ATAAGCTGGAGCTGCAAGAGTGTCTGGAGCACGGCAGAATAGCCAAGTTCAGCAAAGTGAGGACCATTACC
ACCAGGTCAAACTCTATAAAGCAGGGCAAAGACCAGCATTTCCCCGTCTTCATGAACGAGAAGGAGGACAT
CCTGTGGTGCACTGAAATGGAAAGGGTGTTTGGCTTCCCCGTCCACTACACAGACGTCTCCAACATGAGCC
GCTTGGCGAGGCAGAGACTGCTGGGCCGATCGTGGAGCGTGCCGGTCATCCGCCACCTCTTCGCTCCGCTG
AAGGAATATTTTGCTTGTGTGAGCAGCGGCAACAGCAACGCCAACAGCCGCGGCCCCAGCTTCAGCAGCGG
CCTGGTGCCCCTGAGCCTGCGCGGCAGCCACATGGGCCCTATGGAGATATACAAGACAGTGTCTGCATGGA
AGAGACAGCCAGTGCGGGTACTGAGCCTTTTTAGAAATATTGATAAAGTACTAAAGAGTTTGGGCTTTTTG
GAAAGCGGTTCTGGTTCTGGGGGAGGAACGCTGAAGTACGTGGAAGATGTCACAAATGTCGTGAGGAGAGA
CGTGGAGAAATGGGGCCCCTTTGACCTGGTGTACGGCTCGACGCAGCCCCTAGGCAGCTCTTGTGATCGCT
GTCCCGGCTGGTACATGTTCCAGTTCCACCGAATCCTGCAGTATGCGCTGCCTCGCCAGGAGAGTCAGCGG
CCCTTCTTCTGGATATTCATGGACAATCTGCTGCTGACTGAGGATGACCAAGAGACAACTACCCGCTTCCT
TCAGACAGAGGCTGTGACCCTCCAGGATGTCCGTGGCAGAGACTACCAGAATGCTATGCGGGTGTGGAGCA
ACATTCCAGGGCTGAAGAGCAAGCATGCGCCCCTGACCCCAAAGGAAGAAGAGTATCTGCAAGCCCAAGTC
AGAAGCAGGAGCAAGCTGGACGCCCCGAAAGTTGACCTCCTGGTGAAGAACTGCCTTCTCCCGCTGAGAGA
GTACTTCAAGTATTTTTCTCAAAACTCACTTCCTCTTGCTAGCGACTACAAAGACCATGACGGTGATTATA
AAGATCATGACATCGACTACAAGGATGACGATGACAAGTCTAGGGCAGTGGAGAGGGCAGAGGAAGTCTGC
TAACATGCGGTGACGTCGAGGAGAATCCTGGCCCAGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTG
CCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGA
ATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACC
CTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTT
CTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACA
AGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTC
AAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGC
CGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGC
TCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTG
AGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGAC
CGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAA 
 
Legend: 
TALE N-Terminus and C-Terminus 
p16 TALE repeat domain 
Dnmt3a-3L 
2A GFP 
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Figure 3.8.  Jumbled p16 TALE repeat domain. 
 
CTGACCCCCGAGCAAGTCGTCGCCATCGCCAGTAACGGAGGCGGCAAACAAGCCCTGGAGACTGTCCAACG
ACTTTTGCCTGTTCTCTGCCAGGCCCATGGTTTGACTCCTGAGCAGGTGGTGGCTATAGCTTCCCATGACG
GTGGTAAACAAGCTTTGGAGACTGTTCAGAGGCTGCTGCCGGTGTTGTGTCAAGCGCACGGCCTTACGCCG
GAACAGGTCGTGGCGATTGCGTCACATGACGGGGGGAAACAAGCGCTCGAAACCGTGCAACGGCTTCTGCC
CGTCTTGTGCCAGGCTCATGGGCTCACCCCGGAGCAGGTTGTTGCTATCGCATCTAACGGAGGAGGCAAGC
AAGCGTTGGAAACGGTTCAAAGGCTTCTCCCCGTGCTCTGTCAAGCCCACGGACTTACTCCAGAGCAGGTA
GTCGCGATAGCGAGTAACGGAGGGGGTAAGCAAGCTCTCGAAACTGTACAGAGACTGCTTCCGGTACTTTG
CCAGGCACATGGCTTGACACCGGAGCAAGTTGTAGCCATTGCCTCAAACCACGGTGGGAAGCAAGCCCTTG
AGACAGTCCAGCGATTGCTGCCTGTATTGTGTCAAGCTCACGGTTTGACGCCCGAACAAGTCGTAGCTATC
GCTAGCCATGACGGCGGGAAGCAGGCTCTTGAAACAGTTCAGCGGTTGCTTCCCGTACTCTGTCAGGCTCA
CGGCCTGACTCCCGAACAGGTCGTTGCCATAGCCTCTCATGACGGCGGTAAACAGGCCTTGGAAACTGTCC
AAAGACTTCTTCCTGTCTTGTGTCAGGCCCACGGGCTTACCCCCGAGCAGGTTGTGGCCATTGCATCAAAC
ATCGGAGGTAAGCAGGCGCTGGAGACTGTGCAACGCCTTCTGCCAGTTTTGTGCCAGGCGCACGGACTTAC
ACCTGAACAGGTAGTGGCAATTGCAAGCAACATCGGAGGGAAACAGGCCCTCGAAACGGTACAGCGGCTGC
TCCCTGTGCTCTGCCAAGCCCATGGATTGACCCCAGAGCAAGTAGTTGCGATAGCCTCACATGACGGTGGA
AAGCAGGCATTGGAGACAGTGCAGCGCCTGTTGCCCGTTCTTTGCCAAGCTCATGGTCTTACACCCGAGCA
AGTGGTCGCAATCGCGTCTAACCACGGGGGCAAACAGGCTCTCGAAACCGTACAACGACTCCTTCCAGTGC
TTTGTCAAGCGCATGGCCTCACGCCAGAACAGGTGGTAGCGATCGCGAGCCATGACGGGGGGAAACAGGCA
CTTGAAACCGTTCAACGCCTCTTGCCAGTCCTGTGCCAGGCACACGGTCTGACACCAGAGCAGGTGGTTGC
AATTGCGAGTAACGGAGGAGGGAAGCAAGCACTCGAAACAGTACAGCGACTCCTCCCTGTGCTGTGCCAAG
CTCACGGATTGACCCCTGAACAAGTTGTAGCGATAGCATCTAACCACGGCGGAAAACAGGCGCTGGAAACG
GTGCAAAGGCTCCTTCCCGTTCTTTGTCAGGCCCATGGCCTCACTCCGGAACAAGTCGTCGCTATTGCTAG
TAACCACGGTGGCAAGCAGGCCCTTGAAACGGTCCAGAGGTTGTTGCCGGTCCTCTGTCAAGCACATGGGC
TCACACCAGAACAAGTAGTAGCAATAGCCAGCCATGACGGAGGAAAACAAGCACTTGAGACAGTACAAAGA
CTCCTCCCAGTACTGTGCCAAGCACACGGGCTGACGCCTGAACAAGTGGTTGCAATCGCTTCAAACGGAGG
TGGAAAGCAAGCTCTGGAAACTGTTCAGCGCTTGCTCCCGGTTCTGTGTCAGGCGCATGGA 
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Table 3.1. PCR primers for amplification of bisulfite converted genomic DNA.  Primers were 
designed to PCR amplify regions of interest from bisulfite converted genomic DNA.  Each primer 
pair amplifies an approximately 250-300 base pair region within the CpG island closest to the 
transcription start site of the gene analyzed.  In instances where there was not a CpG island near 
the gene, the promoter was evaluated. Amplicons were subsequently used to prepare DNA 
sequencing libraries for DNA methylation analysis. 
Locus Coordinates Forward (5’ to 3’) Reverse (5’ to 3’) 
CDKN2A
_1 
chr9:21,975,07
5-21,975,330 ATTTGGTAGTTAGGAAGGTTGTA 
CCCTAAAATCCCCCCAAATTAAATCTC
C 
CDKN2A
_2 
chr9:21,974,90
9-21,975,178 GGTGGGGAGGAGTTTAGT AACCAACCCCTCCTCTTT 
CDKN2A
_3 
chr9:21,974,59
7-21,974,918 GGGGTTGGTTGGTTATTAGAG CCTAATTCCAATTCCCCTACAAACTT 
CDKN2A
_4 
chr9:21,974,55
8-21,974,863 AGAGGGGGAGAGTAGGTA CCAAAAAACCTCCCCTTTTTCC 
CDKN2A
_CGI2 
chr9:21,970,93
0-21,971,229 GTATGGTTATTGTTTTTGGTGTTT ACCATTCTATTCTCTCTAACAAATCA 
CDKN2A
_CGI3 
chr9:21,968,28
0-21,968,569 AGGTTAAAGATGTGTGGTATATT ACAACCACTAAAACTCATTATATAAC 
CDKN2A
_CGI3_2 
chr9:21,968,55
1-21,968,805 AATGAGTTTTAGTGGTTGTTTATAAT AACACATAAATAAATAAACATCCATT 
ACTB chr7:5,570,376-5,570,636 
TGGGAGTTTAGTGTTTAAGAGATGTTT
A CCCTCTCCCCTCCTTTTAC 
CDKN2B
_1 
chr9:22,009,01
2-22,009,290 AGGAGGGGTAGTGAGGATT ACACTCTTCCCTTCTTTCC 
CDKN2B
_2 
chr9:22,008,86
3-22,009,088 GGGTAATGAAGTTGAGTTTAGG CACCTTCTCCACTAATCCC 
p14ARF chr9:21,995,629-21,995,928 TGGGAATAGTAAAAGTAGGGTAAGG ACACCCACCCACTCAAAC 
MTAP chr9:21,802,505-21,802,762 GGAAAGGTTTGTAAAAGGG AATACCAAAAACCATATCTACAC 
IFNE chr9:21,481,642-21,481,862 GAAAAGGGAATTTGAAAATTTAATGT AATAAAAACCAACAACACCAACACA 
CDKN2C chr1:51,435,514-51,435,751 GGAGGATTTGTTTTTGTAGTTTTG CACAAACACACATACATTCCTAATT 
CDKN2D chr19:10,679,809-10,680,058 TTTATAGGGTTTGTATAATTAGTGG CTACCTCCCTTCCCTCAAA 
CDKN1A chr6:36,651,742-36,651,971 GATTAGTTGGAAGGAGTGAGAGA ACTCAACTACTCCCTATCCACTAAAC 
CDKN1B chr12:12,869,846-12,870,092 GGGTAGAGTTGGGGGTAG ACAAACCTACTCTAACTAACCT 
CDKN1C chr11:2,907,681-2,907,919 GGTTTGGTTTAAGGTTGAGAAG AACCCTCACACACCTACT 
RB1 chr13:48,877,360-48,877,609 GTGATTTTAAAAGGTTAGTAAGTG AAACCTCATCCCTATCCC 
CDK4 chr12:58,145,866-58,146,110 GGTGAGGGGGTTTTTTTAGT ACCCTTCCATAACCAACTC 
CDK6 chr7:92,462,912-92,463,146 GGTTTGGGAGAGGGTAGG ATCCCTCCTCTTCCCTCC 
CCND1 chr11:69,455,880-69,456,104 ATTATAGGGGAGTTTTGTTGAAGTT CAACACAAAAACTAATATTCCATAAC 
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Table 3.2. qPCR primers for gene expression analysis 
Locus Forward (5’ to 3’) Reverse (5’ to 3’) 
HPRT1 GCAGACTTTGCTTTCCTTGG AACACTTCGTGGGGTCCTTT 
CDKN2A 
(p16) 
CCCAACGCACCGAATAGTT AGCAGCAGCTCCGCCACT 
CDKN2A 
(p14ARF) 
AGAACATGGTGCGCAGGT GGGATGTGAACCACGAAAAC 
CDKN2B GCTGTTTCATCAGCAGCCTA CCACAATGGAGCTAGAAGCA 
MTAP CTACCTCAGGGCATGGTTGT TGCTGGCTAAATGCTTGTTG 
IFNE ACCCTTGAACGACATGAAGC AAGAATCATGTCTGGAGAAGTCC 
CDKN2C GTGATTTGGCCAGGCTCTAT AGCCCTCCCCACGTTTATT 
CDKN2D CCAAGGGCAGAGCATTTAAG AAGCAACGTGCACACTTCAG 
CDKN1A GATTAGCAGCGGAACAAGGA CAACTACTCCCAGCCCCATA 
CDKN1B GAGGTGCTTGGGAGTTTTGA TGTTTACACAGCCCGAAGTG 
CDKN1C CAGCGTTCGGTTTTGTTTTT GGGACCAGTGTACCTTCTCG 
RB1 AGGGCTTACTATTTCTGGGTCTT CAATACACGATCTCTGAAGTTCC 
CDK4 CGAGCTCTGCAGCACTCTTA AGAAGGGAAATGGCAGCTTT 
CDK6 TGTCTATCTCCCGGCACTTC TGAAAGCAAGCAAACAGGTG 
CCND1 AGCGCTGTTTTTGTTGTGTG CTTGCCTCAAAGTCCTGCTT 
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Abstract 
 DNA methylation has emerged as an important regulator of development and disease, 
necessitating the design of more efficient and cost-effective methods for detecting and quantifying 
this epigenetic modification. Next-generation sequencing (NGS) techniques offer single base 
resolution of CpG methylation levels with high statistical significance, but are also high cost if 
performed genome-wide. Here, we describe a simplified targeted bisulfite sequencing approach 
in which DNA sequencing libraries are prepared following sodium bisulfite conversion and two 
rounds of PCR for target enrichment and sample barcoding, termed BisPCR2.  We have applied 
the BisPCR2 technique to validate differential methylation at several type 2 diabetes risk loci 
identified in genome-wide studies of human islets.  We confirmed some previous findings while 
not others, in addition to identifying novel differentially methylated CpGs at these genes of 
interest, due to the much higher depth of sequencing coverage in BisPCR2 compared to prior 
array-based approaches.  This study presents a robust, efficient, and cost-effective technique for 
targeted bisulfite NGS, and illustrates its utility by reanalysis of prior findings from genome-wide 
studies.  
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Introduction 
DNA methylation refers to the addition of a methyl group to the 5-carbon position of 
cytosine residues, and in mammalian genomes occurs most commonly in the context of CpG 
dinucleotides.  As an epigenetic mark, this chemical modification does not alter the DNA 
sequence, but rather regulates transcriptional programs to direct processes such as cellular 
differentiation, genomic imprinting, and X-chromosome inactivation, while promoting genomic 
stability (Callinan and Feinberg 2006; Reik et al. 2001; Calvanese et al. 2009; Sheaffer et al. 
2014).  The majority of CpGs throughout the mammalian genome are fully methylated, while the 
remainder exists in an unmethylated or lowly methylated state, corresponding to active regulatory 
elements such as promoters and enhancers (Lister et al. 2009; Stadler et al. 2011; Ziller et al. 
2013; Baubec and Schuebeler 2014; Sheaffer et al. 2014).  Aberrant DNA methylation has been 
implicated in an increasing number of morbidities, particularly cancer and aging-associated 
diseases such as type 2 diabetes, neurological disorders, and cardiovascular disease (Bergman 
and Cedar 2013; Heerboth et al. 2014; Hamm and Costa 2015).  Many of the studies linking DNA 
methylation to disease have been prompted by the observation that only a small fraction of the 
inherited risk of these complex disorders can be explained by genetic variation, as determined by 
genome-wide association studies (GWAS) (Petronis 2010; Rakyan et al. 2011).  DNA 
methylation, along with other epigenetic alterations, may provide the link between environmental 
factors or intrauterine exposure and complex disorders.   
A key challenge in the epigenetics field has been achieving high-resolution genome-wide 
detection of these modifications in sufficient sample sizes to make claims about disease 
association.  In mapping DNA methylation, the most advanced technologies include array-based 
techniques such as the Infinium HumanMethylation450 BeadChip, which assays 450,000 
individual CpGs among 99% of RefSeq genes, and whole genome shotgun bisulfite sequencing 
(WGBS), which maps cytosine methylation across the entire genome at single base resolution, 
covering approximately 30 million CpGs.  While array-based approaches are more cost-effective 
and higher throughput, the restrictive sampling of CpGs provides an incomplete landscape of the 
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methylome (Lee et al. 2013).  However, WGBS experiments are extremely resource-intensive, 
because exhaustive sequencing is required to achieve sufficient coverage to accurately 
determine the percentage of methylation at all CpGs.  Therefore, it is only practical to conduct 
WGBS on a limited number of samples, and coverage is usually in the range of 5-15X per CpG, 
limiting statistical significance of findings.  In both instances, novel findings need to be validated 
in larger populations through targeted methylation analyses.  Thus, there is an increasing need 
for targeted sequencing techniques that are high throughput, cost effective, and provide single 
base resolution. 
 Next generation sequencing (NGS) strategies have been developed as an alternative to 
fluorescence-based pyrosequencing, which is limited by the number of samples that can be 
processed, and the fact that its short read lengths cover only a few CpGs at a time.  These 
protocols entail PCR amplification of target regions from bisulfite-converted genomic DNA, 
followed by DNA sequencing library preparation using techniques such as standard Illumina 
protocols or transposase-based Nextera XT technology (Morrill et al. 2013; Masser et al. 2013). 
While providing precise and accurate DNA methylation data with high statistical significance, DNA 
sequencing library preparation is quite expensive and cumbersome when evaluating large 
numbers of samples or target regions.   
Therefore, we have developed a novel approach for constructing targeted bisulfite NGS 
libraries that are prepared by bisulfite conversion of genomic DNA followed by two rounds of 
PCR, termed BisPCR2, eliminating the need for traditional DNA library preparation procedures 
(Figure 4.1).  In the BisPCR2 method, the entire library preparation process has been reduced to 
a single 50-minute PCR reaction.  We have validated the usefulness of this method in the context 
of type 2 diabetes, first confirming reported differences in DNA methylation at the imprinted 
MEG3 locus, and by validation of previous genome-wide findings of CpG risk loci identified in 
type 2 diabetic human islets (Kameswaran et al. 2014; Dayeh et al. 2014).  
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Results 
The BisPCR2 method for targeted bisulfite sequencing 
In order to simplify targeted bisulfite NGS, we developed a PCR-based method for library 
preparation, termed BisPCR2 (Figure 4.1).  The first step in this procedure is sodium bisulfite 
treatment of genomic DNA (gDNA), which deaminates unmethylated cytosines to uracils, while 
methylated cytosines are protected.  In subsequent PCR amplification reactions, uracils are 
amplified and ultimately sequenced as thymine residues.  The goal of the first PCR (PCR#1) is 
target enrichment to amplify regions of interest from bisulfite converted gDNA.  The target 
enrichment primers have overhangs with partial adapter sequences that are subsequently used to 
amplify barcoded libraries in the second round of PCR (PCR#2).  Target enrichment PCR 
products (PCR#1) for each sample are pooled prior to PCR#2 to simultaneously add the same 
multiplexing indeces to all amplicons of interest.  Following sample barcoding, all PCR#2 
reactions are purified and pooled for sequencing on the Illumina Miseq with 150 base pair paired-
end reads.  We found that purification of final libraries with AMPure XP beads efficiently removed 
primer dimers in comparison to column based PCR purification (data not shown).  To prove that 
BisPCR2 is comparable to traditional targeted bisulfite NGS approaches, we measured DNA 
methylation at the H19 locus in mouse genomic DNA using both methods and found nearly 
identical results (Figure 4.2). 
 
BisPCR2 library construction and sequencing 
In this study, we selected five target loci for evaluation, as described below, and 
compared their DNA methylation profile in five non-diabetic and five type 2 diabetic human islet 
samples.  Donor information is provided in Table 4.1.  Thus, for each of these ten biological 
samples, five PCR#1 amplicons were pooled, purified, and then used as template for the PCR#2 
barcoding reaction.  Target regions ranged in size from 171 to 298 bps (Table 4.2), and PCR#2 
conditions were optimized to prevent amplification bias, particularly of smaller fragments, with the 
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goal of balancing each library with roughly equivalent amounts of each amplicon (Figures 4.3A 
and 4.3B).   
The MiSeq sequencing run produced 14.15 million reads, with 12.75 million passing filter.  
The sample was spiked with 10% PhiX control, and 8.5% of total reads were aligned to the PhiX 
genome.  Approximately 85% of remaining reads, or 10 million, were aligned to the human 
genome.  Therefore, the expected number of reads per amplicon per sample was approximately 
200,000 reads.  The percentage of reads allocated to each of the ten samples ranged from 7.01% 
to 12.45% (Figure 4.3C).  The slight deviation from the expected 10% per sample is likely due to 
small pipetting errors when preparing the sequencing pool.  Across all samples, the average read 
number per locus was 206,411, ranging from 78,000 to 358,000 reads (Figure 4.3C).  The range 
in sequencing depth is likely due to imprecise pooling of PCR#1 products.  The amount of each 
PCR#1 product pooled was based on relative band intensity of one representative sample, non-
diabetic 1 (ND1), run on a 1.5% agarose gel, and does not account for sample to sample 
variability, which we anticipated to be low.  This approximation is suitable for many applications of 
the BisPCR2 method, although samples could be assessed for pooling independently if so 
desired.  Nevertheless, even the minimal read depth of 78,000 allows for exceedingly precise 
determination of methylation levels. 
 
Validation of type 2 diabetes differentially methylated loci 
We tested our BisPCR2 targeted bisulfite sequencing approach by measuring DNA 
methylation of the promoter region of MEG3 in human pancreatic islets.  MEG3 is a complex 
imprinted locus that produces 54 microRNAs, the MEG3 lncRNA, and multiple additional small 
RNA species.  MEG3 was shown to be down-regulated with corresponding promoter 
hypermethylation in type 2 diabetic (T2D) human islets (Kameswaran et al. 2014). As an 
imprinted locus, the MEG3 promoter is expected to be approximately 50% methylated in normal 
human islets, and thus it is an ideal target for validating the BisPCR2 strategy. 
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 Target enrichment primers were designed to amplify a 298 base pair region within the 
MEG3 promoter at position -188 to -493 relative to the transcription start site.  This amplicon 
covered 19 CpGs, and the average CpG methylation across the region was significantly 
increased from 43% in non-diabetic to 61% in type 2 diabetic human islets (p < 0.0001), 
confirming the report by Kameswaran and colleagues.  Of the 19 CpGs covered, 14 had 
significantly increased CpG methylation in type 2 diabetics (p < 0.05) (Figure 4.4A).  To further 
corroborate our findings, using primers directed to the same target region, we technically 
validated our results with pyrosequencing.  Although the same target region was analyzed, the 
fluorescence-based pyrosequencing reaction covered only 2 of the 19 CpGs within the amplicon, 
#15 and #16.  These 2 CpGs showed comparable levels of CpG methylation in the non-diabetic 
and type 2 diabetic samples as the BisPCR2 method (Figure 4.4B).  Thus, we were able to 
technically validate our results with pyrosequencing, and analyze ten times as many CpGs with 
the BisPCR2 method.   
We next sought to employ the BisPCR2 strategy to validate published differentially 
methylated loci in islets from type 2 diabetics (Dayeh et al. 2014). We selected four genes, INS, 
IRS1, CDKN1A, and PDE7B, for validation.  These loci were among those determined by Dayeh 
and colleagues to be differentially methylated in type 2 diabetic human islets in a genome-wide 
screen conducted with the Infinium HumanMethylation450 BeadChip array (Dayeh et al. 2014). 
The insulin gene has also been described as differentially methylated in type 2 diabetic human 
islets through a candidate gene approach (Yang et al. 2011).  We designed PCR#1 primers 
targeting the region -112 to -336 base pairs upstream of the insulin transcription start site 
capturing four CpGs, three of which were previously reported to have increased DNA methylation 
in type 2 diabetic human islets (Dayeh et al. 2014). We found all four CpGs measured had 
significantly increased DNA methylation (p < 0.05) with an average of 24% in non-diabetic 
compared to 46% in type 2 diabetic samples (p < 0.0005) (Figure 4.5A).  This includes one CpG 
from the Infinium array that was not previously identified as differentially methylated, INS CpG #4 
(cg24338752).    
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Individual CpGs within the other three loci had previously been re-analysed by 
pyrosequencing, and we modified these pyrosequencing primers with PCR#1 adapter overhangs 
to adapt these amplicons to the BisPCR2 technology (Dayeh et al. 2014).  By using the BisPCR2 
method with the same amplicons we were able to directly quantify DNA methylation at all CpGs 
within the target region.  At the IRS1 locus, we measured a comparable decrease of 10% CpG 
methylation in type 2 diabetic human islets, from 47% to 37%, at IRS1 CpG #1 (cg04751089), as 
had been reported previously (Figure 4.5B) (Dayeh et al. 2014).  In this amplicon we also 
determined DNA methylation at two adjacent CpGs that were not included in the Infinium array, 
and while the changes trended in a similar direction, there was no significant difference between 
non-diabetic and type 2 diabetic samples. At the CDKN1A locus, we did not find a significant 
difference in DNA methylation at the CpG previously analysed by pyrosequencing, CDKN1A CpG 
#1 (cg21091547), but did observe a significant decrease of 10% at two adjacent CpGs captured 
in this amplicon (Figure 4.5C).  CDKN1A CpG #3 (cg24425727) was also identified as 
differentially methylated to a similar extent in the genome-wide study by Dayeh and colleagues, 
while CDKN1A CpG #2 (cg11920449) was not previously identified as differentially methylated 
(Dayeh et al. 2014).  Lastly, we did not observe a change in DNA methylation at any of the three 
CpGs assayed at the PDE7B locus (Figure 4.5D).  Thus, in our validation study using BisPCR2, 
we were able to confirm some previous genome-wide findings and not others, while making novel 
observations about additional nearby CpGs not covered in prior assays.  
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Discussion 
We were prompted to develop the BisPCR2 method by our need for a high-throughput, 
cost-effective method for interrogating multiple CpGs at base resolution within multiple target loci 
of interest.  Fluorescence-based approaches to targeted bisulfite sequencing are limited by the 
number of CpGs that can be measured at one time, the inability to multiplex, and the reliance of 
measurements on a secondary enzymatic reaction.  Next generation sequencing techniques for 
targeted bisulfite sequencing employ the same strategy of bisulfite conversion and amplification 
of target loci, but result in a far more robust output by directly measuring base content of each 
CpG within an amplicon.  Further, the ability to multiplex means that a single sequencing reaction 
can yield information about multiple target loci for multiple biological samples.  One impediment of 
NGS approaches is the additional step of DNA sequencing library preparation following target 
enrichment, which can be expensive and time consuming.  We have circumvented this challenge 
by modifying the target enrichment PCR primers with overhangs such that DNA sequencing 
libraries can be directly amplified from target enrichment amplicons.  This modification 
dramatically decreases time and expense required for this NGS approach. 
We technically validated the BisPCR2 method at the imprinted MEG3 locus, which was 
previously shown to be hypermethylated in type 2 diabetic human islets (Kameswaran et al. 
2014).  We confirmed previous findings by both BisPCR2 and pyrosequencing and demonstrated 
that BisPCR2 measures DNA methylation at 19 CpGs, while pyrosequencing measures only two 
despite identical target sequence inputs.  Further, our validation study of type 2 diabetes CpG risk 
loci highlights several important considerations about implementing targeted DNA methylation 
analysis, particularly as a diagnostic marker.  In some instances, such as IRS1, our results were 
nearly identical to those reported by Dayeh and colleagues (Dayeh et al. 2014). We found similar 
levels of DNA methylation in normal and type 2 diabetic human islets at IRS CpG #1 
(cg04751089) and found no significant changes at two adjacent CpGs that were not probed for on 
the Infinium HumanMethylation450 BeadChip.  However, in contrast to genome-wide findings, we 
did not observe a change in DNA methylation at PDE7B CpG #2 (cg27306443), or at adjacent 
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CpGs.  While this discrepancy may be due to our limited sample size, it stresses the point that 
CpG methylation at this locus is not a sufficient diagnostic indicator of type 2 diabetes. Our 
findings at the CDKN1A locus highlight a third point, as we did not measure a change in CpG 
methylation at the reported cg21091547 (CDKN1A CpG #1), but did find a significant decrease in 
methylation at two adjacent CpGs, one of which was also identified by Dayeh and colleagues 
(Dayeh et al. 2014). These results again stress the danger of relying on a single CpG for 
reporting methylation changes, and also emphasize the value in incorporating multiple CpGs for 
the understanding of how DNA methylation is implicated in disease risk. 
While we have demonstrated the utility of BisPCR2 in validating findings from genome-
wide DNA methylation analyses, this technology is also suitable for other applications including 
candidate gene approaches and clinical diagnostic assays.  In candidate gene approaches, 
where genome-wide analyses may not be possible, many regions can be surveyed 
simultaneously by pooling multiple PCR#1 products across larger sample sizes than would be 
feasible for fluorescence-based assays. Clinical applications can benefit as well by reducing the 
costs of NGS approaches while collecting high-resolution data about neighbouring CpGs, the 
value of which was discussed earlier.  It should also be noted that our particular study does not 
take full advantage of the sequencing capacity of the MiSeq, as 200,000 reads per amplicon is 
orders of magnitude beyond what would be sufficient to draw statistically significant conclusions.  
Considering a sequencing threshold of 1,000 reads per amplicon, the capacity of the number of 
amplicons and samples that can be analysed in one run could be increased by two hundred-fold.  
This excess capacity could be distributed to additional samples or additional target loci, or a 
combination of both.  We provide 48 single index barcoding primers based on widely used 
Illumina sequencing technology, which would accommodate 250 target loci per sample.  Further, 
the barcoding primers could easily be modified with dual indeces to increase multiplexing 
capacity, which may be of particular utility in a clinical assay.   
BisPCR2 is an efficient, cost-effective, and robust high-throughput technique for 
assessing DNA methylation at targeted loci of interest.  Replacing DNA sequencing library 
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preparation with a single round of PCR represents a significant improvement over other targeted 
bisulfite NGS approaches by reducing time and cost.  This method is easily adaptable to different 
experimental setups to address a wide variety of biological questions relevant to DNA 
methylation. 
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Methods 
Traditional targeted bisulfite NGS library preparation (BisPCRSeq) 
 100 ng of mouse genomic DNA, isolated from the intestinal epithelium of three month old 
C57BL/6J-ApcMin/J mice (Jackson Laboratories), was bisulfite converted using the Epitect 
bisulfite kit (Qiagen).  Template DNA was amplified using KAPA HIFI Uracel+ (KAPA) with 
primers directed to the H19 locus (Forward: 5’ – ATTAGTTAGTGTGGTTTATTATAGGAAG – 3’ 
and Reverse: 5’ – AACCATTCCAAAAATACACACATCTTA – 3’).  Sequencing libraries were 
made using the NEBNext Multiplex Sample Kit (NEB).  These primers were also modified for 
incorporation into the BisPCR2 library preparation protocol, as described below.   
 
Genomic DNA isolation and sodium bisulfite conversion 
 Primary human islets were obtained from the Integrated Islet Distribution Program (IIDP).  
10,000 islet equivalents were obtained from five non-diabetic and five type 2 diabetic donors.  
Genomic DNA (gDNA) was extracted using the Qiagen® AllPrep DNA/RNA mini kit (Cat. No. 
80204) following the manufacturer’s instructions.  500ng of gDNA was treated with sodium 
bisulfite to convert unmethylated cytosines using the Qiagen® EpiTect® Bisulfite Kit (Cat. No. 
59104). Reactions were carried out per the manufacturer’s protocol. 
 
Target Enrichment (PCR#1) 
 Bisulfite converted gDNA was PCR amplified to enrich for regions of interest for DNA 
methylation analysis.  Primers directed to target regions were modified with the following partial 
adapter overhangs:  PCR#1 Left Primer Overhang:  5’ – 
ACACTCTTTCCCTACACGACGCTCTTCCGATCT – 3’; PCR#1 Right Primer Overhang:  5’ – 
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT – 3’.  Primers directed to the MEG3 and 
INS loci were designed using the Qiagen® PyroMark assay Design software.  Primers for 
CDKN1A, PED7B and IRS1 were adapted from a recent study by Dayeh and colleagues (Dayeh 
et al. 2014). Primer sequences and genomic coordinates are provided in Table 4.3.  PCR 
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reactions were prepared with the Qiagen® PyroMark PCR Kit (Cat. No. 978703) per the 
manufacturer’s recommendations using 2.8ng of bisulfite converted gDNA template per reaction 
and the suggested optimized cycling protocol.  All PCR#1 products for individual biological 
samples were pooled based on relative band intensity when 5µl of PCR#1 reaction from a 
representative sample, non-diabetic 1, was analysed on a 1.5% agarose gel.  Final amounts were 
combined as follows:  MEG3: 6µl, CDKN1A: 8µl, PED7B: 4µl, IRS1: 4µl, INS: 4µl, for a total of 
26µl per biological sample.  Each pool of PCR products was purified with the Qiagen® QIAquick 
PCR Purification Kit (Cat. No. 28104) per the manufacturer’s instructions.  A detailed diagram of 
BisPCR2 primer design is provided in Figure 4.6.   
 
Sample barcoding (PCR#2) 
 Unique DNA sequencing barcodes were incorporated into each sample by a subsequent 
round of PCR amplification.  Barcoding primers are provided in Table 4.4.  The Qiagen® 
PyroMark PCR kit was used to amplify 1ng of pooled PCR#1 template.  Thermocycling conditions 
were modified to ensure consistent amplification of PCR products of different sizes and were as 
follows: 95°C – 15 min; 10 cycles: 94°C – 30 sec, touchdown 68°C to 56°C – 30 sec, 72°C – 1 
min; 72°C – 10 min.  PCR products were purified with Agencourt® AMPure® XP beads 
(Beckman Coulter, Cat. No. A63881).  Sample concentrations were measured using the Qubit® 
fluorometer (Life Technologies) dsDNA high sensitivity assay.  Fragment length was determined 
by separating 1ng of sample on an Agilent high sensitivity DNA assay using the 2100 Bioanalyzer 
(Agilent Technologies). The molarity of the libraries was quantified using the KAPA library 
quantification assay (Kapa Biosystems, Cat. No. KK4873).  
 
Next-Generation Sequencing 
 Next generation sequencing was carried out on the Illumina MiSeq using Reagent Kit v2 
following the manufacturer’s instructions.  Briefly, a 2nM pool of BisPCR2 libraries and 2 nM PhiX 
control were each denatured for five minutes with 0.2N NaOH and diluted to final concentrations 
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of 6pM and 8pM, respectively.  The denatured pool was spiked with 10% denatured PhiX control 
and 600µl of the prepared sample was loaded into the reagent cartridge.  The sequencing 
reaction was carried out with 150 base pair paired-end sequencing.  Sequences were aligned to 
an in silico bisulfite-converted human genome using the BS Seeker program, and any CpGs 
covered by the first sequencing read were ignored in the second sequencing read in paired-end 
sequencing (Chen et al. 2010). The fraction of methylated cytosines was calculated as the 
merged frequency of cytosines for CpGs divided by total reads.  Sequencing and DNA 
methylation analysis were carried out by the Next Generation Sequencing Core at the University 
of Pennsylvania (Philadelphia, PA) [GEO: GSE69595].  
 
Pyrosequencing 
 Pyrosequencing was performed to technically validate BisPCR2 at the MEG3 
locus.  Forward and reverse primers designed with Qiagen® PyroMark Assay Design software 
were used for both methods, and for pyrosequencing the reverse primer was 
biotinylated.  Pyrosequencing primer sequences were as follows: Forward: 5’-
GGGGTGATAGTTTTTGGTTTATATT-3’, Reverse: 5’-CCATAACCAACACCCTATAAT-3’, 
Sequencing: 5’-TTTTTATATATTGTGTTTGAATTTA-3’.  Bisulfite-converted genomic DNA from 
human islets, processed as described above, was amplified with the Qiagen® PyroMark PCR Kit 
(Cat. No. 978703) per the manufacturer’s protocol.  The pyrosequencing reaction was carried out 
using Qiagen® PyroMark Gold Q96 CDT Reagents on the PyroMark Q96 MD (QIAGEN) 
according to the manufacturer’s instructions.   
 
Statistics 
 Data are shown as average ± SEM (n = 5).  Average percent CpG methylation was 
compared by two-tailed t-tests, and significance was defined as p < 0.05. 
 
ABBREVIATIONS  
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NGS: Next generation sequencing; GWAS: genome-wide association study; WGBS: whole 
genome bisulfite sequencing; PCR: polymerase chain reaction; gDNA: genomic DNA; ND: Non-
diabetic; T2D: Type 2 diabetic; SEM: standard error of the mean. 
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Figure 4.1. Schema of BisPCR2 method for targeted bisulfite sequencing.  DNA sequencing 
libraries are prepared by bisulfite conversion of genomic DNA followed by two rounds of PCR for 
target enrichment (PCR#1) and subsequent sample barcoding (PCR#2).  Partial adapter 
overhangs are added to target enrichment primers to permit simplified library preparation by PCR.  
PCR#1 amplicons are pooled prior to the PCR#2 reaction for each biological sample.  Due to the 
presence of the unique barcodes, all PCR#2 amplicons can be pooled for a single next- 
generation sequencing run.  
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Figure 4.2.  Comparison of BisPCR2 and traditional targeted bisulfite NGS methods. DNA 
methylation was measured in murine genomic DNA at the H19 locus using both BisPCR2 and 
traditional targeted bisulfite NGS (n=3).  Traditional targeted bisulfite NGS is denoted as 
BisPCRSeq. 
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Figure 4.3.  BisPCR2 DNA sequencing libraries. (A) Bioanalyzer gel visualizing the five 
amplicon fragments of a representative sample, ND1, following PCR#2. (B) Bioanalyzer 
electropherogram quantifying the amount of each fragment in ND1, illustrating the roughly 
equivalent amounts of all five amplicons.  (C) Average reads per amplicon for each sample.  ND, 
non-diabetic; T2D, type 2 diabetic. 
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Figure 4.4. BisPCR2 DNA methylation analysis confirms increased CpG methylation in type 
2 diabetic human islets at the MEG3 locus.  (A) Average percent CpG methylation at the 
MEG3 locus for five non-diabetic and five type 2 diabetic human islet samples measured by 
BisPCR2.  p-values calculated by a two-tailed t-test. *p < 0.05.  Error bars indicate SEM. (B) 
Quantification of average percent CpG methylation by pyrosequencing using the same samples 
and same MEG3 PCR primer sequences as in (A).  Only 2 of 19 CpGs are covered in the 
pyrosequencing assay.  Data displayed as in (A).   
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Figure 4.5. Validation of CpG loci differentially methylated in type 2 diabetic pancreatic 
islets by BisPCR2. Average percent CpG methylation in 5 non-diabetic and 5 type 2 diabetic 
human islet samples at loci previously shown to be differentially methylated in type 2 diabetic 
human islets, including (A) INS, (B) IRS1, (C) CDKN1A, and (D) PDE7B.  Black arrows indicate 
CpGs analysed previously by pyrosequencing by Dayeh and colleagues (Dayeh et al. 2014).  p-
value calculated by two-tailed t-tests. *p < 0.05.  Error bars indicate SEM.    
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Table 4.1.  Human pancreatic islet donor information 
Donor Gender Age (yrs) BMI (kg/m2) 
Non-diabetic 1 M 50 29.1 
Non-diabetic 2 F 59 28.3 
Non-diabetic 3 M 49 31.3 
Non-diabetic 4 M 60 22.5 
Non-diabetic 5 M 51 38.9 
Type 2 diabetic 1 M 58 29.3 
Type 2 diabetic 2 M 43 37 
Type 2 diabetic 3 F 40 33.9 
Type 2 diabetic 4 F 57 48.4 
Type 2 diabetic 5 M 47 NA 
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Table 4.2.  Description of PCR products assessed for DNA methylation analysis. 
Locus Coordinates Region length (bp) Final amplicon (bp) 
MEG3 chr14: 101,291,952-
101,292,257 
298 420 
INS  chr11: 2,182,551-
2,182,775 
225 347 
IRS1 chr2: 227,659,611-
227,659,781 
171 293 
CDKN1A chr6: 36,645,462-
36,645,696 
235 357 
PDE7B chr6: 136,172,765-
136,172,917 
153 275 
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Table 4.3.  PCR#1 primer sequences for amplification of bisulfite converted genomic DNA.  
Forward and reverse target enrichment primers were modified with adapter overhangs.  Locus-
specific portion of primer sequences are in bold text and common adapter overhangs are in plain 
text. 
Primer Sequence (5’ to 3’) Coordinates 
MEG3_F 
ACACTCTTTCCCTACACGACGCTCTTCCGATCTGGGGTGATAGT
TTTTGGTTTATATT chr14: 
101,291,952-
101,292,257 MEG3_R 
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTCCATAACCA
ACACCCTATAAT 
CDKN1A_F 
ACACTCTTTCCCTACACGACGCTCTTCCGATCTGGAGTTATAGA
AATAAAGGATGATAAGTAG chr6: 
36,645,462-
36,645,696 
CDKN1A_R GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTCCCTATAATTACAACAACTTTATTAACCA 
PDE7B_F 
ACACTCTTTCCCTACACGACGCTCTTCCGATCTTGTTTTTTTTTG
TTTGTGGTAATTGATAG chr6: 
136,172,765-
136,172,917 
PDE7B_R 
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTCCCTAAATA
AATAACACCACTTTTCTC 
IRS1_F 
ACACTCTTTCCCTACACGACGCTCTTCCGATCTGGAAAGAATA
GGAAGGGGTAG chr2: 
227,659,611-
227,659,781 
IRS1_R GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTATTTAAACCCCTATACCAACATCAATTTCC 
INS_F 
ACACTCTTTCCCTACACGACGCTCTTCCGATCTTGGGGGTTGA
GGTTGTAATT chr11: 
2,182,551-
2,182,775 
INS_R 
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTACCTCCAAC
TCTCCTAATCTAATAT 
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Table 4.4.  PCR#2 primer sequences for library amplification and barcoding.  Amplification 
with PCR#2 primers adds the remainder of adapter sequence and unique barcodes for up to 48 
samples.  A common forward primer, “Library_Primer1,” is used in combination with each unique 
barcoding reverse primer.  
Primer Name Primer Sequence Barcode 
Library_Prim
er1 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGAC ALL 
libraries 
Primer2_Index
_1 
CAAGCAGAAGACGGCATACGAGATCGTGATGTGACTGGAGTTCAGACGTGT ATCACG 
Primer2_Index
_2 
CAAGCAGAAGACGGCATACGAGATACATCGGTGACTGGAGTTCAGACGTGT CGATGT 
Primer2_Index
_3 
CAAGCAGAAGACGGCATACGAGATGCCTAAGTGACTGGAGTTCAGACGTGT TTAGGC 
Primer2_Index
_4 
CAAGCAGAAGACGGCATACGAGATTGGTCAGTGACTGGAGTTCAGACGTGT TGACCA 
Primer2_Index
_5 
CAAGCAGAAGACGGCATACGAGATCACTGTGTGACTGGAGTTCAGACGTGT ACAGTG 
Primer2_Index
_6 
CAAGCAGAAGACGGCATACGAGATATTGGCGTGACTGGAGTTCAGACGTGT GCCAAT 
Primer2_Index
_7 
CAAGCAGAAGACGGCATACGAGATGATCTGGTGACTGGAGTTCAGACGTGT CAGATC 
Primer2_Index
_8 
CAAGCAGAAGACGGCATACGAGATTCAAGTGTGACTGGAGTTCAGACGTGT ACTTGA 
Primer2_Index
_9 
CAAGCAGAAGACGGCATACGAGATCTGATCGTGACTGGAGTTCAGACGTGT GATCAG 
Primer2_Index
_10 
CAAGCAGAAGACGGCATACGAGATAAGCTAGTGACTGGAGTTCAGACGTGT TAGCTT 
Primer2_Index
_11 
CAAGCAGAAGACGGCATACGAGATGTAGCCGTGACTGGAGTTCAGACGTGT GGCTAC 
Primer2_Index
_12 
CAAGCAGAAGACGGCATACGAGATTACAAGGTGACTGGAGTTCAGACGTGT CTTGTA 
Primer2_Index
_13 
CAAGCAGAAGACGGCATACGAGATTTGACTGTGACTGGAGTTCAGACGTGT AGTCAA 
Primer2_Index
_14 
CAAGCAGAAGACGGCATACGAGATGGAACTGTGACTGGAGTTCAGACGTGT AGTTCC 
Primer2_Index
_15 
CAAGCAGAAGACGGCATACGAGATTGACATGTGACTGGAGTTCAGACGTGT ATGTCA 
Primer2_Index
_16 
CAAGCAGAAGACGGCATACGAGATGGACGGGTGACTGGAGTTCAGACGTGT CCGTCC 
Primer2_Index
_17 
CAAGCAGAAGACGGCATACGAGATCTCTACGTGACTGGAGTTCAGACGTGT GTAGAG 
Primer2_Index
_18 
CAAGCAGAAGACGGCATACGAGATGCGGACGTGACTGGAGTTCAGACGTGT GTCCGC 
Primer2_Index
_19 
CAAGCAGAAGACGGCATACGAGATTTTCACGTGACTGGAGTTCAGACGTGT GTGAAA 
Primer2_Index
_20 
CAAGCAGAAGACGGCATACGAGATGGCCACGTGACTGGAGTTCAGACGTGT GTGGCC 
Primer2_Index
_21 
CAAGCAGAAGACGGCATACGAGATCGAAACGTGACTGGAGTTCAGACGTGT GTTTCG 
Primer2_Index
_22 
CAAGCAGAAGACGGCATACGAGATCGTACGGTGACTGGAGTTCAGACGTGT CGTACG 
Primer2_Index
_23 
CAAGCAGAAGACGGCATACGAGATCCACTCGTGACTGGAGTTCAGACGTGT GAGTGG 
Primer2_Index
_24 
CAAGCAGAAGACGGCATACGAGATGCTACCGTGACTGGAGTTCAGACGTGT GGTAGC 
Primer2_Index
_25 
CAAGCAGAAGACGGCATACGAGATATCAGTGTGACTGGAGTTCAGACGTGT ACTGAT 
Primer2_Index CAAGCAGAAGACGGCATACGAGATGCTCATGTGACTGGAGTTCAGACGTGT ATGAGC 
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_26 
Primer2_Index
_27 
CAAGCAGAAGACGGCATACGAGATAGGAATGTGACTGGAGTTCAGACGTGT ATTCCT 
Primer2_Index
_28 
CAAGCAGAAGACGGCATACGAGATCTTTTGGTGACTGGAGTTCAGACGTGT CAAAAG 
Primer2_Index
_29 
CAAGCAGAAGACGGCATACGAGATTAGTTGGTGACTGGAGTTCAGACGTGT CAACTA 
Primer2_Index
_30 
CAAGCAGAAGACGGCATACGAGATCCGGTGGTGACTGGAGTTCAGACGTGT CACCGG 
Primer2_Index
_31 
CAAGCAGAAGACGGCATACGAGATATCGTGGTGACTGGAGTTCAGACGTGT CACGAT 
Primer2_Index
_32 
CAAGCAGAAGACGGCATACGAGATTGAGTGGTGACTGGAGTTCAGACGTGT CACTCA 
Primer2_Index
_33 
CAAGCAGAAGACGGCATACGAGATCGCCTGGTGACTGGAGTTCAGACGTGT CAGGCG 
Primer2_Index
_34 
CAAGCAGAAGACGGCATACGAGATGCCATGGTGACTGGAGTTCAGACGTGT CATGGC 
Primer2_Index
_35 
CAAGCAGAAGACGGCATACGAGATAAAATGGTGACTGGAGTTCAGACGTGT CATTTT 
Primer2_Index
_36 
CAAGCAGAAGACGGCATACGAGATTGTTGGGTGACTGGAGTTCAGACGTGT CCAACA 
Primer2_Index
_37 
CAAGCAGAAGACGGCATACGAGATATTCCGGTGACTGGAGTTCAGACGTGT CGGAAT 
Primer2_Index
_38 
CAAGCAGAAGACGGCATACGAGATAGCTAGGTGACTGGAGTTCAGACGTGT CTAGCT 
Primer2_Index
_39 
CAAGCAGAAGACGGCATACGAGATGTATAGGTGACTGGAGTTCAGACGTGT CTATAC 
Primer2_Index
_40 
CAAGCAGAAGACGGCATACGAGATTCTGAGGTGACTGGAGTTCAGACGTGT CTCAGA 
Primer2_Index
_41 
CAAGCAGAAGACGGCATACGAGATGTCGTCGTGACTGGAGTTCAGACGTGT GACGAC 
Primer2_Index
_42 
CAAGCAGAAGACGGCATACGAGATCGATTAGTGACTGGAGTTCAGACGTGT TAATCG 
Primer2_Index
_43 
CAAGCAGAAGACGGCATACGAGATGCTGTAGTGACTGGAGTTCAGACGTGT TACAGC 
Primer2_Index
_44 
CAAGCAGAAGACGGCATACGAGATATTATAGTGACTGGAGTTCAGACGTGT TATAAT 
Primer2_Index
_45 
CAAGCAGAAGACGGCATACGAGATGAATGAGTGACTGGAGTTCAGACGTGT TCATTC 
Primer2_Index
_46 
CAAGCAGAAGACGGCATACGAGATTCGGGAGTGACTGGAGTTCAGACGTGT TCCCGA 
Primer2_Index
_47 
CAAGCAGAAGACGGCATACGAGATCTTCGAGTGACTGGAGTTCAGACGTGT TCGAAG 
Primer2_Index
_48 
CAAGCAGAAGACGGCATACGAGATTGCCGAGTGACTGGAGTTCAGACGTGT TCGGCA 
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CHAPTER 5 – Discussion and future directions 
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Overview 
Human islet transplantation is effective in restoring normal glycemic control in type 1 
diabetics  (Rickels et al. 2013).  However, this treatment is limited in its implementation due to 
insufficient number of organ-donors.  Since the primary deficit in diabetes is β-cell dysfunction, 
the research community is invested in finding alternative sources of β-cells for replacement 
therapy.  One such strategy is to induce proliferation of pre-existing β-cells.  This would expand 
the number of β-cells available for transplantation in the case of type 1 diabetes, and perhaps 
provide an opportunity to expand endogenous β-cell populations in type 2 diabetes.  The key 
hurdle in inducing β-cell proliferation is that these cells lose the ability to proliferate with age.  
Deceased organ donors are usually adults, and type 2 diabetes is an age-related disorder, 
meaning the target cell population is one that is inherently least likely to respond to mitogenic 
stimuli.   
I hypothesized that there are epigenetic underpinnings to the age-related decline in 
proliferative capacity, and that targeted epigenetic modifications in adult β-cells might restore 
their proliferative response.  To address this hypothesis, I constructed transcriptome and DNA 
methylome profiles for the β-cell across the human lifespan.  I also developed a novel tool for 
targeting DNA methylation to specific loci, using TALE-DNMT fusion proteins.  As my first target I 
chose the cell cycle inhibitor, p16, encoded by the CDKN2A locus, a well-established mediator of 
age-related decline in proliferative capacity in rodent models.  I successfully increased the 
proliferative capacity of primary human fibroblasts, suggesting that this epigenetic targeting 
approach may be a viable tool for stimulating replication in human β-cells.  Simultaneously, I 
addressed a major need in the DNA methylation research field for an efficient and cost-effective 
method for targeted bisulfite sequencing, termed BisPCR2.  With the appropriate datasets and 
tools in place, future directions of this work will be focused on implementing targeted epigenetic 
modifications in adult human β-cells.  While the foundation for such experiments has been 
established, key challenges must be addressed regarding target identification and delivery of 
targeted epigenetic modifiers to human β-cells. 
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Addressing challenges in target identification  
Analyzing genome wide data sets  
I profiled the landscape of the aging β-cell by assessing gene expression across the 
human life span from three months to 64 years of age.  Previous aging analyses have assessed a 
subset of candidate regulators, often by immunohistochemical methods from autopsy specimens.  
I built RNA-Seq datasets for 23 sorted human β-cell samples so that we can begin to understand 
the dynamics of gene activation for mitogenic sensors, downstream signaling molecules, and cell 
cycle regulators as a function of age.  This dataset is the first of its kind in the number of human 
β-cell samples and the wide range of ages analyzed.  For a subset of eight of these donors I also 
sequenced the entire β-cell DNA methylome at single base resolution to assess the contribution 
of DNA methylation to the aging process.  While these datasets undoubtedly represent a 
significant contribution to the limited knowledgebase of the human β-cell, challenges in analyzing 
them have stunted my ability to identify novel targets to be used in interventions.     
To analyze gene expression data, I sought to conduct a time course analysis in an effort 
to capture dynamic changes in gene expression that may occur across the human lifespan.  
Greater statistical power could be achieved by grouping samples into “young” and “old” 
categories, but the appropriate cutoff for a two state comparison is unknown.  The importance of 
defining an appropriate cutoff is highlighted by my observation that the 18-year old DNA 
methylome showed an intermediate pattern compared to samples on either age extreme (Figure 
2.2D).  If DNA methylation is in fact correlated with gene expression in an age-dependent 
manner, then including these intermediate samples in either group might dilute important 
differences, or make it difficult to draw correlations between gene expression and DNA 
methylation.  While multiple time course analysis tools are available, none are particularly suitable 
to our dataset due to the lack of biological replicates at each time-point.  In attempt to overcome 
this challenge, we conducted linear and log-linear regression analyses of normalized read values.  
While the presence of CDKN2A as a top hit provided a degree of confidence, this particular 
approach is in no way comprehensive and therefore of limited utility.  In the future, we plan to 
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incorporate several additional types of regression analyses, or build a more customized platform 
for identifying common gene expression patterns with age.  
 
Incorporation of single-cell transcriptome and proteomic analyses 
 Peak proliferation of human β-cells in the postnatal period has been suggested to be 
approximately 2%, and this measurement was determined by the cell cycle marker Ki67, which is 
present during all active phases of the cell cycle, but not in G0  (Gregg et al. 2012; Scholzen and 
Gerdes 2000).   Ki67 is not a precise measure of productive cellular replication, meaning the 
percentage of cells completing mitosis may be even smaller.  Thus, in harvesting β-cell 
populations, the true cells of interest are diluted amongst a large number of cells that are 
potentially not of interest.  In using this type of bulk assay, we are making an assumption that all 
β-cells within a single donor behave in a similar manner, such that all β-cells from younger donors 
are poised to replicate, while those from older donors are not.  While one study has suggested 
that in mice all β-cells are of equal capacity to proliferate, it is also possible that only certain 
subpopulations of β-cells are poised to replicate, which would be difficult to discern, for example, 
if only 2 in 100 cells fit into this category  (Brennand et al. 2007).   Single-cell experiments could 
provide a level of granularity that is not achieved in our bulk assays.  Therefore, we are pursuing 
both gene expression and proteomic single cell analyses. 
 The goal of single cell transcriptome analysis is to distinguish the gene expression profile 
of proliferating β-cells and non-proliferating β-cells.  Towards this goal, other lab members are 
currently building RNA-Seq datasets for individual islet cells from young and old donors using the 
Fluidigm C1 system for single cell cDNA preparation.  In this system, a single cell suspension is 
passed through a cartridge that captures individual cells into distinct wells, which serve as 
isolated sites for cDNA preparation.  RNA-Seq libraries are prepared and sequenced externally to 
the C1 system.  Proliferating cells are identified by very high Ki67 mRNA expression.  The 
transcriptome of Ki67+High proliferating β-cells can then be compared to that of the Ki67+Low β-cells 
within the same sample.   
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 Another interesting application of this technology is investigating human endocrine cell 
subtypes.  Our fluorescence-activated cell sorting procedure utilizes cell surface antibodies that 
enrich for different islet cell populations, and we often assess purity by qPCR for endocrine 
hormone gene expression.  Preliminary single cell experiments have identified cells that express 
more than one of the classic endocrine hormones, such as insulin, glucagon and somatostatin, 
which has also been previously reported  (White et al. 2013).   It might be interesting to 
investigate how proliferation is correlated with β-cell subtypes, as assessed by endocrine 
hormone expression.  Single cell transcriptome data serve as a good complement, but not a 
replacement, to bulk assays, especially because the C1 system currently processes only 96 cells 
at a time, and with a proliferation rate of 2% it can be challenging to capture a sufficient number 
of proliferating cells.  Further, the cell capture system is based on cell size, and so differences in 
cell size between proliferating and quiescent cells could bias selection.    
 Other lab members are also currently developing a single-cell proteomic approach to 
complement our genome-wide datasets.  Analyzing gene expression on the protein level is 
essential because transcription can be regulated independently from translation.  For instance, 
even though we commonly observe glucagon mRNA in gene expression data, glucagon is not 
detected at the protein level in β-cells (unpublished).  Cytometry by time-of-flight mass 
spectrometry (CyTOF) is a novel single-cell mass spectrometric technique  (Newell et al. 2012).   
In this procedure, heavy metals isotopes are conjugated to antibodies and cells are then analyzed 
by mass spectrometry.  The key advantages of this procedure over traditional FACS analysis is a 
higher degree of sensitivity by avoiding spectral overlap associated with FACS, and also a larger 
number of channels.  One important limitation is decreased cell sampling efficiency, which we 
have found to be approximately 10% in comparison to >95% for FACS analysis.  Our lab is 
currently profiling β-cells from young and old islet donors by CyTOF.   
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DYRK1A as a target for epigenetic editing 
 Our strategy of profiling the aging β-cell transcriptome and methylome is an example of a 
“bottom-up” search for targets for inducing adult β-cell proliferation.  Other groups have pursued 
“top-down” approaches using high-throughput chemical screens to identify small molecules that 
induce β-cell proliferation  (Wang et al. 2015a; Wang et al. 2015b).   Such screens are usually 
performed with libraries of thousands of chemicals, many of which have been studied in vivo, and 
even in humans.  Further, since the readout is markers of proliferation as opposed to next 
generation high-throughput sequencing, chemical screens are more efficient and cost-effective 
than our “bottom-up” approach.  However, the disadvantages to this approach are that often 
times the mechanism by which a drug works is unknown, or the drug may have unacceptable off-
target effects.  
A recent study by Wang and colleagues offers an interesting opportunity to combine our 
targeted epigenetic editing approach with findings from a chemical screen  (Wang et al. 2015b).   
This screen identified harmine as a potent inducer of β-cell proliferation, which appeared to be 
mediated by inhibition of dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A).  
DYRK1A has been implicated in suppressing β-cell replication by inhibiting the nuclear factor of 
activated T-cells (NFAT) pathway  (Shen et al. 2015).   Despite this exciting finding, due to off-
target effects, harmine cannot be used clinically.  Although DYRK1A expression does not appear 
to increase with age in human β-cells based on our data, epigenetic suppression with TALE-
DNMTs could be a way to leverage the findings from this chemical screen.  TALE-DNMTs can be 
applied as a tool for correcting aberrant changes to the DNA methylome, or more simply as a tool 
for stable transcriptional suppression.  Thus, we are currently pursing DYRK1A TALE-DNMTs as 
a future direction to affect β-cell replication.  In summary, future efforts in target identification will 
be directed towards developing a robust pipeline for analysis of genome-wide gene expression 
data, incorporating single-cell analysis to corroborate our bulk assays, and exploring targets 
identified through other approaches. 
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Addressing challenges in TALE-DNMT delivery to the human β-cell 
Improved TALE-DNMT lentiviral constructs 
Our primary target for epigenetic editing with TALE-DNMTs is p16, due to its well-
established role in mediating the age-dependent decline in proliferative capacity in murine models  
(Krishnamurthy et al. 2006).   Further, our RNA-Seq data show a dramatic increase in CDKN2A 
expression with age in human β-cells (Figure 2.5A).  For the p16 TALE-DNMT validation study in 
primary human fibroblasts, the CDKN2A promoter was selected for targeted DNA methylation, 
and we saw a robust decrease in expression of the p16 transcript.  The CDKN2A promoter 
contains a CpG island and is epigenetically regulated, suggesting this locus is a reasonable 
TALE-DNMT target  (Popov and Gil 2010).   While this region is not differentially methylated in 
young and old human β-cells based on our DNA methylome data, it is still a viable strategy for 
decreasing p16 levels.  We will continue to pursue these specific TALE constructs, and also more 
distal putative regulatory elements associated with CDKN2A that were differentially methylated in 
young and old β-cells (Figure 5.1). 
Our efforts in pursuing targeted epigenetic modifications in human β-cells have been 
hampered by the challenges of working with this cell type in vitro.  Lack of a suitable human β-cell 
line in addition to the limitations of culturing primary human islets ex vivo has thus far prevented 
proof of concept studies in β-cells.  The differences outlined between rodent and human β-cell 
proliferation suggest that it is critical to test our strategy specifically in human cells.  In attempt to 
overcome these limitations, we have used a xenotransplantation model by transplanting human 
islets under the kidney capsule of non-obese diabetic (NOD) severe combined immunodeficiency 
(SCID) mice, in which diabetes is induced by low dose streptozotocin (STZ) treatment  (Levitt et 
al. 2011).   Prior to transplantation, islets are infected with a lentivirus containing the p16 TALE-
DNMT transgene.  We selected lentivirus as the delivery method for TALE-DNMTs because it is a 
well-established technique for stably introducing transgenes into primary human cells.  However, 
this model is subject to its own set of challenges, including poor islet transduction efficiency.  Due 
to the spheroid structure of the islet, cells on the periphery are more accessible than cells towards 
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the core of the islet, which are inaccessible and therefore poorly transduced.  Further, due to the 
loss of the vasculature during islet isolation and culture, the core often becomes necrotic. Future 
efforts in TALE-DNMT delivery will be directed towards optimizing lentivirus transduction and 
exploring alternative delivery methods. 
We initially modified our TALE-DNMT construct to accommodate lentivirus technology by 
minimizing direct repeats, or TALE jumbling, to prevent recombination during integration into the 
genome.  We also had to decrease the size of the TALE repeat domain and eliminate the 2A GFP 
to accommodate constraints on the size of the lentivirus genome.  Given the known limitations of 
lentivirus transduction efficiency in human islets, we recognized the importance of assessing 
proliferation specifically in transduced β-cells.  We planned to detect infected cells using the C-
terminal Flag-tag, which was previously used to detect the fusion protein by western blot  
(Bernstein et al. 2015b).   However, we were not successful in detecting this epitope by 
immunofluorescence or fluorescence-activated cell sorting (FACS) analysis.  This failure could be 
due to the positioning of the Flag epitope in the three-dimensional conformation of the TALE-
DNMT, since the western blot procedure detects the SDS-denatured protein as opposed to the 
native version. 
Since our lab has employed lentivirus to successfully transduce human islets in the past, 
we decided to amend the constructs to improve detection. The first modification we made was to 
move the Flag-tag to the N-terminus, as changing the location of the epitope could alter its 
exposure for antibody detection.  Despite known restrictions of the lentiviral genome size, we 
decided to add back the GFP gene, since in our previous work we had isolated transfected cells 
from non-transfected cells by GFP FACS sorting.   
Another potential opportunity to improve our TALE-DNMT constructs is to increase 
specificity, perhaps by attenuating the DNMT catalytic activity.  In our study of TALE-DNMTs in 
fibroblasts, we found that while the strongest changes in DNA methylation occurred at the TALE 
binding site, there were distance-related changes in DNA methylation, which we termed “near-
target” effects.  Conceptually, if the catalytic activity is weaker, then DNA methylation might be 
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more likely to occur only where the enzyme is localized, in this case the p16 promoter.  Originally, 
the catalytic domain present in our fusion protein consisted of DNMT3a fused to DNMT3L.  The 
DNMT3L subunit does not have inherent catalytic activity, but rather enhances the activity of 
DNMT3a. We hypothesize that removing the DNMT3L domain will attenuate the catalytic activity 
of DNMT3a to allow local effects on DNA methylation while limiting near-target effects.  Removing 
the DNMT3L domain would also accommodate the addition of GFP to keep the construct within 
the recommended lentiviral genome size.  Thus, we modified the TALE-DNMT backbone with the 
N-terminal Flag-tag such that DNMT3L and GFP were each flanked by restriction enzymes for 
convenient removal as necessary.  We prepared new N-flag TALE-DNMT GFP lentiviruses, with 
and without DNMT3L, and a wild-type and mutant version for both constructs.  Testing these 
lentiviruses is a critical next step in moving TALE-DNMTs forward into human islets. 
Another potential future modification to TALE expression constructs is replacing the CMV 
promoter with a β-cell specific promoter, such as that of the insulin gene.  In order to move closer 
to clinical applications, it is important for TALE-DNMTs to have a targeted impact on 
transcriptional regulation, which includes targeting the correct cell type.  This two-step procedure 
of validating TALE-DNMT functionality with one virus in fibroblasts and implementing a different 
virus in human islets is highly inefficient.  Improving transduction efficiency may permit direct in 
vitro validation experiments in human islets to assess TALE-DNMTs for changes in DNA 
methylation and gene expression.    
 
Optimizing lentiviral transduction efficiency 
In addition to improving lentiviral constructs to permit detection and limit “near-target” 
effects, we are also pursuing efforts to optimize transduction efficiency.  One approach is “islet re-
aggregation”, which entails enzymatic dispersion of islets followed by lentivirus infection and re-
aggregation of the endocrine cell suspension by orbital shaking.  While this method results in very 
high transduction efficiency, it also disrupts the three dimensional structure of the islet and any 
intercellular connections, which may be important in paracrine signaling  (Tamaki et al. 2014; 
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Caicedo 2013; Barker et al. 2013).   Further, in our experience, individual re-aggregated islets 
must be cultured in single wells of 12-well plates to prevent islets from clumping together, while 
providing sufficient surface area for orbital shaking.  Usually, we utilize a minimum of 100 islets 
per mouse in a xenotransplantation experiment, making it somewhat impractical to culture 
individual islets for multiple animals.  Another potential strategy for increasing transduction 
efficiency is “islet loosening,” either by enzymatic or chemical disruption.  While such procedures 
have reported transduction efficiencies around 80%, we have not yet optimized the balance 
between sufficient loosening and maintaining islet integrity  (Maria Jimenez-Moreno et al. 2015).   
Thus, there are a number of avenues each with several variables that can be modified towards 
optimizing transduction efficiency. 
 
Alternative TALE-DNMT delivery strategies 
In the case of targeted epigenetic modifiers, genomic integration may not be necessary if 
a stable epigenetic mark is incorporated.  In fact, from a therapeutic standpoint, transient 
expression and a long-term effect may even be preferable.  Thus, we are considering non-viral 
delivery systems for transient transgene expression.  Two such alternatives include modified 
RNAs (modRNAs) and electroporation.  modRNAs are synthetic mRNA molecules generated by 
in vitro transcription with modified cytidine and uridine ribonucleoside bases in addition to 
phosphatase treatment in order to reduce cellular toxicity associated with mRNA transfection.  
These synthetic molecules have been successfully used to generate induced pluripotent stem 
cells (iPSCs), and then to re-differentiate these iPSCs cells to different cell fates  (Warren et al. 
2010).   modRNAs have also been used in vivo in a mouse model of myocardial infarction to 
promote expansion and directed differentiation of endogenous heart progenitors  (Zangi et al. 
2013).   TALE-DNMT modRNAs could be delivered to human islets in vitro to transiently express 
these constructs.  Further, Tamaki and colleagues used an optimized electroporation protocol to 
deliver multiple siRNA to human islets and found robust suppression of several but not all target 
genes, while maintaining islet structure, function and viability  (Tamaki et al. 2014).  
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Electroporation could be used to deliver plasmid DNA, although delivery of modRNAs directly 
would likely promote greater efficiency in generating TALE proteins.   
 
Future utility of BisPCR2  
In our genome-wide assessment of DNA methylation in the aging human β-cell, we sought to 
determine the entire landscape of DNA methylation in young and old β-cells.  This landscape 
provides a solid foundation for understanding the function of DNA methylation globally, and for 
integrating other genome-wide datasets to deepen our understanding of how DNA methylation fits 
in with other mechanisms of epigenetic regulation.  While in some instances such a global 
perspective is necessary, other scientific questions require surveying DNA methylation in a 
targeted fashion at selected regions across many biological samples.  For instance, once we 
identify candidate differentially methylated regions (DMRs), we will likely need to validate findings 
in a larger set of samples.  The most common methods for targeted DNA methylation analysis are 
fluorescence-based assays such as pyrosequencing that detect the relative amount of cytosine 
residues compared to thymidine residues following bisulfite conversion.  With sodium bisulfite 
treatment, unmethylated cytosines are converted to uracils while methylated cytosines are 
protected.  Such fluorescence-based assays are limited by the number of samples that can be 
processed at once, the number of CpGs that can be assessed in a single assay, and the 
dependence on a secondary fluorescence enzymatic reaction.  An alternative to these assays is 
bisulfite conversion followed by next-generation sequencing (NGS), which leverages sample 
barcoding and direct sequencing of base content in an entire DNA fragment, improving upon the 
limitations listed above.    
 The rate-limiting step of NGS is DNA sequencing library preparation, which is a low 
throughput multiple day procedure.  In our assessment of DNA methylation in p16 TALE-DNMT 
experiments, we did leverage an automated library preparation system, but while the hands-on 
bench time was low, it still required more than one day and only eight samples could be 
processed at one time.  Further, we were still subject to occasional technical failures of the 
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automated system.  Since targeted bisulfite sequencing approaches require an initial PCR step to 
enrich for regions of interest, this initial PCR step can be used to introduce partial adapter 
sequences by adding overhangs to the target enrichment primers.  The addition of partial adapter 
overhangs permitted library barcoding by a second round of PCR.  Thus, the BisPCR2 method 
permits entirely PCR-based library preparation that is extremely fast, efficient and inexpensive. 
 In addition to our validation study of type 2 diabetes CpG risk loci in human islets, 
BisPCR2 has gained momentum in several other areas both at the University of Pennsylvania and 
elsewhere.  Ongoing collaborations include validation of findings from genome-wide studies in 
population epigenetics, candidate gene approaches in transgenerational epigenetic inheritance, 
and candidate gene approaches in cancer studies.  One could also envision the clinical 
application of this technology in measuring DNA methylation for diagnostic purposes.  Further, 
others have adapted the BisPCR2 technology to non-DNA methylation studies such as circular 
chromosome conformation capture (4C), which utilizes the PCR-based library preparation 
procedure without the bisulfite conversion step.  Thus, this simplified DNA sequencing library 
technique has extended far beyond our initial study. 
 An opportunity for improvement upon the BisPCR2 technique is to make it even more 
high-throughput.  Despite the undisputed advantages over traditional NGS approaches, hands-on 
time is still required for PCR amplification of each region of interest, pooling and purification of 
samples prior to barcoding, and a final purification step for each library.  Each of these steps is 
relatively simple, but may become tedious when working with large sample sizes or large 
numbers of target regions.  One possibility to improve efficiency is to automate some of these 
steps using robotic instruments that are already being implemented in our lab.  The easiest steps 
to automate are PCR set-up and PCR product pooling.  Automation would also reduce the 
chances of human error when working with large sample sizes.  In summary, BisPCR2 is an 
extremely useful improvement in targeted bisulfite NGS, and beyond, and can be further 
improved to increase utility. 
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Future Perspectives on human β-cell rejuvenation  
 β-cell rejuvenation has the potential to impact type 1 diabetes in the context of pancreatic 
islet transplantation, and type 2 diabetes in the context of expanding residual β-cell mass.  In the 
near term, β-cell rejuvenation in the transplant setting is a more realistic opportunity, since islets 
can be treated ex vivo, thereby circumventing challenges with endogenous drug delivery, such as 
drug safety and metabolism.  There are several hurdles remaining in the islet transplantation field, 
and the one investigated in the present work is the lack of sufficient donors to meet 
transplantation demand.  An appealing strategy for increasing donor supply is to promote β-cell 
replication in human islets isolated from deceased donors ex vivo before transplantation.  By 
working with the native β-cell, there is a greater likelihood of maintaining cellular identity.  This is 
an ongoing challenge in other β-cell replacement strategies such as differentiation from stem cell 
populations or transdifferentiation from other cell types.  Additionally, this strategy preserves the 
intricate three-dimensional structure of the human islet, which mediates paracrine interactions 
between cells and promotes interactions with the microvasculature, which is critical for hormone 
secretion  (Menger et al. 2001).   Islet transplantation is a robust therapy for diabetes because, 
unlike pharmaceutical interventions, the β-cell can respond to dynamic changes in blood glucose 
levels.  Thus, maintaining β-cell identity and islet architecture will optimize the success of this 
strategy.   
 It is generally accepted that islet transplantation is curative in type 1 diabetes, and that 
adult human β-cells can in some instances be induced to proliferate, primarily through over 
expression or inhibition of certain cell cycle regulators.  Thus, combining these two principles 
could greatly decrease the burden of type 1 diabetes.  There are several considerations in 
moving forward towards a clinical application, including achieving sufficient β-cell expansion while 
preventing oncogenicity, and maintaining β-cell function, all of which can likely be addressed.     
 Cellular senescence and oncogenic transformation are opposite extremes of the same 
pathways, and cannot be viewed in isolation.  p16 models this point effectively since it is known to 
be inactivated in a number of cancers, and yet we have shown that p16 transcript levels are 
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extremely low in young human β-cells.  Further, oncogenic transformation and unrestricted 
proliferation is not the result of a single mutagenic event, but rather the consequence of a 
culmination of cellular changes  (Hanahan and Weinberg 2011).   Another critical point is that the 
rate of proliferation in adult human β-cells is so low that a tremendous amount of oncogenic 
stress would probably be required to permit tumor formation.  In the case of p57 suppression in 
human islets, increased proliferation was observed only with the added mitogenic stimulus of 
hyperglycemia in vivo, and even then, proliferation increased by only 3-fold (to 2.71% of β-cells) 
over the course of 20 days of xenotransplantation (Avrahami et al. 2015).  This point leads to the 
opposite concern of whether or not sufficient β-cell expansion can ever be achieved to have a 
meaningful impact on the donor β-cell supply. 
 When dispersed from islet clusters, human β-cells can be induced to proliferate by large 
magnitudes, but at the expense of β-cell identity (Efrat 2008).  Attempts have been made towards 
re-differentiating these cells with varying degrees of success.  However, in the p57 study, 
Avrahami and colleagues demonstrated that newly formed human β-cells in fully intact islets have 
normal glucose responsiveness (Avrahami et al. 2015).   Perhaps inducing β-cell proliferation at a 
lower rate, closer to peak rates observed physiologically, may provide a sufficient balance of 
increasing β-cell mass while maintaining β-cell identity.   
 An outstanding question is whether or not it is required that β-cell expansion occur prior 
to transplantation.  Human islets do not survive for long ex vivo, and for testing our own genetic 
and epigenetic manipulations, we transplant islets into NOD-SCID mice shortly after transduction 
so they can become revascularized as soon as possible.  Further, in the present strategy of 
targeted epigenetic modifications, I have not yet investigated how these modifications are 
maintained over time.  If they are indeed stable, β-cells will continue to replicate after 
transplantation during the remainder of the recipient’s life.  This strategy is potentially risky in the 
context of clinical applicability, because recipients would be transplanted with a sub-therapeutic 
number of islets under the presumption that β-cells will expand in vivo.  If β-cells do not 
sufficiently expand, recipients may require additional transplantation procedures.   
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In discussing expansion of availability of pancreatic islet transplantation, it is important to 
note that graft survival depends upon adequate revascularization and protection from 
inflammatory and adaptive immune response.  The normal human pancreas contains 
approximately 1 million islets, corresponding to roughly one billion β-cells  (Weir and Bonner-Weir 
2013).  Further, according to the National Institute of Diabetes and Digestive and Kidney 
Diseases (NIDDK), transplantation recipients often undergo two infusions of 400,000 to 500,000 
islets (National Diabetes Information Clearinghouse, 2013).  It has been reported that in humans, 
overt type 1 diabetes does not occur until residual β-cell mass is reduced to about 10%  (Klinke 
2008).  Thus, far more islets are being transplanted than are physiologically required to cure 
diabetes.  In addition, islets are subject to graft failure, often within five years of the procedure 
(McCall and Shapiro 2014).   Even marginal improvements in increased β-cell proliferation, in 
combination with improved graft survival, could greatly expand the availability of islet 
transplantation. 
 
Conclusion 
 In this work, we present novel human β-cell RNA-Seq and DNA methylome datasets so 
that we may begin to understand the transcriptional changes that occur in the human β-cell with 
age, and how DNA methylation might be implicated in this process.  We also present a robust tool 
for modifying DNA methylation at target loci to specifically alter gene expression.  We 
demonstrated proof-of-concept for this technique by increasing proliferation in human fibroblasts 
through epigenetic suppression of CDKN2A (p16).  Finally, we present an improved method for 
targeted bisulfite NGS, BisPCR2, which allows more efficient, cost-effective and thorough 
interrogation of DNA methylation at target regions.  Future efforts will be directed towards 
improving the utility of each of these tools to enhance our potential for success in targeted 
epigenetic editing in adult human β-cells.  
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Figure 5.1.  DNA is differentially methylated at the CDKN2A locus comparing young and 
old human β-cells.  Diagram depicting DNA methylation at the CDKN2A locus in young and old 
human β-cells.  Each bar in the plot for young and old groups represents percent methylation for 
an individual CpG ranging from 0-100%.  Differentially methylated regions (DMRs) are indicated 
by blue bars beneath the CDKN2A gene illustration.  The number of CpGs and change in percent 
methylation is indicated beneath each DMR.  Positive values indicate increases in percent DNA 
methylation with age.  DMRs determined as described in Chapter 2 methods.     
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